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ABSTRACT
Poulami Maitra: Statistical Methods for Data from Case-Cohort Studies
(Under the direction of Jianwen Cai)
In epidemiological studies and disease prevention trials, interest often lies in the relation-
ship between certain disease endpoint and some exposure of interest. When the event is rare
and/or some of the covariate information are quite expensive to collect for the entire cohort,
case-cohort designs are widely used to reduce the financial cost of the study while achieving
the same study goals. The case-cohort sampling scheme entails the random sampling of indi-
viduals, called the sub-cohort, along with all the cases. In the situation when the event rate
is not low but resources are limited, the generalized case-cohort design is more appropriate,
where only a fraction of cases are sampled along with the sub-cohort. In this dissertation, we
consider two aspects of case-cohort studies. One is for statistical methods for the analysis of
recurrent events and the other concerns power/sample size calculation for interaction test.
Many methods for the analysis of data from case-cohort studies have been proposed in the
literature. However, most of these methods are for either a single event or multitude of events
of different types on the same subject. There has not been much work on the recurrent events
data under case-cohort sampling scheme. Valid statistical methods that take into account
the correlation between the events from the same individual needs to be developed. In this
dissertation, the first two topics are related to recurrent events. We consider modeling the
recurrent events using the rate model under the original and generalized case-cohort designs.
The first topic considers the multiplicative rates model and the second topic considers additive
rates models. For both types of the rate models, we propose weighted estimating equation
approach for the parameter estimates for both sampling designs. We showed that the proposed
estimators are consistent and asymptotically normally distributed. We conducted simulation
studies to examine the performance of our proposed estimators in finite samples and they
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performed well. For the multiplicative rates model, we illustrated the proposed method to
assess the relationship between prior measles infection and acute lower-respiratory-infections
(ALRI) in a double-blinded randomized clinical trial, conducted in Brazil. We illustrated our
proposed method for additive rates model to study the effect of FEV1 on the recurrence of
pulmonary exacerbation in patients with cystic fibrosis.
In the third topic, we address another aspect of the case-cohort design. All the previous
work in the literature concern sample size and power calculation in case-cohort data for a
dichotomized main effect. However, in certain situations, one might be interested in the
association of a covariate and time to event response in different biomarker groups, which
may be expensive to measure. We extend the existing idea for the single binary main effect
to the interaction between the variable and the dichotomized biomarker in the presence of a
rare event. We propose different power formulas based on the simplification of a generalized
log-rank test for the case-cohort design. A cost efficiency formula comparing the case-cohort
design to a simple random sample is derived. We examine the performance of the bounds
based on the same test. Simulation studies are conducted to illustrate the efficiency for the
case-cohort design. We illustrate the use of the formula based on information from the pooled
databases of Lung Adjuvant Cisplatin Evaluation (LACE) and Cancer and Leukemia Group
B (CALGB) 9633.
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CHAPTER 1: INTRODUCTION
Large epidemiologic cohort studies or disease prevention trials are expensive as they re-
quire the follow-up of several thousand individuals for a long period of time before producing
valuable results (Prentice 1986). The cost mainly arises from the culmination of the raw ma-
terials for covariate data ascertainment for all the cohort members. Such raw materials may
include blood serum samples, tissue specimens, occupational exposure records, etc. When the
disease is rare, much of the covariate data on the disease-free subjects is inessential. Pren-
tice (1986) cited the multiple risk factor intervention trial (MRFIT Research Group, 1982),
a randomized trial of 12,866 subjects, who were followed-up for an average of seven years
and reportedly cost US $100 million. Such studies provide a primary application area for the
case-cohort design. In the prevention trial context, a case-cohort design would reduce the
cost of assembling the cohort history while allowing for the tracking of the history for the
subcohort on an on-going basis.
The case-cohort study design was first proposed by Prentice (1986). It is a retrospective
study design nested within a prospective cohort. Specifically, the entire cohort is followed for
the disease of interest over time. At a certain time during follow-up, a case-cohort sample
is drawn. The case-cohort sample consists of a random sample from the cohort and all
subjects who had developed the disease by that time. The expensive or hard to measure
covariates are then collected on subjects in the case-cohort sample. Prentice (1986) studied the
proportional hazards model for case-cohort data and obtained an estimating equation using
pseudo-likelihood approach. In this dissertation, we propose methods to analyze recurrent
event data from case-cohort studies.
Recurrent events are common in biomedical research. Andersen and Gill (1982) extended
the Cox proportional hazards model to include recurrent events by modeling the intensity
1
process of the multivariate counting process. Prentice et al. (1981), Wei et al. (1989), Lawless
and Nadeau (1995), Sun et al. (2004), among others considered marginal rates (or mean)
model to evaluate the effect of the risk factors on recurrent event data. Some examples
include the occurrence of new tumours in patients with superficial bladder cancer (Byar, 1980),
recurrent seizures in epileptic patients (Albert 1991), rejection episodes in patients receiving
kidney transplants (Cole et al. 1994), repeated infections in HIV-patients (Li and Lagakos
1997) and repeated cardiovascular events in patients (Cui et al. 2008). The two primary
frameworks to study the association between the risk factors and the disease recurrence are
the additive and multiplicative rates models. Most modern analysis of survival data address
multiplicative models for relative risk (rates) using proportional rates models, mostly due to
desirable theoretical properties along with the easy interpretation of results (Pepe and Cai
1993, Lawless 1995, Lin et al. 2000, Schaubel et al. 2006, Kang and Cai 2009a). However,
researchers may be interested in the risk (rate) difference, rather than the relative measure,
attributed to the exposure. Further, the risk difference is more relevant to the public health
as it translates directly to the number of disease cases that may be avoided by eliminating the
exposure (Kulich and Lin 2000). Consequently, the additive rates models can be considered
as an alternative to the multiplicative model (Schaubel et al. 2006, Yin and Cai 2004, Zeng
and Cai 2010, Liu et al. 2013, Kang et al. 2013, He et al. 2013).
All the aforementioned articles considered the full cohort. However, in the three decades
from Prentice’s (1986) seminal paper on case-cohort data, there has been many theoretical
developments and application to different studies in the literature (e.g. Self and Prentice
(1988), Lin and Ying (1993), Barlow (1994), Borgan et al. (1995), Chen (2001), Zeng et al.
(2006), Kang and Cai (2009a), Dong et al. (2014)). Estimation procedures have been proposed
to model single-event data or clustered failure times data, arising from case-cohort studies
but methodologies to address the rates model for such data are limited. Lu and Tsiatis
(2006) and Zhang et al. (2011) developed marginal models for clustered failure times data,
in which the clusters are usually formed by the dependent subjects. Chen and Chen (2014)
extended Prentice’s (1986) idea to recurrent events with certain clustering feature, which
was represented by properly modified Cox-type self-exciting intensity model. However, there
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has not been much work on modeling the marginal rates/mean model for recurrent events
under such sampling scheme. Using the intensity model (Andersen and Gill 1982) to analyze
recurrent events assumes that all the influence of the prior events on future recurrence is
through only the possibly time-varying covariates (Lin et al. 2000). Since, this may not be
the case in practice, less restrictive methods need to be developed for such data from case-
cohort studies. Motivated by these, we propose statistical methods for modeling recurrent
events data from case-cohort studies. We will consider both the multiplicative and additive
rates models in analyzing recurrent events data from case-cohort studies.
Another aspect of case-cohort studies is the design of such studies. In this new era of
cancer research, large amounts of data are often available after the completion of Phase III
trials. There is a growing interest in using this available data to discover new biomarkers that
can be helpful in predicting the best treatment for a particular patient. The advantages of
using information collected in completed Phase III trials are : (a) the data is already available
for further analysis and (b) even if the clinical trail may indicate that the treatment is not
effective, the collected information can still be used for biomarker discovery. In developing
personalized treatment program, genomic biomarkers are often used which are often quite
expensive to measure and maybe time-consuming. In such cases, case-cohort study design
can be applied if only a very small proportion of the cohort experiences the disease endpoint of
interest. The selection of the subset in the second phase can be flexible, utilizing information
collected in the first phase, such as the patient’s disease status, treatment effects and any
auxiliary information. Power and/or sample size will need to be considered to design such a
study. Cai and Zeng (2004) and Cai and Zeng (2007)) proposed simple formula to calculate
the power for the main effect under case-cohort studies and the bounds under generalized case-
cohort design, respectively. In this dissertation, we will develop power/sample size formula
for testing the interaction between an exposure of interest and some expensive biomarker on
a rare event under case-cohort design.
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CHAPTER 2: LITERATURE REVIEW
In this Chapter, we review the literature on the statistical methods for : (i) univariate
failure time data arising from case-cohort studies, (ii) correlated failure time data, more
specifically, recurrent events from prospective studies and their marginal analysis, (iii) sample
size calculation for effects in presence of case-cohort studies when the event is rare. We review
the literature on statistical methods for univariate failure time data in Section 2.1, case-
cohort studies in Section 2.2, recurrent events analysis from prospective studies in Section 2.3
(including marginal models using multiplicative models and frailty models), additive rates
models in Section 2.4, and Power/sample size calculation for case-cohort data in Section 2.5.
2.1 Univariate Failure Time Models
The Cox proportional hazards model (Cox 1972) has been one of the most widely used
procedures to study the effects of covariates on failure time. This model assumes that the
effect of the covariate on the hazard function is constant over time. A more general version
of the Cox model assumes that the hazard function of the failure time, T, associated with the
covariates Z, is given by
λ(t | Z(t)) = λ0(t)exp
{
β′0Z(t)
}
, (2.1)
where λ0(t) is the unspecified baseline hazard function and β0 is a p-dimensional vector of
unknown parameters.
Let C denote the censoring time and X = min(T, C) denote the observed time. Let N(t)
be the counting process and Y (t) = I(X > t) be the at-risk process. Further, let us define
∆ = I(T 6 C) as the indicator of failure. Each failure time is assumed to be subject to
independent right-censorship. Let (Xi,∆i,Zi); i = 1, 2, . . . , n denote the i-th independent
copy of (X,∆,Z) and τ denotes the study end point. The regression parameter can be
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estimated by the partial likelihood score function introduced by (Cox 1975) :
U(β) =
n∑
i=1
ˆ τ
0
(
Zi(t)− S
(1)(β, t)
S(0)(β, t)
)
dNi(t), (2.2)
where S(0)(β, t) = 1n
∑n
j=1 Yj(t)exp(βZj(t)) and S
(1)(β, t) = 1n
∑n
j=1 Yj(t)Zj(t)exp(βZj(t)).
Under some regularity conditions, the maximum partial likelihood estimator, βˆ, defined as
the solution to the score equation, U(β) = 0 converges to a normal distribution as n → ∞
with mean β0 and a variance which can be consistently estimated by −
[
δ
δβ′U(β) |β=βˆ
]−1
(Andersen and Gill 1982).
2.2 Case-Cohort Studies
Epidemiologic studies are considered to be one of the most reliable methods for assessing
the variation in rate of mortality and to study the effect of covariates on the rate in the
population. When the event of interest is rare or the relationship that is of interest is complex,
cohort studies would require large number of subjects and/or long periods of follow-up in
order to accumulate enough failures to have sufficient statistical power to make meaningful
conclusions. However, this would increase the cost of collecting such covariate information on
all subjects, if feasible. Prentice (1986) proposed the case-cohort design to reduce the number
of subjects for whom the covariate information is collected, hence reducing the overall cost.
This method involves the selection of a random sample from the entire cohort, which is called
the sub-cohort and the assembly of the covariate information on the individuals in this sub-
cohort as well as the subjects who experienced the event of interest during the follow-up
period. The sub-cohort also provides a basis for monitoring the covariates during the follow-
up of the cohort. Studying the relative risk process is quite natural in understanding the
effect of the covariate history on the event rates. Based on the relative risk regression model
(Cox 1972), the hazard function of the i-th subject, at time t, is modeled by
λ(t | Zi) = λ0(t)r {β0Zi(t)} , (2.3)
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where r(.) is a known function with r(0) = 1. The pseudo-likelihood function for the estima-
tion of β0 has the form :
L˜(β0) =
n∏
i=1
 rii∑
l∈R˜(ti)
rli

∆i
, (2.4)
where R˜(t) = D(t)∪ Sc, Sc is the set of all individuals in the sub-cohort, D(t) is the set
of all individuals who have observed a failure at time t. It can be written as D(t) =
{i | Ni(t) 6= Ni(t−)} and rli = Yl(ti)r {β0Zl(ti)}. Covariate information is assumed to be
available only for the set, K(t)∪ Sc at time t, where K(t) = {i | Ni(t) = 1}. The maximum
pseudo-likelihood estimate, βˆPL is defined by U˜(βˆPL) = 0 where U˜(β) is defined as
U˜(β) =
δ
δβ′
logL˜(β) =
n∑
i=1
U˜(β) =
n∑
i=1
∆i
cii − ∑
l∈R˜(ti)
bli∑
l∈R˜(ti)
rli
 , (2.5)
where bli = Yl(ti)Zl(ti)r {β0Zl(ti)}; cii = biir′ {β0Zi(ti)} and r′(t) = δδβ′ r(t). Prentice (1986)
showed that the variance of n−1/2U(β0) is given by
V˜ (β) = I(β) + 2
n∑
i=1
∆i∆˜(ti)
∑
k|tk<ti
∆kvki,
where I(β) = − δδβ′U(β), vki = −
∑
j∈R˜(ti)
(
Bk+bik−bjk
Rk+rik−rjk
)′ (
cji − BiRi
)
rjiR
−1
i , Ri =
∑
k∈R˜(ti) rki,
Bi =
∑
k∈R˜(ti) bki and ∆˜(t) = 1 if R˜(t) 6= Sc, 0, o.w. Hence, by Taylor series expansion, we
have the variance of n1/2
(
βˆPL − β0
)
is given by I(β0)
−1V˜ (β0)I(β0)−1. A natural estimator
of the cumulative baseline rate is proposed as
Λˆ0(t) = n˜n
−1
ˆ t
0
∑
l∈Sc
Yl(u)r
{
βˆ′PLZl(u)
}−1 dN¯(u),
where N¯(t) =
∑n
i=1 N¯i(t) and n˜ is the size of the random sub-cohort. Self and Prentice (1988)
noted that the efficiency of the relative risk parameter estimation depends on the number of
subjects experiencing the event.
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Self and Prentice (1988) developed the asymptotic distribution theory for the case-cohort
maximum pseudo-likelihood estimator and related quantities, with slightly different pseu-
dolikelihood and variance estimator from the ones proposed by Prentice (1986). In their
formulation of the risk set, only the sub-cohort individuals were considered, whereas in the
original Prentice (1986) paper, the risk set included a non-subcohort individual that fails at
a particular time point. In Self and Prentice (1988), they considered a similar relative risk
regression model as (2.3). The maximum pseudolikelihood estimator, βˆsp, is defined as the
solution to U(β) = δδβ′ logL˜(β) = 0, where we have
logL˜(β) =
∑
i∈C
ˆ τ
0
log
[
r
{
β′Zi(t)
}]
dNi(t)−
ˆ τ
0
log
∑
j∈Sc
Yj(t)r
(
β′Zj(t)
)
 dNi(t),
(2.6)
where C is the cohort and Sc is the subcohort of size n˜. Under some regularity conditions,
they proved that βˆsp converges in probability to β0 and n
−1/2U(β0) converges to a Normal dis-
tribution with mean zero and variance Σ(β0)+∆(β0), where Σ(β) = −limn→∞ 1n ∂
2
∂β∂β′ logL˜(β)
and ∆(β) consists of the contributions of the covariance among the components induced by
the random sampling and have a complicated expression. Hence, by the Taylor series expan-
sion, n1/2
(
βˆsp − β0
)
converges to a Gaussian distribution with mean 0 and covariance matrix
Σ(β0)
−1 + Σ(β0)−1∆(β0)Σ(β0)−1. Self & Prentice (1988), in their paper, propose consistent
estimators for Σ(β0) and ∆(β0). For the cumulative hazard function, Λ0(t), the proposed
estimator is given by
Λ0(t) = n˜n
−1
ˆ t
0
∑
l∈Sc
Yl(u)r
{
βˆ′spZl(u)
}−1 dN¯(u). (2.7)
n1/2
(
βˆsp − β0
)
and n1/2
(
Λ˜0(t)− Λ0(t)
)
are shown to converge weakly and jointly to Gaus-
sian random variables with zero mean and appropriate limiting covariances. It is also shown
that the Prentice’s (1986) estimator, βˆPL, and the Self and Prentice (1988) estimator, βˆsp, are
asymptotically equivalent provided an individual’s contributions to S(0) and S(1) are asymp-
totically negligible. The variance estimate that is proposed by Prentice (1986) is somewhat
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different from the one proposed by Self and Prentice (1988) but it has been shown to converge
to Σ(β0)
−1 + Σ(β0)−1∆(β0)Σ(β0)−1.
The variance estimators proposed in these two papers (Prentice 1986, Self and Pren-
tice 1988) are quite complicated. There have been many methods proposed to estimate the
variance of the estimators from the pseudo-likelihood. Wacholder et al. (1989) proposed a
bootstrap estimate of the variance of the covariate effect estimator. Their method echoes the
original case-cohort sampling scheme by resampling cases and sub-cohort controls separately.
This method is quite intensive computationally and would be quite time-consuming for large
studies but it avoids the direct computation of the covariance among score components.
Barlow (1994) proposed a robust estimator of the variance based on the influence of an
individual observation on the overall score. In the paper, the author assumed the standard
Cox Proportional Hazard regression model for the relative risk as seen in equation (2.3). The
conditional probability of failure at time tj is given by
pi(tj) =
Yi(tj)wi(tj)ri(tj)∑n
k=1 Yk(tj)wk(tj)rk(tj)
,
where the weight of the i-th subject at time t is given by
wi(t) =

1 if dNi(t) = 1,
m(t)
m˜(t) if dNi(t) = 0 and i ∈ Sc,
0 if dNi(t) = 0 and i 6∈ Sc
where m(t) is the number of disease-free individuals in the full-cohort who are at risk at time
t and m˜(t) is the number of disease-free individuals in the random sub-cohort who are at risk
at time t; ri(t) = exp{β′0Zi(t)}. One can easily note that Prentice (1986) used the weights
as binary indicator, it being = 1 for the i-th individual at time t if dNi(t) = 1 or i ∈Sc
and zero, otherwise. The Self & Prentice method used only the denominator summed over
the subcohort members in the likelihood. The estimation of the unknown parameter follows
directly from the log-likelihood of the conditional probability, i.e.,
∑n
i=1
´ τ
0 log (pi(t)) dNi(t) =
8
∑
t
∑n
i=1 dNi(t)log (pi(t)). The robust variance estimator that was proposed in the paper,
using the infinitesimal jackknife estimator, is given by Vˆ (β˜) = 1n
∑n
i=1 eˆieˆ
′
i where eˆi = β˜ −
β˜−(i) = I−1(β˜)cˆi(t0), ci(t0) is defined as the influence of an observation on the overall score
for a particular individual i at time t0 and eˆi is the change in β˜ if the i-th observation is
deleted. Further, ci(t0) is given by
ci(t0) =
ˆ t0
0
Yi(t) [dNi(t)− λi(t)] (Zi(t)− EZ(t)) dN¯(t),
where EZ(t) =
∑n
i=1 pi(t)Zi(t). I(β˜) is the information matrix generated by the pseudo-
likelihood function. We can estimate ci(t0) by cˆi(t0) =
´ t0
0 Yi(t) [dNi(t)− pˆi(t)]
(
Zi(t)− EˆZ(t)
)
×dN¯(t) and I(β˜) = ∑t∑i pˆi(t) [zi(t)− Eˆ(t)] [zi(t)− Eˆ(t)]′.
Lin and Ying (1993) tackled the problem of missing covariate data under Cox Propor-
tional Hazards regression model, of which the case-cohort design was a special case. They
proposed an approximated partial-likelihood score function for the estimation of the regres-
sion parameters. A new variance-covariance estimator which is much easier to calculate than
that Prentice (1986) and Self and Prentice (1988) was also proposed. The standard Cox PH
regression model was assumed, as given in equation (2.1). Suppose that the data consist of
iid random quintuplets (Xi,∆i, Zi(.), H0i(.),Hi(.)) where Zi(.) = {Zi1(.), Zi2(.), . . . , Z1p(.)}′
may not be fully observed and H0i(.) is an indicator function and Hi(.) is a p×p matrix with
the indicator functions H1i(.), H2i(.), . . . ,Hpi(.) being the diagonal elements. Considering the
original case-cohort design, we have Hi(.) = Ip which is the p×p identity matrix and H0i(.) is
1 if the i-th subject belongs to the sub-cohort and zero, otherwise. The approximate partial
likelihood score function can be written as
U˜H(β) =
n∑
i=1
∆iHi(Xi){Zi(Xi)− EH(β,Xi)},
where EH(β,Xi) =
S
(1)
H (β,Xi)
S
(0)
H (β,Xi)
; S
(d)
H (β, t) =
1
n
∑n
i=1H0i(t)Yi(t)exp{β′Zi(t)}Zi(t)⊗d. Let us
define the root of the estimating equation, U˜H(β) = 0, by β˜H . Under certain regularity
conditions, n1/2
(
β˜H − β0
)
can be shown to converge weakly to a Gaussian random variable
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with mean zero and variance given by A−1(β0)V (β0)A−1(β0), where An(β) = − 1n δδβ′ U˜H(β),
limn→∞An(β) = A(β), V (β) = E
(
W1(β)
⊗2),
Wi(β) = ∆iHi(Xi){Zi(Xi)−eH(β,Xi)}−
ˆ Xi
0
h(t)
h0(t)
H0i(t){Zi(t)−eH(β, t)}exp(β′Zi(t))dΛ0(t),
where eH(β, t) =
s
(1)
H (β,t)
s
(0)
H (β,t)
, s
(d)
H (β, t) = E(S
(d)
H (β, t)) for d = 0, 1; h(t) = E(Hi(t)), hk(t) =
E(Hki(t)) for all k = 0, 1, . . . , p. Therefore, The covariance matrix can be approximated by
A−1n (β˜H)Vˆ (β˜H)A−1n (β˜H) where Vˆ (β) =
1
n
∑n
i=1 Wˆi(β)
⊗2 and
Wˆi(β) = ∆iHi(Xi){Zi(Xi)− EH(β,Xi)}
− 1
n
n∑
l=1
∆lYi(Xl)H0i(Xl)Hl(Xl)exp{β′Zi(Xl)} × (Zi(Xl)− EH(β,Xl))
S
(0)
H (β,Xl)
.
For the case-cohort design, the variance estimator A−1n (β˜H)Vˆ (β˜H)A−1n (β˜H) is much easier to
calculate, even when we have time-dependent covariates, than Prentice (1986) and Self and
Prentice (1988). Another advantage of the proposed method is that incomplete covariate
information on the covariates is allowed. Furthermore, the form of the proposed estimator
remains unchanged under multiple sub-cohort augmentations. A natural estimator of the
cumulative hazard function is proposed as
Λ˜(β˜H , t) =
n∑
i=1
I(Xi 6 t)H0i(Xi)∆i
nS
(0)
H (β˜H , Xi)
=
ˆ t
0
H0i(u)dNi(u)
nS
(0)
H (β˜H , u)
.
The process n1/2
(
Λ˜(β˜H , t)− Λ0(t)
)
converges weakly to a Gaussian process with mean zero
and covariance function
ψ(t, s) =
ˆ t∧s
0
dΛ0(u)
s(0)(β0, u)
+J ′(t)A−1(β0)V (β0)A−1(β0)′J(s)−J ′(s)A−1(β0)G(t)−J ′(t)A−1(β0)G(s),
(2.8)
where J(t) =
´ t
0
s(1)(β0,u)dΛ0(u)
s(0)(β0,u)
and G(t) = E[
´∞
0
´ t∧v
0
H0i(u)exp{β′0Zi(u)}dΛ0(u)
s(0)(β0,u)
×
(
Hi(v)− H0i(v)h0(v) h(v)
)
(Zi(v)− eH(v))× Yi(v)exp{β′0Zi(v)}]. ψ(t, s) can be consistently es-
timated by simply replacing the parameters by the sample counterparts. The authors noted
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that this might not be the best choice if H0i(Xi) = 0 for most of the non-zero ∆i’s. Hence,
for the original case-cohort design, the authors recommend to use the formula proposed by
Self and Prentice (1988) as seen in equation (2.7) rather than this.
Chen and Lo (1999) proposed a class of estimating equations for case-cohort design based
on the partial likelihood score function, which lead to simple estimators that improve Pren-
tice’s pseudolikelihood estimator. The authors explored the usual Cox PH model (2.3), with
r(.) being replaced by exp(.) and did not include any time-dependent covariates. They
observed the triplets (Xi,∆i, Zi) for the i-th individual. One can note that
E(Z | X = t,∆ = 1) =
E
(
Zeβ
′ZI(X > t)
)
E (eβ′ZI(X > t))
=
pE
(
Zeβ
′ZI(X > t) | ∆ = 1
)
+ (1− p)E
(
Zeβ
′ZI(X > t) | ∆ = 0
)
pE (eβ′ZI(X > t) | ∆ = 1) + (1− p)E (eβ′ZI(X > t) | ∆ = 0) ,
(2.9)
where p = P(∆ = 1). Let F 1 and F 0 be the conditional joint distributions of (X, Y) given
∆ = 1 and ∆ = 0 respectively. Further, suppose that R1 is the index set of random sample
of k1 cases and R0 is the index set of random sample of k0 censored individuals. Then,
one can estimate F l, l = 0, 1 by the respective empirical counterpart, Rl. Hence, replacing
the population quantities by the empirical analogues, the authors proposed the following
estimating function :
U(β) =
∑
i∈R1
ˆ ∞
0
[
Zi −
(pˆ/k1)
∑
j∈R1t Zje
β′Zi + {(1− pˆ)/k0}
∑
j∈R0t Zje
β′Zi
(pˆ/k1)
∑
j∈R1t e
β′Zi + {(1− pˆ)/k0}
∑
j∈R0t e
β′Zi
]
dNi(t). (2.10)
The authors considered several cases with different estimates of p depending on how much
information one has about the data and considered the consistent estimator of the unknown
parameters, β0, and the corresponding covariance terms for the asymptotic distribution of
n1/2
(
βˆCL − β0
)
with mean zero. If the entire cohort is well-defined with n as the total
cohort size, n1 is the number of cases in the cohort and n0 is the number of censored subjects
and n∗0 is the number of censored subjects in the sub-cohort. Then the estimating function
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reduces to
U(β) =
n∑
i=1
ˆ ∞
0
[
Zi −
∑
j∈R1t Zje
β′Zi + (n0/n
∗
0)
∑
j∈R0t Zje
β′Zi∑
j∈R1t e
β′Zi + (n0/n∗0)
∑
j∈R0t e
β′Zi
]
dNi(t) = 0. (2.11)
The solution to this equation, βˆcl, is consistent for β0 and n
1/2
(
βˆcl − β0
)
converges to a
Gaussian distribution with mean zero and variance given by
σ2 =
1
n
Σ−11 +
(
1
n∗0
− 1
n
)
Σ−11
[
Σ−10 − pV1 −
1− p
p
E⊗20
]
Σ−11 ,
where Σ1 = var(W
∗), Σ0 = var(W ), V1 = var(W | ∆ = 1), E0 = E(W | ∆ = 0), W ∗ =
{Z − m(Y )}∆, W = ´∞0 {Z − m(t)}eβZI(Y > t)dΛ0(t), m(t) = E(Z | Y = t,∆ = 1).
Kulich and Lin (2000) demonstrated the use of case-cohort data in estimating the regression
parameter of an additive hazards regression model, where the conditional hazard function
given a set of the covariates is the sum of an arbitrary baseline hazard and a function of the
unknown regression parameter and the covariates. We have discussed this in details when
discussing the literature for additive rates models.
Chen (2001) proposed a more efficient estimator by using local averages type of weights.
The paper focuses on a unified approach for the parameter estimation of Cox PH model
under different cohort sampling schemes, like nested case control, case-cohort and classical
case-cohort methods. The sample reuse approach proposed via local averaging leads to more
efficient estimators and this method is applicable to more complex sampling designs. The
estimating equation they propose is the following :
U(β) =
n∑
i=1
ˆ ∞
0
[hi(t)−
∑n
j=1W
∗
j (t)hj(t)exp(β
′Zj(t))Yj(t)∑n
j=1W
∗
j (t)exp(β
′Zj(t))Yj(t)
]W ∗i (t)dNi(t) = 0, (2.12)
where Yj(t) = 1(Tj ∧ Cj ≥ t) when one has only one event, Zj(t) is the vector of co-
variates corresponding to the j-th subject, hi(.) are the sample analogues of a covariate-
related process and W ∗j (t) is the weight at time t. Chen & Lo considered the weights to
be W ∗j (t) = ∆j + (1 − ∆j)δjn0/n∗0, where ∆j is the 1(event occurs for the j-th subject),
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δj = 1(j-th individual is sampled), n0 & n
∗
0 is the number of censored individuals in the co-
hort and the subcohort, respectively. Chen (2001) proposed the following weight function,
W ∗j (t) = W
∗
j = δj/rn(Xj , δj), where Xj = Tj ∧ Cj (when we have only one event) and
rn(t, d) =
∑n
l=1 δl∆l1(xl ∈ [ti−1, ti])∑n
l=1 δl1(xl ∈ [ti−1, ti])
if d =1 and t ∈ [ti−1, ti]
=
∑n
l=1(1− δl)∆l1(xl ∈ [sj−1, sj ])∑n
l=1(1− δl)1(xl ∈ [sj−1, sj ])
if d =0 and t ∈ [sj−1, sj ],
where 0 = t0 ≤ t1 ≤ . . . ≤ tan = τ and 0 = s0 ≤ s1 ≤ . . . ≤ sbn = τ are two partitions
which satisfy certain conditions, resulting in more efficient estimation of the parameters. The
author noted that the existing work on case-cohort sampling on survival analysis is highly
dependent on the specific sampling design and the methods result in inefficient estimates of the
regression parameters. Under the regularity conditions, the solution to equation (2.12), βˆh,
is consistent for β0 and the asymptotic distribution of n
1/2
(
βˆh − β0
)
is Gaussian with mean
zero and variance Σ−1h,Z (Σh,h + Σ
∗
h) Σ
−1
h,Z with Σh,Z = cov(Mh˜,MZ˜), Σh,h = cov(Mh˜,Mh˜),
Σ∗hcov(Wh˜,Mh˜), Mh =
´ τ
0 h(t)dM(t), Wh˜ = (1/pi−1)(Mh˜−Moh˜), Moh˜ = E(Mh˜ | Y,∆), h˜(t) =
h(t)−E(h(t)). Kulich and Lin (2004) developed a class of weighted estimating equations with
time-dependent weight functions for stratified case-cohort designs. The authors in this paper
considered the Cox (1972) regression model as described in (2.3) with exp(.) as the function
r(.). They considered a cohort of n subjects who can be divided into K mutually exclusive
strata based on a discrete random variable V. They assumed that V affects the failure time
only through the covariates, i.e., T is independent of V given Z(.). The data observed is
the following : (Xki = Tki ∧ Cki,∆ki, Zki(t), 0 6 t 6 τ, Vki, ξki) for the individuals in the
sub-cohort and (Xki,∆ki, Zki(Xki)) for all the cases outside the sub-cohort. The estimating
equation is given by
U(β) =
K∑
k=1
nk∑
i=1
ˆ τ
0
[Zki(t)− EC(β, t)] dNki(t) = 0, (2.13)
where EC(β, t) =
S
(1)
C (β,t)
S
(0)
C (β,t)
, S
(d)
C (β, t) =
∑K
k=1
∑nk
i=1 %ki(t)Zki(t)Yki(t)e
β′Zki(t)∑K
k=1
∑nk
i=1 %ki(t)Yki(t)e
β′Zki(t) , %ik(t) = ∆ki + (1 −
∆ki)ξkiαˆk(t), which is based on the weights proposed by Kalbfleisch and Lawless (1988). ξi
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is the indicator that the individual is included in the sub-cohort and αˆk(.) is a function of
the controls (because of the separation between the cases and the controls). The authors
proposed a doubly weighted estimator
αˆk(t) =
{
nk∑
i=1
(1−∆ki)Aki(t)
}−1{ nk∑
i=1
ξki(1−∆ki)Aki(t)
}
,
where Aki(t) is a diagonal matrix with m potentially different random processes on the diag-
onal. Redefine the at-risk covariate average as EDW (β, t) = {S(0)DW (β, t)}−1S(1)DW (β, t) where
S
(1)
DW (β, t) and S
(0)
DW (β, t) are the matrix counterparts of S
(1)
C (β, t) and S
(0)
C (β, t), respec-
tively. Based on these, the authors showed that, under certain regularity conditions, βˆDW is
a consistent estimator of β0 and n
1/2
(
βˆDW − β0
)
converges to a Gaussian distribution with
mean 0 and variance I−1F + I
−1
F ΣDW I
−1
F , where IF =
´ τ
0
[
s(2)(β,t)
s(0)(β,t)
− e(β, t)⊗2
]
s(0)(β, t)dΛ0(t),
s(d)(β, t) = E(Zi(t)Yi(t)e
β′Zi(t)), d = 0,1,2; e(β, t) = s
(1)(β,t)
s(0)(β,t)
, ΣDW =
∑K
k=1 qk
1−αk
αk
Ek
{
(1−∆i)
´ τ
0
(
Rki(t)− µ−1k (t)Aki(t)ψk(t)
)
dΛ0(t)
}⊗2
with qk = P (V = k), αk = P (ξ =
1 | V = k), Rki(t) = (Zki(t)− e(β, t)) eβ′Zki(t)Yki(t), µk = E [(1−∆ki)Aki(t)] and ψk(t) =
E [(1−∆ki)Rki(t)].
Nan (2004) developed semi-parametric efficient estimators, obtained by solving the the
efficient score equation with the help of the Newton-Raphson algorithm. Lu and Tsiatis
(2006) proposed a general class of semi-parametric transformation model. They considered
weighted estimating equations for simultaneous estimation of the regression parameters and
the transformation function. The semi-parametric linear transformation model is specified by
H(T ) = −β′0Z + ,
where T is the survival time, H is an unknown monotone increasing function, β0 is the p-
dimensional unknown regression parameters and  is the error term which has a continuous
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distribution, independent of the censoring process and covariates. The corresponding esti-
mating equations are given by
n∑
i=1
pii
[
dNi(t)− Yi(t)dΛ{H(t) + β′Zi}
]
= 0 (t > 0), H(0) = −∞,
n∑
i=1
ˆ ∞
0
Zipii
[
dNi(t)− Yi(t)dΛ{H(t) + β′Zi}
]
= 0.
The authors showed that the resulting regression estimators are asymptotically normal, with
a closed form variance-covariance matrix that can be consistently estimated by the usual
plug-in estimators. Lu and Shih (2006) extended the case-cohort design to clustered data,
where each clustered comprises of correlated individuals, whose structure of dependence is
kept unspecified. The estimating equation is defined as
U(β) =
n∑
i=1
m∑
j=1
[
Zij(Xij)− E¯(β,Xij)
]
δij ,
where E¯(β, t) = S¯
1(β,t)
S¯0(β,t)
, S¯d(β, t) =
∑n
i=1
∑m
j ∆ijYij(t)e
β′Zij(t)Zij(t)
⊗d, ∆ij is an individual
indicator that equals 1 if individual (i, j) is selected for the subcohort, and 0, otherwise and
δij is the indicator of whether the j-th individual in the i-th cluster observes the event or
is censored. Kang and Cai (2009a) considered marginal hazards model for case-cohort data
with multiple disease outcomes. Time to different events are modeled simultaneously in order
to compare the effect of a risk factor on different types of diseases. They have proposed valid
statistical methods that take the correlations among the outcomes from the same subject into
account. They have considered the multiplicative intensity process model, which is specified
by
λik(t | Zik(t)) = Yik(t)λ0k(t)eβ′0Zik(t),
where λ0k(t) is an unspecified baseline hazard function for disease outcome k and β0 is the
vector of unknown parameters. Defining the estimating equation, similar to (2.13), it is shown
that the parameter estimators are consistent and asymptotically normal and the correspond-
ing variance-covariance term can be easily replaced by the sample counterparts. Zhang et al.
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(2011) developed estimating equation for clustered failure time data assuming a marginal haz-
ards model, with a common baseline hazard and common regression coefficient across clusters.
One of the key advantages of the case-cohort design is its ability to use the same sub-cohort for
several diseases or for sub-types of diseases (Prentice 1986, Wacholder et al. 1989, Langholz
and Thomas 1990, Wacholder 1991). The availability of the case-cohort sub-cohort may be
useful for study monitoring and can be considered to be a natural comparison group at all
disease occurrence times for all of the different diseases. Chen and Chen (2014) extended
the case-cohort design to recurrent events with specific clustering feature using a modified
Cox-type self- exciting intensity model. Under this model, conditional on the covariates and
history of events upto time t, the intensity function of N(.) (simple point process) is given by
λ(t) = µ(t)exp{Ψ(t, θ)},
where Ψ(t, θ) = β′Z(t) + φ(t), µ(t) is the unspecified baseline intensity, Z(t) is the time-
varying p-dimensional vector of covariate, β is the vector of regression coefficients, φ(t) is
a self-exciting term depending on past events of the process and θ is the combined finite
dimensional parameters to be specified. The pseudo-likelihood score equation for θ is given
by
log L(θ) =
n∑
i=1
ˆ Ci
0
[
ψi(t, θ)−
∑n
j=1 jψj(t, θ)Yj(t)exp{Ψj(t)}∑n
j=1 jYj(t)exp{Ψj(t)}
]
dNi(t) = 0, (2.14)
where ψ(t, θ) = ∂∂θΨ(t, θ). The authors went onto show the asymptotic properties of the
solution to the above equation, under certain regularity conditions.
2.3 Recurrent Events Data
In many longitudinal studies and for several medical conditions, subjects experience re-
peated or recurrent events. Some examples include the occurrence of new tumors in patients
with superficial bladder cancer (Byar, 1980), recurrent seizures in epileptic patients (Albert
1991), rejection episodes in patients receiving kidney transplants (Cole et al. 1994), repeated
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infections in HIV-patients (Li and Lagakos 1997), repeated cardiovascular events in patients
(Cui et al. 2008). In this section, we look at the different ways one can model the recurrent
event data and the assumptions that are attached to it. In the following subsections, we will
summarize the marginal models (more specifically, intensity models and rate & mean mod-
els) which do not assume anything about the nature of the dependence among the recurrent
events and the frailty model which explicitly specifies the relationship among the repeated
events.
2.3.1 Marginal Models using Multiplicative Models
Prentice et al. (1981) considered two stratified proportional hazards type of regression
models for modeling the intensity function in terms of the covariates and the failure time
history. The main diference between the two models is that one of them specifies the baseline
intensity function as a function of time from the beginning of study, while the other specifies
it as a function of time from the subject’s immediately preceding failure. Let Z(t) = {z(u) |
u 6 t} be the covariate process upto time t and N(t) = {n(u) | u 6 t}, where n(u) is
the number of failures on a study subject prior to time t. The counting process N(t) is
equivalent to random failure time, T1, T2, . . . , Tn(t) in [0, t). The authors define the hazard
or the intensity function at time t as the instantaneous rate of failure at time t given the
covariate and counting process.
λ{t | N(t), Z(t)} = lim
δt→0
P (t 6 Tn(t)+1 6 t+ δt | N(t), Z(t))
δt
⇒ λ{t | N(t), Z(t)} = λ0s(t)eβ0sz(t), time from the beginning of study (2.15)
or λ{t | N(t), Z(t)} = λ0s(t− tn(t))eβ0sz(t), time from the immediately preceeding failure,
(2.16)
where λ0s(t) (s = 1, 2, . . .) are arbitrary baseline intensity functions and the stratification
variable, s = s(N(t), Z(t)) may change as a function of time for a particular subject and β0s
is the stratum specific regression coefficient. The authors propose two different likelihood
functions for the two quite different models considered. The likelihood function for the model
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where they studied the time from the beginning of the study is given by
L(β0) =
∏
s>1
ds∏
i=1
exp[β′0zsi(tsi)]∑
l∈R(tsi,s) exp[β
′
0zl(tsi)]
,
where R(t, s) is the risk set at time t for the s-th stratum. For the time from the last observed
failure, we have
L(β0) =
∏
s>1
ds∏
i=1
exp[β′0zsi(tsi)]∑
l∈R˜(usi,s) exp[β
′
0ztl+u+si(tsi)]
,
where R˜(t, s) is the risk set at gap-time t stratum-s. tl is the last failure time on subject l
prior to entry into stratum s. The authors note that ordinary asymptotic likelihood methods
can be applied to both the likelihood functions (Cox 1975) though consideration should be
given to the size and to the number of failures in each stratum. Andersen and Gill (1982)
explored the Cox PH regression model (as in equation (2.1)). The authors extended the Cox
PH model for a single failure time data where the effect of the covariate is proportional on
the hazard, to the multivariate counting process, where the effect of the covariate process
is proportional on the intensity function. They showed that Mi(t) = Ni(t) −
´ t
0 dΛi(t) are
local square-integrable martingales on the time interval [0, 1]. The solution to the estimating
equation U(β) = 0 is denoted by βˆ, where U(β) is defined as in (2.2), with Yi(t) defined as
an indicator function showing whether the individual is still under observation or not. They
showed that βˆ is consistent for β0 and n
−1/2U(β0) converges to a Gaussian distribution with
mean zero and variance, Σ(β0), where Σ(β) =
´ 1
0
(
s(2)(β,t)
s(0)(β,t)
− s(1)(β,t)
s(0)(β,t)
⊗2)
s(0)(β, t)λ0(t)dt.
Wei et al. (1989) noted that many survival studies record the times to two or more failures
per subject, where the failure types might be completely different or they may be repetitions
of the same type. The authors proposed to model the marginal distribution of each failure
time variable with a Cox-type PH regression model. In this approach, no structure is imposed
on the dependence of the different failure times for each subject. The hazard function for the
k-th type of failure time of the i-th subject is given by
λk(t | Zki(t)) = λk0(t)eβ0kZki(t), k = 1, 2, . . . ,K, i = 1, 2, . . . , n. (2.17)
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The k-th failure-specific partial likelihood (Cox, 1975) is defined as
Lk(β0) =
n∏
i=1
exp[β′0Zki(Xki)]∑
l∈R(Xki) exp[β
′
0Zli(Xki)]
,
where R(t) = {i : Xki > t} is the set of individuals who are at risk of observing the k-th type
of failure just prior to time t. Under certain regularity conditions, the solution to the partial
likelihood equation, ∂Lk(β)∂β = 0, given by βˆk, will be consistent for the unknown parameter,
βk0. n
1/2(βˆ − β0) = n1/2(βˆ1 − β01, βˆ2 − β02, . . . , βˆK − β0K) converges asymptotically to a
Normal distribution with zero-mean and variance Q with elements equal to Dij(βˆi, βˆj), i,
j = 1, 2, . . . ,K and Dij(βˆi, βˆj) can be consistently estimated by Aˆi(βˆi)
−1Bˆ(βˆi, βˆj)Aˆj(βˆj)−1
with Aˆi(βi)
−1 = 1n
∑
k ∆ik
[
S(2)(βi,Xik)
S(0)(βi,Xik)
− (S(1)(βi,Xik)
S(0)(βi,Xik)
)⊗2
]
, Bˆ(βˆi, βˆj) =
1
n
∑
kWik(βˆi)Wjk(βˆj)
′,
Wik(βk) =
[
∆ik −
∑n
m=1
∆imYik(Xim)e
β′kZik(Xim)
S(0)(βi,Xik)
]
×
[
Zik(Xim)− S
(1)(βi,Xik)
S(0)(βi,Xik)
]
,
S(d)(β, t) = 1n
∑n
i=1 Zi(t)Yi(t)e
β′Zi(t).
Pepe and Cai (1993) looked at different methods to display and analyze multiple failure
time data. The authors looked at the rate function. They defined the rate functions as
rF (t) = lim∆→0 1∆P [event occurred in (t, t+ ∆) | at risk and no event observed at t] (rate of
first infection) and rR(t) =
lim∆→0 1∆P [event occurred in (t, t + ∆) | at risk and event previously observed at t] (rate of
recurrent infection). Suppose that rF and rR are functions of time that involve certain
parameters, α and γ as rFα and r
R
γ respectively. The likelihood for α is given by
L(α) =
∏
ti∈D
rFα (ti)exp
{
−
ˆ ti
0
rFα (u)du
}
×
∏
tj∈D
rFα (tj)exp{−
ˆ tj
0
rFα (u)du}
 ,
where D is the set of times when the event occurred for the first time; O is the set of
observation times for subjects censored or lost to follow-up due to competing risk events.
The corresponding score function is given by
SF (α) =
ˆ
fα(t)
{
dNF (t)− Y F (t)rFα (t)dt
}
, (2.18)
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where fα(t) =
∂logrFα (t)
∂α , N
F (t) = the number of individuals who had the event observed by
time t, and Y F (t) = the number of individuals under observation and who had not observed
any prior event at t. By definition, E
(
dNF (t)/Y F (t) | Y F (t)) = rFα (t)dt. The authors note
that under mild regularity conditions, the solution to the estimating equation (2.18) should
be a consistent estimator of α, even when fα(t) is somewhat different from
∂logrFα (t)
∂α . They
further noted that setting fα(t) at this quantity would yield the most efficient estimator.
The authors also observed that likelihood-based estimation of rRγ would require specifying a
model for the joint distribution of recurrence times within the same individual, but one can
get consistent estimates of γ from an estimating equation like (2.18).
SR(α) =
n∑
i=1
SRi (α) =
n∑
i=1
ˆ
Iγ(t)
{
dNRi (t)− Y Ri (t)rRα (t)dt
}
= 0, (2.19)
where NRi (t) is the number of events observed by time t for the i-th individual with previously
observed events, Y Ri (t) is the indicator that the i-th individual, with previously observed
events, is at-risk of an event at t, and Iγ(t) is some bounded deterministic vector-valued
function whose dimension is the same as the dimension of γ. The authors showed that the
solution to the estimating equation (2.19), γˆ, is consistent estimator of γ and n−1/2SR(t) D−→
N(O, V (t)), where V (t) is the variance- covariance matrix for SRi (t) and one can get the
asymptotic distribution of γˆ from Taylor series expansion.
Lawless and Nadeau (1995) presented non-parametric methods and regression models to
estimate the cumulative mean function (CMF), defined as M(t) = E(Ni(t)), where Ni(t) is the
number of events occurring in time [0, t]. The main objective is to estimate M(t) based on the
observed times times, which are defined as ti1 6 ti2 6 . . . 6 tiri for the i-th individual over the
interval [0, τi] (i = 1,2,. . ., k) and the individuals are independent. For simplicity, the authors
presented the results in a discrete-time framework. Define δi(t) = 1, if t 6 τi, 0 o.w., to denote
whether an individual observed an event. Further, let ni(t) > 0 denote the number of events
that occur at time ‘t’ for the i-th individual so that m(t) = E{ni(t)} and M(t) =
∑t
s=0m(s).
The maximum likelihood estimator the authors proposed is given by Mˆ(t) =
∑t
s=0
n.(s)
δ.(s)
, 0 6
t 6 τ = maxi(τi), where n.(t) =
∑k
i=1 δi(t)ni(t) and δ.(t) =
∑k
i=1 δi(t). The authors proposed
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the variance of Mˆ(t) as var(Mˆ(t)) =
∑k
i=1
∑t
s=0
∑t
u=0
δi(s)δi(u)
δ.(s)δ.(u)
cov(ni(s), ni(u)). The authors
further extended the idea to develop similar approach for a flexible family of regression models.
The following regression model
E(ni(t)) = mi(t) = m0(t)Pi(t)g(zi(t), β0)
was considered, where β0 is a p-dimensional vector of regression parameters, g is a positive
valued function, m0(t) > 0 is the baseline mean function and Pi(t) is some known function.
Noting that m0(t) =
n.(t)
R(t,β0)
and R(t, β0) =
∑k
i=1 δi(t)gi(t), the estimating equation for β is
given by
∑k
j=1
∑
l∈Dj
{
∂loggl(tj)
∂β −
∂R(tj ,β)
∂β
}
= 0, where Dj represents the set of individuals
with events at tj , including repetitions for an individual at that time. Under mild conditions,
the solution to this estimating equation, βˆ, is consistent for β0. Defining
Wi(β, s) =
∂loggi(s)
∂β
− ∂logR(s, β)
∂β
,
Bˆ1i(t) =
t∑
s=0
δi(s)Wi(βˆ, s)[ni(s)− gˆi(s)mˆ0(s)],
where gˆi(s) = Pi(s)g(xi, βˆ), Bˆ1 =
1
k
∑k
i=1 Bˆ1iBˆ
′
1i and Aˆ1 =
1
k
∑k
i=1
∑τ
s=0 δi(s)mˆ0(s)
∂gˆi(s)
∂βˆ
×Wi(βˆ, s)′, we have k1/2
(
βˆ − β0
)
converges asymptotically to a Gaussian distribution with
mean 0 and a sandwich variance term ˆvar(βˆ) = Aˆ−11 Bˆ1(Aˆ
−1
1 )
′. Lawless (1995) discussed
different ways of introducing covariates in the analysis of recurrent events and the distinction
between rate (and mean) function and intensity functions event process characterizations.
The author defines the rate of occurrence function is r(t) = ∂E(N(t))∂t and the mean function
is given by
E [N(t)] =
ˆ t
0
r(u)du (2.20)
where r(t) can be the intensity function (but usually they are quite different). Covariates can
be introduced into the rate or mean functions as r(t; z) = ρ(t)φ(z). Note that this type of
marginal model is different from Wei et al. (1989), where they have modeled the distribution
of time to the j-th event (j = 1,2,. . .) and the hazard function is given by hj(t; z) = hoj(t)e
βz.
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Renewal type of models based on intervals between successive events would be characterized
by
λ(t;Hit, zi) = hj(t− tij)exp(βjzi),
where Ni(t−) = j (Gail et al. 1980) specifies that for each subject the times to the first event
and between successive events are independent random variables and they do not necessarily
have the same distribution; Ht = {N(s) | s < t} is the history of the process up to time t; tij
is the j-th observed event time for the i-th individual and βj are the regression parameters.
The authors used Lawless and Nadeau’s (1995) approach to estimate β, yielding R0(t) =´ t
0
dN(u)∑n
i=1 δi(u)φi(zi,β)
and N(u) is the total number of events observed at u. The authors further
proposed the joint distribution of n1/2
(
βˆ − β, Rˆ0(t)−R0(t)
)
. They noted that the marginal
analyses for means are quite easy to interpret and may be made robust to other assumptions
about the recurrent event process, provided that the observation period [0, τi] for the i-th
individual (for all i) are independent of the corresponding event process.
Cook et al. (1996) investigated robust non-parametric tests, in the sense, that these meth-
ods do not rely on distributional assumptions of the event-generating process, for recurrent
event data. They have further explored a family of generalized pseudo-score statistics (Lawless
and Nadeau 1995) in which weight functions may be chosen to generate tests sensitive to var-
ious types of departure from the null hypothesis (which states that the mean functions for the
treatment and control groups are identical). Denote Ni(t) as the number of events experienced
by the i-th subject and t is the time on the study; dNi(t) = limδt→0 [Ni(t)−Ni(t− δt)]. Yi(t)
be an indicator variable which takes value 1 if subject i is observed to be at risk at time t, and
is zero, otherwise and Λi(t) = E{Ni(t)}. The authors note that Nelson (1988) and Lawless
and Nadeau (1995) have stated the well known non-parametric Nelson-Aalen estimator,
Λˆ(t) =
n∑
i=1
ˆ t
0
Yi(u)dNi(u)∑n
j=1 Yj(u)
=
ˆ t
0
dN.(u)
Y.(u)
.
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Under mild conditions, the results in Lawless & Nadeau (1995) can be extended to get
σ(t, s) = n
n∑
i=1
[ˆ t
0
ˆ s
0
Yi(u)Yi(v)
Y.(u)Y.(v)
cov(dNi(u), dNi(v))
]
,
where σ(t, s) = ncov(Λˆ(t), Λˆ(s)), Y.(u) > 0, 0 < u 6 max(t, s). Assuming that Y.(u) → ∞
as n → ∞ for all u ∈ (0,max(t, s)] and σ(t, s) converges to a positive definite limit, Λˆ(t) is
consistent for Λ(t) and σ(t, s) would be estimated by
σˆ(t, s) = n
n∑
i=1
[ˆ t
0
ˆ s
0
Yi(u)Yi(v)
Y.(u)Y.(v)
(dNi(u)− dΛˆ(u))(dNi(v)− dΛˆ(v))
]
.
The authors showed that under some additional conditions, n1/2{Λˆ(t)−Λ(t)}, t > 0 converges
to a mean zero Gaussian process with covariance function equal to σ(t, s) over some inter-
val 0 < t, s,6 τ . The authors also considered stratified designs and the forms are natural
extensions of the above. Chang and Wang (1999) focused on conditional regression anal-
ysis, given the ordinal nature of recurrent events per subject. A semi-parametric hazards
model, including the structural and episode specific parameters considered as stratification
variable, has been proposed for modeling the data. Spiekerman and Lin (1999) proposed a
Cox-type regression model to model the marginal distribution of multivariate failure time
data. They used different baseline hazard functions for different failure types and proved that
the maximum quasi-partial-likelihood estimator of the regression parameters are consistent
and asymptotically normal. Lin et al. (1999) proposed a simple non-parametric estimator for
the multivariate distribution function of the gap times between successive events of the same
type, with each individual experiencing multiple repetitions of the same, when the follow-up
time is subject to right censoring.
Lin et al. (2000) provided the rigorous justification for the methods outlined in Pepe and
Cai (1993) and Lawless and Nadeau (1995) papers. The authors note that the main difference
between the Andersen and Gill (1982) paper and the above mentioned papers is the following
condition which implies that all the influence of prior events on future recurrence is through
23
the time varying covariates at time, t.
E(dN∗(t) | Ft−) = E(dN∗(t) | Z(t)),
where N∗(t) is the number of events that occurred over the interval [0, t], Z(t) is the covariate
process and Ft is the σ-field generated by {N(s), Z(s) | 0 6 s 6 t}. The authors recommended
to relax this assumption because the dependence of the recurrent events may not be adequately
captured by the time-varying covariates and there was no method at the time to verify the
assumption. Defining E(dN∗(t) | Z(t)) = dµz(t), the model that the authors worked with is
dµz(t) = exp{β′0Z(t)}dµ0(t), (2.21)
where µ0(t) is a known continuous function. N
∗(t) would not be fully observed as the subjects
are followed for a limited amount of time. Let C denote the censoring variable and it is
assumed that the censoring mechanism is independent in the sense that E(dN∗(t) | Z(t), C >
t) = E(dN∗(t) | Z(t)). N(t) = N∗(t ∧ C) and Y (t) = I(C > t). Hence for each individual,
the observable data is (Ni(.), Yi(.), Zi(.)). The partial likelihood score function is given by
U(β, t) =
n∑
i=1
ˆ t
0
{Zi(u)− E(β, t)}dNi(u),
where E(β, t) = S
(1)(β,t)
S(0)(β,t)
, S(d)(β, t) = 1n
∑n
i=1 Yi(t)Zi(t)exp{β′Zi(t)}, d = 0,1,2. Note that, the
estimating equation would be given by U(β, τ) = 0. It is shown by using empirical processes
theory that the solution to the estimating equation, βˆ, converges almost surely to β0 and
n1/2U(β0, t) (0 6 t 6 τ) converges weakly to a zero-mean Gaussian process with covariance
function
Σ(t, s) = E
[ˆ t
0
{Zi(u)− e(β0, u)}dMi(u)
ˆ s
0
{Zi(v)− e(β0, v)}′dMi(v)
]
,
where dMi(t) = I(Ci > t) [dN∗i (t)− exp{β′0Zi(t)}dµ0(t)] and e(β, t) = s
(1)(β,t)
s(0)(β,t)
, s(d)(β, t) =
E(S(d)(β, t)). Further, n1/2(βˆ−β0) converges weakly to Gaussian distribution with mean zero
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and variance Γ = A−1ΣA−1, where A = E
{´ τ
0 (Zi(t)− e(β, t))⊗2Yi(t)exp{β′0Zi(t)}dµ0(t)
}
,
which is also positive definite. The Aalen-Breslow type estimator is used to estimate µ0(t)
and is defined as µˆ0(t) =
´ t
0
dN¯(u)
nS(0)(βˆ,u)
, t ∈ [0, τ ] with N¯(t) = ∑ni=1Ni(t). The covariance
matrix would then be estimated by Γˆ = Aˆ−1ΣˆAˆ−1, Aˆ = − 1n ∂U(βˆ,τ)∂β′ = 1n
∑n
i=1
´ τ
0 {Zi(t) −
E(βˆ, t)}dµˆ0(t), Σˆ = 1n
∑n
i=1
´ τ
0 {Zi(u)−E(βˆ, u)}dMˆi(u)
´ τ
0 {Zi(v)−E(βˆ, v)}′dMˆi(v) and Mˆi(t)
= Ni(t)−
´ t
0 Yi(u)exp(βˆ
′Zi(u))dµ0(u). The authors proceeded further to incorporate a random
weight function, Qˆ(β, t), which is non-negative, bounded and monotone in t and converges
almost surely to a continuous deterministic function, q(t), t ∈ [0, τ ]. The terms are similar
to the ones shown with a q(.) term in them. Further, it is shown that n1/2{µˆ0(t)− µ0(t)} is
asymptotically equivalent to n−1/2
∑
Ψi(t) where
Ψi(s) =
ˆ s
0
dMi(t)
s(0)(β0, t)
− h′(β0, t)A−1
ˆ τ
0
{Zi(t)− e(β0, t)}dMi(t),
h(β0, t) =
´ t
0 e(β0, u)dµ0(u), and the covariance function is given by ξ(t, s) = E(Ψ(t)Ψ(s)).
Pen˜a et al. (2001) derived Nelson-Aalen and Kaplan-Meier type of estimators for the non-
parametric estimator of the cumulative distribution function of the time to occurrence of
recurrent events, in presence of censoring.
Cai and Schaubel (2004) considered modeling the rate function for the recurrent events,
when there are different types of events. The rate function corresponding to the k-th event
type is E(dN∗ik(t) | Zik) = g(β′0Zik)dµ0k(t), where N∗ik(t) =
´ t
0 dN
∗
ik(u) is the number of events
of type k at time t for the i-th subject. Further, let Cik and Yik(t) = I(Cik > t) be indicator
functions denoting the event-type-specific censoring time and at-risk function, respectively.
Hence, the observed process is denoted by Nik(t) =
´ t
0 Yik(u)dN
∗
ik(u). They proposed a
slightly different estimating equation, analogous to generalized estimating equation (Liang
and Zeger 1986).
U(β) =
n∑
i=1
K∑
k=1
ˆ τ
0
Zik(t)
g(1)(β′Zik(t)
g(β′Zik(t)
[
dNik(t)− Yik(t)g(β′Zik(t))dµ0k(t)
]
= 0 (2.22)
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and
∑n
i=1
´ s
0 [dNik(t)− Yik(t)g(β′Zik(t))dµ0k(t)] = 0 ∀s ∈ (0, τ ], where P (Yik(τ) = 1) > 0
∀k = 1, 2, . . . ,K. The authors showed that the solution to the estimating equation, βˆ,
would be a consistent estimator of β0 and n
1/2
(
βˆ − β0
)
converges weakly to a Gaussian
distribution with mean zero and variance Σ(β0), where Σ(β) = A(β)
−1V (β)A(β)−1 with
A(β) =
∑K
k=1
´ τ
0 vk(bz, t)s
(0)
k (β0, t)dµ0k(t), where vk(β, t) =
s
(2)
k (β,t)
s
(0)
k (β,t)
− ( s
(1)
k (β,t)
s
(0)
k (β,t)
)⊗2, s(d)k (β, t) =
E(S
(d)
k (β, t)) and S
(d)
k (β, t) =
1
n
∑n
i=1 Yik(t)Zik(t)e
β′Zik(t), for d = 0,1,2;
V (β) = E
[
(
∑K
k=1 U1k(β))
⊗2
]
with Ui,k(β) =
´ τ
0
(
Zik(t)
g(1)(β′Zik(t)
g(β′Zik(t)
− s
(1)
k (β,t)
s
(0)
k (β,t)
)
dMik(t, β),
dMik(t, β) = dNik(t) − Yik(t)g(β′Zik(t))dµ0k(t). Schaubel and Cai (2005) proposed meth-
ods of estimating parameters in two semi-parametric proportional rates/means models for
recurrent events with clustering among subjects. One of the models considered the baseline
rate function to be common across clusters, while the other model had cluster-specific baseline
rates. All these methods have looked at the marginal distribution of the rate function or the
mean function (and sometimes, the intensity function). Huang and Chen (2003) investigated
a marginal proportional hazards model for gaps between recurrent events. They also estab-
lished a connection between the gap times and the clustered data with informative cluster
size.
2.3.2 Frailty Models
The marginal models discussed in the previous section does not explicitly model the intra-
subject correlation. When one in interested in the effect of the risk factors on the failure times,
rather than the correlation among the events for each subject, the marginal model approach
suits this purpose quite well. However, in some situations, the strength and nature of depen-
dencies within each individual’s recurrent event times might be of interest and for such cases,
the frailty models have been developed and studied extensively in the literature. The frailty
model explicitly formulated the underlying dependence structure through an unobservable
random variable. This unknown quantity is called the frailty. The key assumption is that
the individual failure times are independent conditional on the frailty term for each individ-
ual. Considering the Cox PH model, the intensity of the i-th individual for the k-th event,
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conditional on the frailty term, wi would be given by
λi(t | wi) = wiλ0(t)exp(β′0Zi(t)), (2.23)
where the frailty terms are independent and identically distributed, having some parametric
distribution. Various choices are possible for the density of the frailty model, including the
positive stable distribution, inverse-Gaussian distribution, log-normal distribution, the most
common being the gamma distribution, because of mathematical convenience.
The parameter estimates are obtained through the EM algorithm, using the partial like-
lihood in the maximization step (Klien 1992). Therneau and Grambsch (2001) showed that
another approach to estimate the distribution of the shared frailty would be to use penalized
partial likelihood. One important thing to note is that in equation (2.23), β0 is to be inter-
preted conditional on the frailty term. There has been extensive debate over which method
is more naturally suited for correlated data. The marginal modeling approach does not de-
pend on any models for the underlying correlation structure and would result in more robust
results under misspecification of the correlation structure. On the other hand, if it is possible
to learn more about the structure, one might prefer the frailty model to get more efficient
estimators. When the main purpose of the analysis is to model the effect of the covariates
and the dependence can be treated as a nuissance, it is more preferable to use the marginal
models, whereas if the interest lies in the nature of the dependency and quantifying that,
the conditional frailty model would be much more sensible. Hence, the choice of the type of
model depends on the goal of the study.
2.4 Additive Rates Models for Marginal Analysis
The models that have been discussed thus far assumes multiplicative risk models as the
effect of the covariates is multiplicative. In epidemiological studies, one might be interested
in the risk difference, rather than the risk ratio. The risk difference can be translated directly
into the number of disease that would be avoided by removing a particular exposure (Kulich
and Lin 2000). In certain settings, for example, in studies of health care utilization, absolute
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covariate effects are of direct interest. Based on an additive model, the predicted change in
rate attributable to a covariate can be easily predicted without information on the baseline
cost. The cost savings associated with a proposed intervention program in health intervention
studies can be directly calculated from an additive model, whereas information on baseline
cost is required if a multiplicative model is fitted. Further, the effect is not directly represented
by the regression coefficient in the multiplicative model. When one is interested in the risk
difference as the measure of interest, the additive rates model provides a good alternative to
the widely studied Cox (1972) proportional hazards model. Since temporal effects are not
assumed to be proportional for each covariate, the additive risk model would be more useful
in providing information about the temporal influence of each covariate which is not available
from the Cox PH model. Specifically, in studies of excess risk, where the background risk
and the excess risk can have very different temporal forms, additive risk models seem to be
biologically more plausible than proportional hazard models (Huffer and McKeague 1991).
Under the additive risk model, the hazard function for the failure time, T associated with
Z(.) takes the form
λ(t | Z) = λ0(t) + β′0Z(t), (2.24)
where λ0(t) is the unspecified baseline hazard function and β0 is the p-dimensional vector of
regression parameters. Lin and Ying (1994) were the first to develop semi-parametric esti-
mating equation for equation (2.24) along with the asymptotic distribution. They proposed
to estimate β0 using the following estimating equation which mimics the partial likelihood
score function for the additive hazards model.
U(β) =
n∑
i=1
ˆ τ
0
[
Zi(t)− Z¯(t)
] {
dNi(t)− Yi(t)β′Zit
}
, (2.25)
where Z¯(t) =
∑n
i=1 Yi(t)Zi(t)∑n
i=1 Yi(t)
. One can easily obtain βˆ by solving equation U(β) = 0 and it is
given by
βˆ =
[
n∑
i=1
ˆ τ
0
Yi(t)
{
Zi(t)− Z¯(t)
}⊗2
dt
]−1 [ n∑
i=1
ˆ {
Zi(t)− Z¯(t)
}
dNi(t)
]
. (2.26)
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Under some regularity conditions, βˆ is a consistent estimator of β0 and the asymptotic dis-
tribution of n1/2(βˆ − β0) is p-variate Gaussian with mean zero and sandwich variance term
which can be consistently estimated by A−1BA−1 where
A =
1
n
n∑
i=1
ˆ τ
0
Yi(t)
{
Zi(t)− Z¯(t)
}⊗2
dt, B =
1
n
n∑
i=1
ˆ τ
0
{
Zi(t)− Z¯(t)
}⊗2
dNi(t).
The estimators for the baseline cumulative hazard function, Λ0(t), and the survival function,
S(t, Z), were proposed and their asymptotic properties were explored. To ensure mono-
tonicity, modified estimators of the above quantities, Λˆ∗0(t) = maxs6t Λˆ0(s) and Sˆ∗0(t, Z) =
maxs6t Sˆ0(s, Z) have also been proposed. These estimators were shown to be asymptotically
equivalent to the original estimators.
Kulich and Lin (2000) studied additive hazards models in case-cohort design scheme. They
proposed a weighted estimating equation by modifying (2.25) as
UW (β) =
n∑
i=1
ρi
ˆ τ
0
(
Zi(t)− Z¯W (t)
) [
dNi(t)− Yi(t)β′Zi(t)dt
]
, (2.27)
where
Z¯W (t) =
∑n
i=1 ρiYi(t)Zi(t)∑n
i=1 ρiYi(t)
, ρi = ∆i + (1−∆i) ξi
pi
, pi = P (ξi = 1).
The resulting estimator, βˆH , has the following closed form :
βˆW =
[
n∑
i=1
ρi
ˆ τ
0
Yi(t)
{
Zi(t)− Z¯W (t)
}⊗2
dt
]−1 [ n∑
i=1
ˆ {
Zi(t)− Z¯W (t)
}
dNi(t)
]
.
Under certain regularity conditions, they showed that βˆW is consistent for β0 and n
1/2(βˆW −
β0) has a Gaussian distribution with mean zero and sandwich variance term, corresponding
to two different sampling situations. They further proposed an estimator of the cumulative
hazard function as
ΛˆW0(t) =
ˆ
t
∑n
i=1 dNi(u)∑n
i=1 ρiYi(u)
−
ˆ t
0
βˆW Z¯W (t)dt.
n1/2(ΛˆW0(t) − Λ0(t)) converges asymptotically to a Gaussian process on [0, τ ] with mean 0
and appropriate variance term. The additive hazards model has been applied to interval
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censored data (Lin et al. 1998, Martinussen and Scheike 2002), competing risk analysis of
case-cohort studies (Sun et al. 2004), and the recurrent gap times (Sun et al. 2006). Yin
and Cai (2004) proposed additive hazards regression model to multivariate failure time data
where they considered correlation between different time points for the individuals. Schaubel
et al. (2006) proposed the semi-parametric additive rates model to fit recurrent events. The
authors noted that the model can be used for any process with non-negative increments. The
model assumes that the covariates affect the unspecified baseline rate additively. As in the
multiplicative model, the additive rates model is defined as
E [dN∗i (t) | Zi(t)] = dµ0(t) + β′0Zi(t)dt, (2.28)
where dN∗i (t) = N
∗
i (t + dt) − N∗i (t) (dt ↓ 0) equals the increment in N∗i (t) over the small
interval (t, t+dt] and E [dN∗i (t) | Zi(t), Ci > t] = E [dN∗i (t) | Zi(t)]. Note that unlike intensity
functions, the expectation is not considered, conditional on the entire history. In general, the
intensity and rate functions can be related by
E [dN∗i (t) | Zi(t)] = E [E {dN∗i (t) | Fi(t)} | Zi(t)] .
The estimator of β0 can be easily obtained by solving (2.25) where dNi(t) = I(Ci > t)dN
∗
i (t)
and Yi(t) = I(Ci > t). Let us define Mi(t, β) = Ni(t) −
´ t
0 Yi(u){dµ0(u) + β′Zi(u)du} which
has mean zero at β = β0. Following Liang and Zeger (1986)’s generalized estimating equations
the authors defined the following estimating functions for β0 and µ0(t).
n∑
i=1
ˆ t
0
I(Ci > u)dMi(u, β) = 0. (2.29)
n∑
i=1
ˆ t
0
I(Ci > u)Zi(u)dMi(u, β) = 0. (2.30)
Solving these two equations, we get βˆ, which is explicitly defined in (2.26) with the asymptotic
distribution of n1/2{βˆ−β0} to be of the same form as the sandwich estimator described earlier.
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The estimator of the baseline mean is given by
µˆ0(t, β) =
ˆ t
0
∑n
i=1 Yi(u) {dNi(u)− β′Zi(u)du}∑n
i=1 Yi(u)
.
Similarly, as before, to ensure monotonicity, the baseline mean is estimated as µ˜0(t, βˆ) =
max06s6t µˆ0(s, βˆ). Note that, it is possible for the increments in µˆ0(s, βˆ) be negative. Rather
than constraining βˆ to force the baseline rate estimator to be positive, the baseline mean is
constrained to be monotone non-decreasing.
Ma (2007) explored additive risk model with case-cohort data, with weights similar to
Chen and Lo (1999). A class of estimating equations have been proposed, each depending on
a different prevalence ratio estimate. Asymptotic properties of the proposed estimators and
inference based on the m out of n nonparametric bootstrap are investigated. Liu et al. (2010)
considered a more flexible additive-multiplicative rates model for analysis of recurrent event
data, in which some covariate effects are additive while others have multiplicative effect on
the rate function. The estimating equation for the regression parameters is given by
E [dN∗i (t) |Wi(t)] = g
(
γ′0Zi(t)
)
dt+ h
(
β′0Xi(t)
)
dµ0(t),
where Wi(t) = (Zi(t),Wi(t)) is the set of covariates, µ0 = (γ
′
0, β
′
0)
′ is p-dimensional of
unknown regression parameters, g and h are known link functions, µ0(.) is an unspecified
continuous baseline mean function for subjects with covariates Zi(t) and Xi(t) such that
g (γ′0Zi(t)) = 0 and h (β′0Xi(t)) = 1. The authors propose estimating equation, mimicking
the generalized estimating equations.
n∑
i=1
ˆ t
0
dMi(u, θ) = 0,
n∑
i=1
ˆ τ
0
Qi(u, θ)dMi(u, θ) = 0,
where Qi(t, θ) is a smooth p-dimensional vector-valued function of Wi(t) and β, not involv-
ing µ0(t); Mi(t, θ) = Ni(t)−
´ t
0 Yi(u) {g (γ′Zi(t)) dt+ h (β′Xi(t)) dµ0(t)}. The estimators for
these regression parameters from these equations are shown to be consistent and asymptoti-
cally normally distributed under appropriate regularity conditions. Kang et al. (2013) studied
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marginal additive hazards model for case-cohort studies with multiple disease outcomes. The
estimating equation is very similar to (2.27) with another summation, for the disease cate-
gory. He et al. (2013) proposed semi-parametric additive rates model, noting that individuals
within a cluster might not be independent and that creates another level of complexity in re-
current events data. Liu et al. (2013) proposed an additive transformation model for modeling
recurrent events. The rate function is defined by
µ(t | Z) = µ0(t) +Q(t, β′0Z(t)),
where β0 is the vector of regression parameters, µ0(.) is an unspecified non-negative function
with µ0(0) = 0, and Q(t, x) is a pre-specified non-negative link function with Q(0, x) = 0
for any x. Yu et al. (2014) and Cao and Yu (2017) propose different estimating equations to
model the additive hazards model for generalized case-cohort (GCC) sampling and optimal
GCC sampling respectively.
The additive and multiplicative risk models provide two major frameworks for studying
the association between risk factors and the event occurrence (e.g., some disease of interest
or death). Most survival analyses focus on multiplicative models for relative risk using the
proportional hazards theory, mainly due to the easy interpretability of the risk ratio, desirable
theoretical properties and the availability of computer programs to fit the models readily.
However, in many biomedical studies the researchers might be interested in risk difference,
rather than the relative risk or the PH assumptions are not valid which might lead to biased
results if the multiplicative models are fit, ignoring the conditions (O’Neill, 1986). In such
situations, it is recommended to use the additive rates model than the more easily available
multiplicative model.
2.5 Sample Size Calculation for Case-Cohort Design
When the event is rare or the cost of collecting the covariate data for the entire cohort is
high, there has been a lot of work done in analyzing case-cohort data. Previous sections have
addressed the analyses of case-cohort data; this section would focus on the design aspect of the
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case-cohort sampling scheme. Sample size and power calculation are important components
at the design stage of any study. Specifically, for the case-cohort studies, it is very helpful
in determining the size of the subcohort needed for the study. It is also of interest to know
how much more power may be gained by using a case-cohort design, compared with a simple
random sample design conditional on the costs involved in the study.
Cai and Zeng (2004) proposed methods for computing sample size and power for case-
cohort studies. The authors presented two log-rank type test statistics and derived the sample
size and power for them. Denote the number of subjects in the j-th group (1,2) by nj , Tij is
the potential failure time and Cij is the censoring time and one observes Xij = min(Tij , Cij)
with ∆ij = I(Tij 6 Cij), n = n1 + n2. ξij is the indicator that the i-th subject from the
j-th group is selected in the sub-cohort. Λj , j = 1, 2 is the cumulative hazard function of the
failure time in group j and the null hypothesis is H0 : Λ1(t) = Λ2(t). The test statistic would
be given by
Tsp =
n1∑
i=1
∆i1w(Xi1)Y˜2(Xi1)
Y˜1(Xi1) + Y˜2(Xi1)
−
n2∑
i=1
∆i2w(Xi2)Y˜1(Xi2)
Y˜1(Xi2) + Y˜2(Xi2)
, (2.31)
where w(.) is the weight function and Y˜k(Xik) = qY¯k(Xik), k = 1,2, where q is the sampling
fraction for the sub-cohort. This statistic is exactly the score function of the pseudo-partial
likelihood function given by Self and Prentice (1988). Using that, the distribution of this
would be easily derivable. Instead of using Y˜k, the authors also proposed another way of
approximating the total risk set by
Y ∗j (t) =
n
n˜
nj∑
i=1
I(Xij > t, ξij = 1,∆ij = 0) +
nj∑
i=1
I(Xij > t,∆ij = 1).
As in (2.31), one can get another test statistic by simply replacing Y˜j(t) by Y
∗
j (t). Further-
more, the asymptotic variance of n−1/2Tsp can be estimated by
σˆ2sp = σˆ
2 +
2(1− qˆ
n
2∑
j=1
nj∑
i=1
∆ijw(Xij)Y˜1(Xij)Y˜2(Xij)(
Y˜1(Xij) + Y˜2(Xij)
)2

2∑
j′=1
nj′∑
i′=1
∆i′j′w(Xi′j′)I(Xi′j′ 6 Xij)
Y˜1(Xi′j′) + Y˜2(Xi′j′)


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− (1− qˆ
n
2∑
j=1
nj∑
i=1
∆ijw(Xij)Y˜1(Xij)Y˜2(Xij)(
Y˜1(Xij) + Y˜2(Xij)
)3 ,
where σˆ2 = 1n
[∑n1
i=1
∆i1w(Xi1)Y˜2(Xi1)
2
(Y˜1(Xi1)+Y˜2(Xi1))
2 +
∑n2
i=1
∆i2w(Xi2)Y˜1(Xi2)
2
(Y˜1(Xi2)+Y˜2(Xi2))
2
]
is the consistent estimate
for the variance of the log-rank test based on the entire data set, qˆ = nn˜ . The asymptotic
variance of the other test statistic was estimated by σˆ2sp as well. The authors compared the
sample size and power based on these statistics and the log-rank test based on the entire
cohort and that based on only the sub-cohort. Cai and Zeng (2007) extended this idea
to generalized case-cohort design, when the event is not rare. As described earlier, in a
generalized case-cohort design, one randomly samples without replacement a subcohort from
the full cohort in the first step and then in the second step, another sample is randomly taken
without replacement from the remaining failures. The observed data in this case would be,
(Xi, (ξi + (1− ξi)∆iηi) , Zi,∆i) , i = 1, 2, . . . , n. Assuming that Z is a dichotomous variable,
one can construct the following test statistic :
Wn =
ˆ τ
0
w(t)Y˜1(t)Y˜2(t)
Y˜1(t) + Y˜2(t)
{
dN˜1(t)
Y˜1(t)
− dN˜2(t)
Y˜2(t)
}
,
where τ is the study duration, w(t) is the weight function, Y˜j(t) =
∑n
i=1 I(Xi > t, Zi = j)×[
ξi∆i +
ξi(1−∆i)
p +
∆(1−ξi)ηi
q
]
and N˜j(t) =
∑n
i=1 ∆iI(Xi > t, Zi = j)
{
ξi +
ξi(1−∆i)
p
}
. Denot-
ing α(t) = P (Z=1,C>t)P (C>t) , one can see that n
−1/2Wn converges weakly to a Gaussian distribution
with mean zero and variance σ2W = σ
2+1−pp V ar(ν(X,Z)(1−∆))+P (∆=1)(1−p)(1−q)q V ar(µ(X,Z) |
∆ = 1, ξ = 0) with ν(X,Z) = − ´ X0 w(t)(1−α(t))dΛ(t)I(Z = 1) +
´ X
0 w(t)α(t)dΛ(t)I(Z = 2)
and µ(X,Z) = ν(X,Z) +w(Z)(1−α(Z))I(X = 1)−w(Z)α(Z)I(Z = 2). Stratified sampling
is commonly used in the survey sampling to improve the estimation precision for the pop-
ulation quantity of interest. Hu et al. (2014) derived the sample size/power calculation for
a stratified case-cohort (SCC) design, based on a stratified test statistic. The test statistic
looks very similar to (22) and can be defined as
Tsp =
L∑
l=1
Tsp,l =
nl1∑
i=1
∆li1w(Xli1)Y˜l2(Xli1)
Y˜l1(Xli1) + Y˜l2(Xli1)
−
nl2∑
i=1
∆li2w(Xli2)Y˜l1(Xli2)
Y˜l1(Xli2) + Y˜l2(Xli2)
,
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where L is the number of groups. Since each of the groups are independent among themselves,
the variance term would be similar to σ2sp, summed over all possible strata. The authors
investigated and compared the proportional, balanced, and optimal sampling design methods
and derived the corresponding sample size calculation formula. In the next chapter, we discuss
our proposed work.
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CHAPTER 3: MULTIPLICATIVE RATES MODEL FOR RECURRENT
EVENTS IN CASE-COHORT DATA
3.1 Introduction
In large epidemiological studies and disease prevention trials, the majority of the effort
and cost arises from the assembling of the covariate measurements and follow-up information
on all the individuals. When the disease incidence is low and some exposures are expensive
to measure, it is not feasible and not cost effective to measure the expensive variable on all
individuals in the cohort. To reduce cost and achieve the same study goals as the cohort
study, Prentice (1986) proposed the case-cohort study design. Under this design, a random
sample is selected from the entire cohort, named sub-cohort, and covariate information is
collected on only this sub-cohort and the individuals who experience the event.
Development of statistical methods for data from case-cohort studies is an active research
area. For univariate failure time data, Self and Prentice (1988), Wacholder et al. (1989),
and Barlow (1994) considered efficient and robust estimation of the variance of the case-
cohort estimator. Borgan et al. (1995) considered a more general sampling frame whereas
Lin and Ying (1993) viewed the case-cohort design as a special case of the missing data
problem. Borgan et al. (2000) developed methods for the analysis of exposure stratified case-
cohort design and Breslow and Wellner (2006) considered weighted likelihood for two-phase
stratified samples. Chen (2001) and Kulich and Lin (2004) developed sample reuse methods
via local averaging leading to more efficient estimation. Nonetheless, correlated failure time
data are quite common in biomedical and public health research. Lu and Shih (2006) and
Zhang et al. (2011) developed estimating equation for clustered failure time data assuming
a marginal hazards model, accounting for correlation within clusters, which are formed by
correlated subjects. Kang and Cai (2009a) considered marginal hazards model for case-cohort
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data with multiple disease outcomes. However, methods for analyzing recurrent events data
from case-cohort studies are scarce.
Recurrent events are commonly encountered in biomedical research. Our motivating ex-
ample is from a doubly-blind, placebo-controlled community trial conducted in northeastern
Brazil in a cohort of children aged between 6 to 48 months (Barreto et al. 1994). The
primary objective of this study was to evaluate the effect of high doses of vitamin A on acute-
lower-respiratory-tract infection (ALRI). One thousand two hundred and four children were
randomized to receive vitamin A supplement or placebo. They were followed for 1 year. An
episode of ALRI was defined as cough plus a respiratory rate of 50 breaths per min or higher
for children under 12 months, and 40 breaths per min or higher for older children(Barreto
et al. 1994). About 15.38% of the children had at least one ALRI episode during their follow-
up period. The number of episodes ranged from 1 to 6, resulting in a total of 305 episodes.
As a secondary objective, it is of interest to examine whether the child ever had measles is
related to ALRI. It can be expensive to verify the measles information because it is based on
the parents’ acknowledgement. With the relatively low ALRI rate, a case-cohort sampling
design can be more cost-effective in this situation.
Various methods have been proposed for analyzing recurrent event data from the full
cohort. These include modeling the intensity functions of the recurrent event process (An-
dersen and Gill 1982), rate/mean function (Pepe and Cai 1993, Lawless and Nadeau 1995,
Cook et al. 2009, Lin et al. 2000), and the gap times between each recurrence (Huang and
Chen 2003, Schaubel and Cai 2004). However, methods for analyzing recurrent events data
from case-cohort studies is limited. Chen and Chen (2014) extended the case-cohort design
to recurrent events with specific clustering feature using a modified Cox-type self-exciting
intensity model. Such model makes the assumption that the dependence of the recurrent
events is captured by some time-varying covariates. This assumption may not be easily veri-
fiable. An alternative is to model the marginal rate or mean function. The marginal rates or
means model does not require such assumption (Lin et al. 2000) and the parameters in this
model have population average interpretation, which is desirable in many population studies.
However, analysis methods for marginal rates model have not been investigated for recurrent
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events data from case-cohort study design.
The main goal of this article is to propose case-cohort designs for recurrent events data and
the estimation procedures for data from such designs. We considered two different situations.
One is when the recurrent events are not very common in which case we will include into the
case-cohort sample all individuals who developed events during the follow-up. The second
situation is when the recurrent events are relatively common, when the proportion of subjects
who experienced at least one event is about 20% − 50%. In such case, we propose to only
include into the case-cohort study a sample of those who developed events during the follow-
up. We refer to the first situation as traditional case-cohort design and the second as the
generalized case-cohort design.
In this chapter, we propose weighted estimating equations for estimating the parameters
in the marginal rates regression model for recurrent events in case-cohort studies. The chapter
is organized as follows. In section 3.2, the design of the study and the estimation procedure
are proposed. The asymptotic properties of the estimators are studied in section 3.3. The
finite sample properties are investigated by simulations in section 3.4. In section 3.5, we
illustrate the proposed method on a case-cohort study based on the ALRI data on children
in Brazil. In the section 3.6, we provide some final remarks.
3.2 Model and Estimation
Suppose there are n independent individuals in the cohort. Let N∗i (t) be the number of
recurrent events for the individual i over the time interval [0, t), Ci is the censoring time. Zi(.)
= (ZEi (.)
′, ZCi (.)
′)′ is the p-dimensional covariate of interest for the individual i, where ZEi (.)
is the set of expensive-to-measure variables and ZCi (.) is the set of all other covariates. Let T
∗
ij
denote the j-th recurrent event time for the individual i. The observed time is Tij = T
∗
ij ∧Ci,
j = 1, 2, . . . , ni + 1, where ni is the number of events that are observed for individual i, and
N =
∑n
i=1 ni is the total number of observed events. Let Yi(t) = 1(Ci ≥ t), Ni(t) = N∗i (t∧Ci)
=
∑ni
j=1 I(Tij ≤ t) =
∑ni
j=1 I(T
∗
ij ≤ t)Yi(t), ∆i = 1− I(minj(T ∗ij) ≥ Ci) which is the indicator
that individual i experienced at least one event, and τ denote the study ending time. The rate
function for an individual is denoted as E (dN∗(t) | Z(t)) = dµz(t). We assume the following
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proportional rates model:
dµZ(t) = e
θ′0Z
E(t)+γ′0Z
C(t)dµ0(t)⇒ µZ(t) =
ˆ t
0
eθ
′
0Z
E(u)+γ′0Z
C(u)dµ0(u), (3.1)
where µ0(.) is an unspecified continuous baseline mean function and θ0 and γ0 are the vectors
of unknown parameters. Denoting β0 = (θ
′
0, γ
′
0)
′, we can rewrite the rates model as dµZ(t) =
eβ
′
0Z(t)dµ0(t) and the mean function is given by µ0(t) =
´ t
0 e
β′0Z(u)dµ0(u) for all t ∈ [0, τ ].
Note that the covariates are allowed to be time-dependent. We assume that the possibly
time-dependent covariates are external (Kalbfleisch and Prentice (2002)), i.e., they are not
affected by the recurrent event process.
3.2.1 Case-cohort study design for recurrent events
In this subsection, we introduce two sampling schemes for the recurrent event data. The
first deals with the situation that the event is not common in the population. In this case, we
draw a random sample from the full cohort and supplement that with all the cases. We call
this sampling scheme the original case-cohort design. The second sampling scheme is for the
situation that the event is relatively common and we cannot afford to sample all individuals
with events. An example for the common recurrent event is the randomized double-blinded
trial conducted by Genentech Inc. in the early 1990’s to study the effect of rhDNase on
pulmonary exacerbations among patients with cystic fibrosis (Therneau and Hamilton 1997).
Even though, the pulmonary exacerbation rate is ∼ 40%, the variable FEV1 may be quite
expensive to measure. Under such situation, we propose to sample only a fraction of those
who have events for the case-cohort sampling. We call this sampling scheme the generalized
case-cohort design with recurrent events.
3.2.2 Estimation under the original case-cohort design
Under the case-cohort sampling, we select a sub-cohort from the entire cohort by simple
random sampling. Let ξi denote the indicator function for individual i being selected into the
subcohort; α˜ = n˜n is the subcohort proportion where n˜ is the number of individuals selected
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in the sub-cohort and n is the number of individuals in the full cohort. We call an individual
a case if the individual experienced at least one event and an individual a non-case if the
individual did not have an event during the study period. Hence, the observable information
for individual i is {Ti,∆i, ξi, ZCi (t), ZEi (t), t ∈ [0, τ ]} if individual i is in the case-cohort
sample. In other words, we have {Ti,∆i, ξi, Zi(t), 0 ≤ t ≤ τ} if ∆i = 1 or ξi = 1 and
{Ti,∆i, ξi, ZCi (t), t ∈ [0, τ ]} when ∆i = 0 and ξi = 0. When information on the covariates for
all the individuals are available, one can consider the following estimating equation for the
full cohort data (Lin et al. (2000)):
U(β) =
n∑
i=1
ˆ τ
0
{
Zi(t)− S
(1)(β, t)
S(0)(β, t)
}
dNi(t) = 0, (3.2)
where S(d)(β, t) = 1n
∑n
i=1 Yi(t)Zi(t)
⊗deβZi(t), ∀d = 0, 1. One can easily solve the estimating
equation by some iterative algorithm, for example, the Newton-Raphson iteration method.
However, because the data are not complete in case-cohort studies, (3.2) cannot be used
directly. We consider a weighted estimating equation approach based on the idea of inverse
probability of selection weighting. The estimating equation considered for estimating β0 is
the following:
Uˆ I(β) =
n∑
i=1
ˆ τ
0
{
Zi(t)− S˜
(1)(β, t)
S˜(0)(β, t)
}
dNi(t) = 0, (3.3)
where S˜(d)(β, t) = 1n
∑n
i=1w
I
i (t)Yi(t)Zi(t)
⊗deβZi(t), ∀d = 0, 1, wIi (t) = ∆i + (1 − ∆i) ξiαˆ(t) ,
where αˆ(t) =
∑
i(1−∆i)ξiYi(t)∑
i(1−∆i)Yi(t) is the estimator of the true sampling parameter, α. The weight
is 1 for all the cases and is αˆ(t)−1 for the non-cases in the sub-cohort. Similar idea for the
weights was considered by Kalbfleisch and Lawless (1988).They considered the time-invariant
version of αˆ(t), which was given by α˜. Borgan et al. (2000) used a similar idea for univariate
failure time data from stratified case-cohort studies. We denote the solution to this equation
by βˆI . Our proposed Breslow-Aalen type estimator of the baseline mean function is given by
µˆ0(βˆ
I , t) =
ˆ t
0
∑n
i=1 dNi(u)
nS˜(0)(βˆI , u)
. (3.4)
40
3.2.3 Estimation under the generalized case-cohort design
For the generalized case-cohort design, we sample a fraction of cases outside of the sub-
cohort. Let ηi be an indicator for individual i who is a case but outside the sub-cohort
being sampled. Let q˜ =
n∗1
n1−n˜1 denote the sampling proportion for the additional cases,
where n∗1, n1 and n˜1 are the number of selected individuals who have experienced at least one
event but are not in the subcohort, individuals who experienced at least one event in the full
cohort and those who were in the subcohort respectively. Under this design, the covariate
information is available for the subcohort members and the selected cases (ηi = 1). Hence,
the observable information for individual i is {Ti,∆i, ξi, ηi, Zi(t) : t ∈ [0, τ ]} when ξi = 1 or
ηi = 1 and {Ti,∆i, ξi, ZCi (t), t ∈ [0, τ ]} if ξi = 0 and ηi = 0. Using the inverse of probability of
being sample as the weight, our proposed estimating equation for the Generalized case-cohort
sampling scheme is
Uˆ II(β) =
n∑
i=1
ˆ τ
0
wIIi (t)
{
Zi(t)− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
}
dNi(t) = 0, (3.5)
where Sˆ(d)(β, t) = 1n
∑n
i=1w
II
i (t)Yi(t)Zi(t)
⊗deβZi(t), ∀d = 0, 1, and the weight function is
given by wIIi (t) =
(1−∆i)ξi
αˆ(t) +∆iξi+
∆i(1−ξi)ηi
qˆ(t) where qˆ(t) =
∑
i ∆i(1−ξi)ηiYi(t)∑
i ∆i(1−ξi)Yi(t) is the estimator of
the true sampling parameter q. We denote the solution of this equation by βˆII . The Breslow-
Aalen type estimator of the baseline mean function is µ˜0(βˆ
II , t) =
´ t
0
∑n
i=1 w
II
i (u)dNi(u)
nSˆ(0)(βˆII ,u)
.
3.3 Asymptotic properties
In this section, we investigate the asymptotic properties of the estimators. Define the
following terms:
e(β, t) =
s(1)(β, t)
s(0)(β, t)
, ϑ(β, t) =
s(2)(β, t)s(0)(β, t)− s(1)(β, t)⊗2
(s(0)(β, t))2
, Z˜i(t) = Zi(t)− e(β, t),
dMi(t) = dNi(t)−Yi(t)eβ′0Z(t)dµ0(t), MZ˜,i(β) =
ˆ τ
0
Z˜i(t)dMi(t), dMZ˜,i(β, t) = Z˜i(t)dMi(t),
A(β) =
ˆ τ
0
ϑ(β, t)s(0)(β, t)dµ0(t).
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We define the norm for the vector m, matrix M , and function f as the following: ‖m‖ =
maxi |mi|, ‖M‖ = maxi,j |Mij |, ‖f‖ = supt |f(t)|. The estimator under the traditional
case-cohort sampling scheme is a special case of the generalized case-cohort sampling scheme,
so its asymptotic property is a special case of the generalized case-cohort sampling scheme.
Hence, in the Appendix, we focus the proofs on the asymptotic properties of the estima-
tors under the generalized case-cohort design, βˆII and µˆII0 (βˆ
II , t). The regularity conditions
and the outline of the proofs are provided in the Appendix. The asymptotic properties are
summarized in the following theorems.
Theorem 1. Under the regularity conditions in the Appendix, for k = I or II, βˆk is a
consistent estimator of β0. n
1/2{βˆk − β0} converges to a Gaussian distribution with mean
zero and variance given by
Σk(β0) = A(β0)
−1
[
Q(β0) +
1− α
α
V I(β0) + I(k = II)(1− α)1− q
q
P (∆1 = 1)V
II(β0)
]
A(β0)
−1,
where
Q(β) = E
(
MZ˜,1(β)
)⊗2
,
V I(β0) = var
(
(1−∆1))
ˆ τ
0
[
R1(β0, t)− Y1(t)E((1−∆1)R1(β0, t))
E((1−∆1)Y1(t))
]
dµ0(t)
)
,
V II(β0) = var
(ˆ τ
0
[
dMZ˜,1(β0, t)−
Y1(t)E(dMZ˜,1(β0, t) | ∆1 = 1, ξ1 = 0)
E(Y1(t) | ∆1 = 1)
]
| ∆1 = 1, ξ1 = 0)
)
,
A(β) =
ˆ τ
0
ϑ(β, t)s(0)(β, t)dµ0(t), Ri(β, t) = Yi(t)Z˜i(t)e
βZi(t).
Each of these terms, A(β0), Q(β0), V
I(β0) and V
II(β0) can be estimated respectively by
their sample counterparts, Aˆ(βˆk), Qˆ(βˆk), Vˆ I(βˆk) and Vˆ II(βˆk). Aˆ(β) = − 1n ∂U(β)∂β , Qˆ(β) =
1
n
∑n
i=1
ξi
α˜
(
MZ˜,i(β)
⊗2
)
, MˆZ˜,i(β) = ∆i
∑ni
j=1
(
Zi(Tij)− Sˆ
(1)(β,Tij)
Sˆ(0)(β,Tij)
)
− 1n
∑n
j=1
∑nj
k=1
∆jYi(Tjk)e
βZi(Tjk)
Sˆ(0)(β,Tjk)
×
(
Zi(Tjk)− Sˆ
(1)(β,Tjk)
Sˆ(0)(β,Tjk)
)
, Vˆ I(β) = 1n
∑n
i=1
ξi
α˜
[
1−∆i
n
∑n
j=1
∑nj
k=1
∆j
Sˆ(0)(β,Tjk)
{
RˆIi (β, Tjk)−
Yi(Tjk)Eˆ((1−∆1)R1(β,Tjk))
Eˆ((1−∆1)Y1(Tjk))
}]⊗2
, Vˆ II(β) = 1∑n
i=1 ∆i(1−ξi)
∑n
i=1
ηi
q˜ ∆i(1− ξi)
[{
MZ˜,i(β)−
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∑n
j=1
∑nj
k=1
Yi(Tjk)Eˆ(dMZ˜,j(β,Tjk)|∆j=1,ξj=0)
Eˆ(Y1(Tjk)|∆j=1)
}]⊗2
, dMˆZ˜,i(β, Tij) =
(
Zi(Tij)− Sˆ
(1)(β,Tij)
Sˆ(0)(β,Tij)
)
(
∆i − Yi(Tij)eβZi(Tij)dµˆk0(β, Tij)
)
, RˆIi (β, t) =
{
Zi(t)− Sˆ
(1)(β,t)
Sˆ(0)(β,t)
}
Yi(t)e
β′Zi(t), Eˆ ((1−∆1)
R1(β, t)) =
1
n
∑n
i=1
ξi
α˜ (1−∆i)RˆIi (β, t), Eˆ
(
dMZ˜,1(β, t) | ∆i = 1, ξi = 0
)
= 1∑n
i=1 ∆i(1−ξi)
∑n
i=1
ηi
q˜ ∆i(1−ξi)dMˆZ˜,i(β, t), Eˆ ((1−∆1)Y1(β, t)) = 1n
∑n
i=1(1−∆i)Yi(t), Eˆ (Y1(β, t) | ∆1 = 1) =
1∑n
i=1 ∆i
∑n
i=1 ∆iYi(t).
To obtain the asymptotic distribution of the baseline mean function µˆ0(t), we need to first
define the metric space, D[0, τ ], consisting of right continuous functions f(t) with left-hand
limits and f : [0, τ ]→ R. The metric for this space is defined by, d(f, g) = supt∈[0,τ ]{| f(t)−
g(t) |}, f(t), g(t) ∈ D[0, τ ]. The following theorem summarizes the asymptotic properties of
µˆk0(t).
Theorem 2. Under the regularity conditions, for k = I or II, we can show that µˆk0(β, t)
converges in probability to µ0(t) uniformly in t ∈ [0, τ ]. Further, defining Wn(t) = µˆk0(βˆk, t)−
µ0(t), we have n
1/2Wn(t) converges to a Gaussian distribution with mean zero. The variance-
covariance function between Wn(t) and Wn(s) is given by
φk(t, s)(β0) = E (νi(β0, t)νi(β0, s))+
1−α
α E (ψi(β0, t)ψi(β0, s))+I(k = II)(1−α)1−qq P (∆1 = 1)
×E (ζi(β0, t)ζi(β0, s) | ∆i = 1, ξi = 0) ,
where
νi(β, t) = r(β, t)
′A(β)−1MZ˜,i(β, t) +
ˆ t
0
{s(0)(β, u)}−1dMi(u),
ψi(β, t) =
[
r(β, t)′A(β)−1(1−∆i)
ˆ τ
0
{
Ri(β, u)− Yi(u)E((1−∆i)Ri(β, u))
E((1−∆i)Yi(u))
}
dµ0(u)
+(1−∆i)
ˆ t
0
Yi(u)
(
eβ
′Zi(u) − Yi(u)E((1−∆i)Yi(u)e
β′Zi(u))
E((1−∆i)Yi(u))
)
dµ0(u)
s(0)(β, u)
]
,
ζi(β, t) =
r(β, t)′A(β)−1 ˆ τ
0
dMZ˜,i(β0, t)− Yi(t)E
[
dMZ˜,1(β0, t)(β0, t) | ∆1 = 1, ξ1 = 0
]
E [Y1(t) | ∆1 = 1, ξ1 = 0]

+
ˆ t
0
1
s(0)(β, u)
(
dMi(u)− Yi(t)E [dM1(u)(β0, t) | ∆1 = 1, ξ1 = 0]
E [Y1(t) | ∆1 = 1, ξ1 = 0]
)]
,
r(β, t) = − ´ t0 e(β, u)s(0)(β, u)dµ0(u).
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Similarly, each of these terms can be consistently estimated by their sample counterparts.
φˆk(t, s)(β) = 1n
∑n
i=1
ξi
α˜ (νˆi(β, t)νˆi(β, s)) + I(k = I)
1
n
1−α˜
α˜
∑n
i=1
ξi
α˜
(
ψˆi(β, t)ψˆi(β, s)
)
+I(k =
II) 1n
1−q˜
q˜ Pˆ (∆1 = 1)(1− α˜) 1∑ni=1 ∆i(1−ξi) ∑ni=1 ηiq˜ (ζˆi(β, t)ζˆi(β, s)) , νˆi(β, t) = rˆ(β, t)′Aˆ(β)−1
MˆZ˜,i(β, t) +
´ t
0{Sˆ(0)(β, u)}−1dMˆi(u), rˆ(β, t) = − 1n
∑n
i=1
∑ni
j=1
I(Tij≤min(t,Ci))Sˆ(1)(β,Tij)
Sˆ(0)(β,Tij)2
,
´ t
0
dMˆi(u)
Sˆ(0)(β,u)
=
∑ni
l=1
I(Til≤min(t,Ci))
Sˆ(0)(β,Til)
− 1n
∑n
j=1
∑nj
l=k
∆jI(Tjk≤min(t,Cj))Yi(Tjk)eβ
′Zi(Tjk)
Sˆ(0)(β,Tjk)2
, ψˆi(β, t) =[
rˆ(β, t)′Aˆ(β)−1(1−∆i)
´ τ
0
{
Rˆi(β, u)− Yi(u)Eˆ((1−∆i)Yi(u)Ri(β,u))Eˆ((1−∆i)Yi(u))
}
dµˆ0
k(u) + (1−∆i)
´ t
0 Yi(u)(
eβ
′Zi(u) − Yi(u)Eˆ((1−∆i)Yi(u)eβ
′Zi(u))
Eˆ((1−∆i)Yi(u))
)
dµˆ0k(u)
Sˆ(0)(β,u)
]
, ζˆi(β, t) =
[
rˆ(β, t)′Aˆ(β)−1∆i(1− ξi)
{
MZ˜,i(β)
− ´ τ0 Yi(u)Eˆ(dMZ˜,1|∆1=1,ξi=0)Eˆ(Y1(u)|∆1=1)
}
+ ∆i(1− ξi)
´ t
0
1
Sˆ(0)(β,t)
(
dMi(u)− Yi(u)Eˆ(dM1(u)|∆1=1,ξ1=0Eˆ(Y1(u)|∆1=1)
)]
,
Eˆ((1−∆i)Yi(u)eβ′Zi(u)) = 1n
∑n
i=1(1−∆i) ξiα˜ Yi(t)exp{β′Zi(t)}.
Studying the variance components, we can identify three sources of variation in ΣII(β0)
and φII(t, s)(β0). The three components correspond to the variation due to the different sam-
pling present in the data: one from the cohort, one because of the sampling of the subcohort
from the cohort, and the last is from the sampling of the cases outside the subcohort. Further,
note that for the original case-cohort design, since no randomness arises from sampling cases
outside the random sub-cohort, the third term does not arise in the variance term of βˆI .
3.4 Simulation Results
We have conducted extensive simulation studies to examine the finite sample properties
of the proposed estimators. To generate the recurrent event times, we have adopted Jahn-
Eimermacher et al. (2015)’s algorithm. We consider the following random-effects intensity
model to generate the recurrent events:
λ(t | Z(t), ϑ) = ϑeβ0Z(t)λ0(t) (3.6)
where ϑ is an unobserved unit-mean positive random variable that is independent of Z. We de-
rived the functions, Λ˜t and Λ˜
−1
t , from the intensity process using the formula Λ˜t(u | Z(t), ϑ) =
Λ(u + t | Z(t), ϑ) − Λ(t | Z(t), ϑ). Independent random numbers, ai, are drawn from a uni-
form distribution on [0,1]. The following recursive algorithm is applied to obtain the recurrent
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event data for individual i: ti1 = Λ
−1(−log(ai1) | Zi(ti1), ϑ), ti,j+1 = ti,j + Λ˜−1ti,j (−log(ai,j+1) |
Zi(ti,j+1), ϑ), j = 1, 2, . . . , ni. We assumed that ϑ has a Gamma distribution with mean 1 and
variance σ2. We considered binary covariate generated from Bernoulli (0.5) and continuous
covariate from Uniform (0,1). We considered different cohort sizes: 1000, 2000 and 4000 and
the number of simulated data sets being considered is 1000. We considered σ2 such that mean
recurrence is 3 for those who had at least one event. We considered β0 to be 0.5 or 0.
Table 3.1 summarizes simulation results for situations that the proportion of individuals
who experienced at least one event was low (5%, 10%, 20%). For the case-cohort sampling,
the sub-cohort sampling proportion was 25% and all cases were sampled. The simulation
results show that the coefficient estimates are approximately unbiased for all the situations
we considered. From Table 3.1, we note that the proposed estimated standard errors provide
good estimates of the true variability of βˆI in all the situations except for when both the full
cohort and the event rate are very small. As the cohort size increases, the performance of the
estimated standard error improves. The variance of βˆI decreases as the cohort size and/or
the event proportion increases. The coverage rate of the nominal 95% confidence intervals
using the proposed method is in the 92 − 95% range in all the situations considered except
when the event rate along with the cohort size are small. As the cohort size or event rate
increases, the 95% confidence interval coverage rate improves.
Table 3.1: Summary of Simulation Results of βˆI for Multiplicative Model
Z β0 Cohort Event Bias Model Empirical Coverage
Size proportion Std. Error Std. Dev.
Bernoulli(0.5) 0.5 1000 0.05 -0.003 0.474 0.535 0.85
0.10 -0.031 0.342 0.323 0.91
0.20 -0.034 0.225 0.228 0.94
2000 0.05 0.002 0.344 0.349 0.90
0.10 -0.023 0.227 0.231 0.93
0.20 -0.013 0.161 0.165 0.94
4000 0.05 -0.02 0.245 0.245 0.93
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0.10 -0.025 0.161 0.153 0.95
0.20 -0.023 0.113 0.116 0.93
0 1000 0.05 -0.0006 0.360 0.368 0.90
0.10 -0.0002 0.287 0.288 0.94
0.20 0.008 0.219 0.222 0.94
2000 0.05 0.008 0.256 0.261 0.92
0.10 -0.005 0.205 0.208 0.93
0.20 0.003 0.154 0.154 0.95
4000 0.05 0.0146 0.181 0.188 0.94
0.10 0.0013 0.145 0.146 0.95
0.20 -0.0037 0.109 0.110 0.94
Unif(0,1) 0.5 1000 0.05 -0.05 0.746 0.777 0.86
0.10 -0.022 0.566 0.589 0.90
0.20 -0.045 0.392 0.395 0.94
2000 0.05 -0.036 0.531 0.547 0.90
0.10 -0.02 0.404 0.416 0.92
0.20 -0.011 0.279 0.281 0.94
4000 0.05 0.008 0.381 0.399 0.91
0.10 -0.025 0.279 0.274 0.95
0.20 -0.023 0.197 0.200 0.94
0 1000 0.05 -0.006 0.627 0.636 0.89
0.10 -0.006 0.509 0.507 0.92
0.20 0.006 0.382 0.380 0.94
2000 0.05 0.005 0.443 0.466 0.92
0.10 -0.007 0.357 0.362 0.92
0.20 0.0009 0.266 0.263 0.94
4000 0.05 0.021 0.312 0.322 0.93
0.10 0.004 0.255 0.254 0.94
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0.20 -0.002 0.189 0.189 0.95
Table 3.2 summarizes the simulation results for situations when the proportion of events
is not low (40%, 30% and 25%). We considered generalized case-cohort sampling. The
sub-cohort sampling proportion is 10% and sampling proportion for the cases outside the
sub-cohort is also 10%. The simulation results show that the coefficient estimates are approx-
imately unbiased, the proposed variance estimator is close to the empirical variance, and the
95% confidence interval coverage is close to the nominal level for all the situations considered.
Table 3.2: Summary of Simulation Results of βˆII for Multiplicative Model
Z β0 Cohort Event Bias Model Empirical Coverage
Size proportion Std. Error Std. Dev.
Bernoulli(0.5) 0.5 1000 0.25 -0.017 0.5 0.548 0.93
0.30 0.018 0.429 0.460 0.92
0.40 0.014 0.358 0.370 0.93
2000 0.25 0.005 0.357 0.381 0.93
0.30 0.01 0.305 0.327 0.93
0.40 0.001 0.253 0.263 0.94
4000 0.25 -0.015 0.253 0.254 0.95
0.30 0.008 0.217 0.219 0.95
0.40 -0.003 0.178 0.179 0.96
0 1000 0.25 -0.004 0.5 0.54 0.93
0.30 0.004 0.434 0.439 0.94
0.40 -0.002 0.348 0.38 0.93
2000 0.25 -0.009 0.358 0.373 0.93
0.30 -0.007 0.307 0.32 0.94
0.40 0.001 0.249 0.254 0.94
4000 0.25 0.007 0.253 0.259 0.95
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0.30 -0.004 0.218 0.222 0.94
0.40 0.006 0.177 0.178 0.95
Unif(0, 1) 0.5 1000 0.25 0.004 0.858 0.966 0.92
0.30 -0.003 0.736 0.806 0.93
0.40 0.003 0.610 0.625 0.94
2000 0.25 -0.026 0.62 0.64 0.94
0.30 0.0099 0.53 0.55 0.94
0.40 -0.016 0.436 0.459 0.93
4000 0.25 -0.01 0.442 0.457 0.94
0.30 0.0004 0.376 0.391 0.94
0.40 -0.004 0.312 0.319 0.95
0 1000 0.25 -0.018 0.864 0.923 0.92
0.30 0.004 0.742 0.77 0.94
0.40 0.008 0.60 0.64 0.92
2000 0.25 -0.015 0.620 0.664 0.92
0.30 -0.0085 0.531 0.539 0.94
0.40 -0.0027 0.430 0.431 0.94
4000 0.25 0.012 0.437 0.457 0.94
0.30 -0.017 0.378 0.388 0.94
0.40 0.003 0.305 0.310 0.94
3.5 Application to ALRI data
A doubly-blinded placebo-controlled community trial was conducted in a cohort of 1207
children in northeastern Brazil, who were followed up from December 1990 to December 1991
(Barreto et al. 1994, Amorim and Cai 2015). The primary aim of the original trial was to study
the effect of high doses of Vitamin A on diarrhea and acute-lower-respiratory-tract-infections
(ALRI). The age of the children at baseline ranged from 6 to 48 months. They were randomly
48
assigned to vitamin A supplement or placebo. For the purpose of our analysis, 1190 children
were eligible: sixteen subjects had missing information on one of the variables of interest and
one child was shifted to Vitamin A from Placebo. Daily information on respiratory rates were
collected (3 times a week) with a recall period of 48 to 72 hours. An episode of ALRI was
defined as cough plus a respiratory rate of 50 breaths per min or higher for children under
12 months of age, and 40 breaths per min or higher for older children(Barreto et al. 1994,
Amorim and Cai 2015). At these visits, if the child reported cough, then the respiratory rates
were measured twice. A new episode of ALRI was defined if there was an interval of 14 or
more days (Barreto et al. 1994). Censoring occurred when children were lost to follow-up or
the study reached its end. The number of children who had at least one event was 185 with
event proportion of 15.37%.
We constructed a case-cohort sample based on this cohort study to illustrate our pro-
posed method. We consider the indicator variable for children ever having measles to be the
expensive variable which is only available for the case-cohort sample. We are interested in
studying the effect of past occurrence of measles on ALRI. We considered the probability of
sub-cohort selection to be 0.2. The total sample size for the case-cohort data is 376 with 238
in the subcohort. The following covariates were considered in the analysis: treatment group
(vitamin A vs placebo), child’s gender (male vs female), age at baseline (dichotomized based
on whether the child is older than 12 months or not), an indicator for the presence of a toilet
in the child’s house (which is considered as a proxy for hygienic habits), and the indicator for
children experiencing measles in their lifetime (based on the information provided by their
parents). For the analysis, we considered placebo, female gender, child’s age ≤ 12 months,
no presence of toilet at home, and never experiencing measles as the reference groups. Table
3.3 summarizes the distribution of the baseline variables in the subcohort and the full cohort.
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Table 3.3: Baseline Characteristics of the Acute Lower-Respiratory-Tract Infections study
Variables Full Cohort (n = 1190) Subcohort (n˜ = 238)
Treatment (Vit. A: 1 vs. Placebo: 0) 0.5017 0.4790
Gender (Boys: 1, Girls: 0) 0.5244 0.5462
Age (≤ 1 yr: 1, > 1 yr: 0) 0.1311 0.1597
Toilet at home (Yes: 1) 0.7361 0.7479
Table 3.3 shows that the distribution of the variables in the subcohort are very similar to
that in the full cohort. We applied our proposed method to the case-cohort sample.
Table 3.4: Estimates and standard errors for the multiplicative rates model with data from
case-cohort sample from the ALRI study
Effects Proposed method
Case-Cohort (α˜ = 0.2)
Estimate SE
Treatment (Reference: Placebo) 0.0534 0.1995
Gender (Ref: Female) -0.0056 0.1965
Age (Ref: > 12 months) 1.6859 0.3102
Toilet at home(Ref: Absence) -0.9033 0.1759
Measles Indicator (Ref: Never) 0.0853 0.3395
Table 3.4 provides results from the model adjusting for covariates. Dichotomized age and
presence of toilet at home are significant predictors of the recurrence of ALRI among young
children, adjusting for the other variables in the model. Among the other variables, from
Table 3.4, high doses of Vitamin A, gender and prior measles indicator are not significantly
associated with recurrence of ALRI. Further, controlling for all other variables, children in
households with toilets are at a 0.595 times lower risk, of developing ALRI, than the children
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living in household without a toilet. Similarly, the risk of ALRI recurrence among children
who are younger than 12 months are 5.397 times that of children who are older than 12
months.
In the above analysis, we defined a case as an individual who has experienced at least one
event. One can use different definitions of a ‘case’ for recurrent events, based on the number
of events. It is of interest to examine the performance of the estimates based on the different
case definition for sampling. We conducted some simulations by sampling from the ALRI
study. Sub-cohort proportion was selected as 20% and the number of simulations considered
is 1000. We have considered three definitions for ‘case’: subjects who experienced at least
one event, at least two events, or at least three events. Table 3.5 shows the results from the
simulations for the different ‘case’ definitions. We note that the standard errors were the
lowest with the at least one case definition. This could be due to the smaller supplementary
case samples with the other definitions.
Table 3.5: Estimates and standard errors for different definitions of case for case-cohort
sample from the ALRI study
Effects Case Definition
≥ One Event ≥ Two events ≥ Three events
Estimate SE Estimate SE Estimate SE
Treatment -0.0272 0.197 -0.0299 0.202 -0.0268 0.205
Gender -0.118 0.196 -0.121 0.202 -0.132 0.205
Age 1.697 0.290 1.701 0.320 1.702 0.336
Toilet at home -0.691 0.182 -0.695 0.186 -0.698 0.188
Prior Measles 0.0538 0.339 0.0488 0.361 0.0458 0.365
3.6 Final Remarks
This article proposes methods of fitting marginal multiplicative rates model for both the
case-cohort and the generalized case-cohort designs with time-varying weights. The proposed
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estimators are natural generalizations of the full cohort estimators and has easy interpretation.
The proposed estimators are consistent and asymptotically distributed. They perform well
in finite samples. Throughout this article, for the case-cohort analysis, we have assumed
simple random sampling for the subcohort and all individuals who have experienced the event.
Bernoulli sampling of the subcohort is another sampling scheme that can be considered.
In our approach, we do not use all the covariate information that are available for the entire
cohort. Developing a more general method taking advantage of those covariates information
to improve the efficiency of the estimators is worthy of future research. We have considered
event proportion (individuals with atleast one event) around 25%− 50% to be corresponding
to a relatively common event. It can be noted that when the event proportion is > 50%, then
simple random sample of the entire cohort should yield sufficient data to achieve the desirable
power. Extension of this approach to additive rates model and for multiple types of recurrent
events are under further investigation.
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CHAPTER 4: ADDITIVE RATES MODEL FOR RECURRENT EVENTS
WITH CASE-COHORT DATA
4.1 Introduction
The additive and multiplicative rates models are two different frameworks to study the
association between various risk factors and time to event data. Most modern survival analy-
ses focus on the multiplicative model for relative risk using Cox’s (1972) proportional hazards
model, mainly because of the availability of computer programs and the easy interpretability
of the results. However, investigators are sometimes interested in the risk difference because
it translates directly into the number of event cases that can be avoided by eliminating the ex-
posure (Kulich and Lin 2000). As a result, depending on the interest, an additive rates model
can be considered instead of a multiplicative rates model, especially when the multiplicative
model assumption does not hold.
Aalen (1980) first proposed the additive hazards model as an alternative to the Cox (1972)
proportional hazards model. The author noted that since the covariate effects are not assumed
to be proportional, the additive model is capable of providing information about the temporal
influence of each covariate that is not available from the Cox model. Several authors have
studied theoretical developments of such models for univariate failure times. These include
semi-parametric estimation procedure by Lin and Ying (1994), application to current status
data (Lin et al. 1998), modeling in presence of auxiliary covariate information (Jiang and
Zhou 2007), among others. Yin and Cai (2004) extended the idea to multivariate failure time
data. Schaubel et al. (2006) and He et al. (2013) proposed semi-parametric additive rates
models for clustered recurrent event data.
All the aforementioned articles assume that data are fully available for all the members
in the cohort. However, in epidemiology studies, cost constraints often make it infeasible to
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collect information on all the individuals in the cohort, especially when some covariates are
expensive to measure. Usually, the majority of the cost comes from the assembling of the
covariate data and most of the information on the event-free individuals in the cohort are
redundant if the event rate is low. The case-cohort sampling scheme (Prentice 1986) is one
of the several study designs that have been proposed to reduce cost in large epidemiological
cohort studies. The key principle of this design is to obtain covariate information on only a
random subset of the cohort (which is called the sub-cohort) and all individuals in the cohort
who experience the event of interest (cases). This leads to the case-cohort studies being
considered as an appealing alternative to full-cohort studies for large-scale epidemiological
studies where the event is rare or the covariates are quite expensive to measure. When the
event rate is not rare, due to financial limitation or technical difficulties, measuring important
covariates in the entire cohort may be impractical. In such situation, it is advisable to consider
cost-effective sampling designs for selecting subjects from the cohort to reduce the study cost,
without losing much of the efficiency. One such study design is the generalized case-cohort
design (Kulich and Lin 2004) where covariate information is collected for the sub-cohort and
a random sample of the remaining cases. Kulich and Lin (2000), Kang et al. (2013), Yu et al.
(2014), Dong et al. (2014), Kim et al. (2016), Cao and Yu (2017) among others developed the
semi-parametric inference of additive hazards models for two-phase designs, more specifically
case-cohort and generalized case-cohort studies.
Despite the abundance of methodologies in the time-to-event literature for analyzing single
event case-cohort data, methods to analyze recurrent events under the case-cohort design have
been limited. In this paper, we look at the additive rates model for modeling recurrent events
under the generalized case-cohort design, in order to reduce the cost of collecting expensive
covariate information. Our illustrating example is a randomized double-blind clinical trial
which was carried out by Genentech in 1992 to study the effect of rhDNase on pulmonary
exacerbations in patients with cystic fibrosis (Therneau and Hamilton 1997). Six hundred
and sixty-five patients were followed up for 169 days and data on multiple exacerbations
were collected during this period with about 36.54% of the individuals (rhDNase and Placebo
combined) experiencing at least one such event. We will use this data to illustrate our
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proposed method under generalized case-cohort design.
In the next section, we propose a weighted estimating equation approach for estimating
the parameters in the marginal hazard regression model for recurrent event data from case-
cohort studies. The asymptotic properties of the proposed estimators are studied in section
4.3. The outlines of the proofs of the asymptotic properties are given in the appendix. In
section 4.4, simulation studies were considered to examine the finite sample properties. In
section 4.5, we illustrated the proposed method on a case-cohort study based on the rhDNase
clinical trial. We conclude the paper with a brief discussion.
4.2 Model and Estimation
Suppose there are n independent individuals in the cohort. Let N∗i (t) be the number of
recurrent events for the individual i over the time interval [0, t), Ci is the censoring time. Zi(.)
= (ZEi (.)
′, ZCi (.)
′)′ is the p-dimensional covariate of interest for the individual i, where ZEi (.)
is the set of expensive-to-measure variables and ZCi (.) is the set of all other covariates. Let T
∗
ij
denote the j-th recurrent event time for the individual i. The observed time is Tij = T
∗
ij ∧Ci,
j = 1, 2, . . . , ni + 1, where ni is the number of events that are observed for individual i, and
N =
∑n
i=1 ni is the total number of observed events. Let Yi(t) = 1(Ci ≥ t), Ni(t) = N∗i (t∧Ci)
=
∑ni
j=1 I(Tij ≤ t) =
∑ni
j=1 I(T
∗
ij ≤ t)Yi(t), ∆i = 1− I(minj(T ∗ij) ≥ Ci) which is the indicator
that individual i experienced at least one event, and τ denote the study ending time. The rate
function for an individual is denoted as E (dN∗(t) | Z(t)) = dµz(t). We assume the following
additive rate model :
dµZ(t) = dµ0(t) +
(
θ′0Z
E(t) + γ′0Z
C(t)
)
dt⇒ µZ(t) = µ0(t) +
ˆ t
0
{
θ′0Z
E(u) + γ′0Z
C(u)
}
du,
(4.1)
where µ0(.) is an unspecified continuous baseline mean function and θ0 and γ0 are the vectors
of unknown parameters. Denoting β0 = (θ
′
0, γ
′
0)
′, we can rewrite the rates model as dµZ(t) =
µ0(t) + β
′
0Z(t)dt and the mean function is given by µZ(u) = µ0(u) +
´ u
0 β
′
0Z(t)dt for all
u ∈ [0, τ ]. Note that the covariates are allowed to be time-dependent. We assume that the
possibly time-dependent covariates are external (Kalbfleisch and Prentice 2002), i.e., they are
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not affected by the recurrent event process. If the data were complete, the true regression
parameter β0 can be estimated from the following estimating equations (Schaubel et al. 2006):
n∑
i=1
ˆ t
0
Yi(u)dMi(u) = 0 (4.2)
n∑
i=1
ˆ t
0
Yi(u)Zi(u)dMi(u) = 0, (4.3)
where Mi(t) = Ni(t) −
´ t
0 Yi(u) {dµ0(u) + β′0Zi(u)du}. Combining the above two equations,
we have
U(β) =
n∑
i=1
ˆ τ
0
(
Zi(t)− Z¯(t)
) [
dNi(t)− Yi(t)β′0Zi(t)dt
]
= 0, (4.4)
where Z¯(t) =
∑n
i=1 Yi(t)Zi(t)∑n
i=1 Yi(t)
. The above estimating equation can be solved explicitly to obtain
an estimator of β given by βˆ =
[
1
n
∑n
i=1
´ τ
0 Yi(t)
{
Zi(t)− Z¯(t)
}⊗2
dt
]−1 (
1
n
∑n
i=1
´ τ
0 {Zi(t)
−Z¯(t)}× dNi(t)) . However, for case-cohort data, since we do not have information on all
the individuals, the estimating cannot be applied directly.
4.2.1 Case-cohort study design for recurrent events
In this subsection, we introduce two sampling schemes for the recurrent event data. We
call an individual a case if the individual experienced at least one event and an individual a
non-case if the individual did not have any event during the study period. The first sampling
scheme deals with the situation that the event is not common in the population. An example of
such situation is a doubly-blind, placebo-controlled community trial conducted in northeastern
Brazil among young children to evaluate the effect of high doses of vitamin A on acute-lower-
respiratory-tract infection (ALRI)(Barreto et al. 1994). The event of interest occurs in only
about 15% of the cohort. In this case, we draw a random sample from the full cohort and
supplement that with all the cases. We call this sampling scheme the original case-cohort
design with recurrent events. The second sampling scheme is for the situation described in
Section 4.1. In this case, the event is relatively common and we cannot afford to sample
all individuals with events. Under such circumstance, we propose to sample only a fraction
of those who have events for the case-cohort sampling. We call this sampling scheme the
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generalized case-cohort design with recurrent events.
4.2.2 Estimation under the original case-cohort design
Under the case-cohort sampling, we select a sub-cohort from the entire cohort by simple
random sampling. Let ξi denote the indicator function for individual i being selected into the
subcohort; α˜ = n˜n is the subcohort proportion where n˜ is the number of individuals selected
in the sub-cohort and n is the number of individuals in the full cohort. The observable
information for individual i is {Ti,∆i, ξi, ZCi (t), ZEi (t), t ∈ [0, τ ]} if individual i is in the case-
cohort sample. In other words, we have {Ti,∆i, ξi, Zi(t), 0 ≤ t ≤ τ} if ∆i = 1 or ξi = 1 and
{Ti,∆i, ξi, ZCi (t), t ∈ [0, τ ]} when ∆i = 0 and ξi = 0. We considered the following estimating
equation to estimate β0.
U I(β) =
n∑
i=1
ˆ τ
0
wIi (t)
{
Zi(t)− Z¯I(t)
} [
dNi(t)− Yi(t)β′Zi(t)dt
]
= 0, (4.5)
where Z¯I(t) =
∑n
i=1 w
I
i (t)Yi(t)Zi(t)∑n
i=1 w
I
i (t)Yi(t)
, wIi (t) = ∆i + (1 − ∆i) ξiαˆ(t) , where αˆ(t) =
∑
i(1−∆i)ξiYi(t)∑
i(1−∆i)Yi(t) is
the estimator of the true sampling parameter, α. The weight is 1 for all the cases and is
αˆ(t)−1 for the non-cases in the sub-cohort. Similar idea for the weights was considered by
Kalbfleisch and Lawless (1988) for a single event. They considered the time-invariant version
of αˆ(t), which was given by α˜. Borgan et al. (2000) used a similar idea for univariate failure
time data from stratified case-cohort studies. We denote the solution to this equation by βˆI .
Our proposed Breslow-Aalen type estimator of the baseline mean function is given by
µˆ0(βˆ
I , t) =
ˆ t
0
∑n
i=1w
I
i (u)
[
dNi(u)− Yi(u)(βˆI)′Zi(u)du
]
∑n
i=1w
I
i (u)Yi(u)
. (4.6)
4.2.3 Estimation under the generalized case-cohort design with recurrent events
For the generalized case-cohort design, we sample a fraction of cases outside of the sub-
cohort. Let ηi be an indicator of being sampled for individual i who is a case but outside the
sub-cohort being sampled. Let q˜ =
n∗1
n1−n˜1 denote the sampling proportion for the additional
cases, where n∗1, n1 and n˜1 are the number of selected individuals who have experienced at least
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one event but are not in the subcohort, individuals who experienced at least one event in the
full cohort and those who were in the subcohort respectively. Under this design, the covariate
information is available for the subcohort members and the selected cases (ηi = 1). Hence,
the observable information for individual i is {Ti,∆i, ξi, ηi, Zi(t) : t ∈ [0, τ ]} when ξi = 1 or
ηi = 1 and {Ti,∆i, ξi, ZCi (t), t ∈ [0, τ ]} if ξi = 0 and ηi = 0. Using the inverse of probability of
being sampled as the weight, our proposed estimating equation for the generalized case-cohort
sampling scheme is
U II(β) =
n∑
i=1
ˆ τ
0
wIIi (t)
{
Zi(t)− Z¯II(t)
} [
dNi(t)− Yi(t)β′Zi(t)dt
]
= 0, (4.7)
where Z¯II(t) =
∑n
i=1 w
II
i (t)Yi(t)Zi(t)∑n
i=1 w
II
i (t)Yi(t)
. The weight function is given by wIIi (t) =
(1−∆i)ξi
αˆ(t) +∆iξi+
∆i(1−ξi)ηi
qˆ(t) where qˆ(t) =
∑
i ∆i(1−ξi)ηiYi(t)∑
i ∆i(1−ξi)Yi(t) is the estimator of the true sampling parameter q.
We denote the solution of this equation by βˆII . The Breslow-Aalen type estimator of the
baseline mean function is
µˆ0(βˆ
II , t) =
ˆ t
0
∑n
i=1w
II
i (u)
[
dNi(u)− Yi(u)(βˆII)′Zi(u)du
]
∑n
i=1w
II
i (u)Yi(u)
. (4.8)
Throughout this article, we use superscript I or II depending on whether the quantity corre-
sponds to the original case-cohort design or the generalized case-cohort design respectively.
4.3 Asymptotic properties
In this section, we investigate the asymptotic properties of the estimators. Define the
following terms: e(t) = E(Yi(t)Zi(t))E(Yi(t)) , A = E
[´ τ
0 Yi(t)
{
Zi(t)
⊗2 − e(t)⊗2} dµ0(t)] , Z˜i(t) =
Zi(t)− e(t), dMi(t) = dNi(t)− Yi(t) [dµ0(t) + β0Zi(t)] ,MZ˜,i(β) =
´ τ
0 Z˜i(t)dMi(t). Further,
the norms of a vector, a, is defined as ‖a‖ = maxi |ai|, for a matrix A by ‖A‖ = maxi,j‖Aij‖
and for a function f by ‖f‖ = supt |f(t)|. The estimator under the classical case-cohort
sampling scheme is a special case of the generalized case-cohort sampling scheme, so its
asymptotic property is a special case of the generalized case-cohort sampling scheme. Hence,
in the Appendix, we focus the proofs on the asymptotic properties of the estimators under the
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generalized case-cohort design, βˆII and µˆII0 (βˆ
II , t). The regularity conditions and the outline
of the proofs are provided in the Appendix. The asymptotic properties are summarized in
the following theorems.
Theorem 3. Under the regularity conditions in the Appendix, for k = I or II, βˆk is a
consistent estimator of β0. n
1/2{βˆk − β0} converges to a Gaussian distribution with mean
zero and variance given by
Σk(β0) = A
−1
[
Q(β0) +
1− α
α
V I(β0) + I(k = II)(1− α)1− q
q
P (∆1 = 1)V
II(β0)
]
A−1,
where
A = E
[ˆ τ
0
Yi(t)
{
Zi(t)
⊗2 − e(t)⊗2} dt] , Q(β) = E (MZ˜,1(β))⊗2 ,
V I(β0) = E
(
(1−∆1)
ˆ τ
0
[
dR1(β0, t)− Y1(t)E((1−∆1)dR1(β0, t))
E((1−∆1)Y1(t))
])⊗2
,
V II(β0) = var
(
MZ˜,i(t)−
ˆ τ
0
Yi(t)E(dMZ˜,1(t) | ∆1 = 1, ξ1 = 0)
E(Y1(t) | ∆1 = 1) | ∆i = 1, ξi = 0
)
,
dRi(β, t) = Yi(t)Z˜i(t){dµ0(t) + β0Zi(t)dt}.
Each of these terms, A, Q(β0), V
I(β0) and V
II(β0) can be estimated respectively by their
sample counterparts, Aˆ, Qˆ(βˆk) and Vˆ I(βˆk), where Aˆ = − 1n ∂U
k(β)
∂β , Qˆ(β) =
1
n
∑n
i=1
ξi
α˜(
MZ˜,i(β)
⊗2
)
, MˆZ˜,i(β) =
´ τ
0 {Zi(t)− Z¯k(t)}dMˆki (β, t), dMˆki (β, t) = dNi(t)−Yi(t){dµˆ0(β, t) +
β′Zi(t)dt}, ˆ¯Zk(β, t) =
∑n
i=1 wˆi
k(t)Zi(t)Yi(t)∑n
i=1 wˆi
k(t)Yi(t)
, dRˆIIi (β, t) =
{
Zi(t)− Z¯II(t)
}
Yi(t)
{
dµˆII0 (β, t)+
β′Zi(t)dt} , dµˆII0 (β, t) =
∑
i w
II
i (t){dNi(t)−Yi(t)β′Zi(t)dt}∑
j w
II
j (t)Yj(t)
, Eˆ (∆1(1− ξ1)dR1(β, t)) = 1n
∑n
i=1
ηi
q˜ ∆i(1−
ξi)dRˆ
II
i (β, t), Eˆ (∆1(1− ξ1)Y1(β, t)) = 1n
∑n
i=1 ∆i(1 − ξi)Yi(t). Based on these, we have the
following estimates of the second and third terms of the variance as
Vˆ I(β) =
1
n
n∑
i=1
ξi
α˜
(1−∆i) n∑
j=1
nj∑
k=1
{
RˆIIi (β, Tjk)−
Yi(Tjk)Eˆ ((1−∆1)dR1(β, Tjk))
Eˆ ((1−∆1)Y1(Tjk))
}⊗2 ,
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Vˆ II(β) =
1
n
n∑
i=1
ηi
q˜
[
∆i(1− ξi)
{
MˆZ˜,i(β)−
ni∑
k=1
ˆ Tik
0
Eˆ(dMZ˜,1(t) | ∆1 = 1, ξ1 = 0)
Eˆ(Y1(t) | ∆1 = 1)
}]⊗2
.
To obtain the asymptotic distribution of the baseline mean function µˆ0(t), we need to
first define the metric space, D[0, τ ], consisting of right continuous functions f(t) with left-
hand limits and f : [0, τ ] → R. The metric for this space is defined by d(f, g) = supt∈[0,τ ]{|
f(t) − g(t) |} for f(t), g(t) ∈ D[0, τ ]. The following theorem summarizes the asymptotic
properties of µˆk0(t).
Theorem 4. Under the regularity conditions in Appendix, for k = I or II, µˆk0(β, t) converges
in probability to µ0(t) uniformly in t ∈ [0, τ ]. Further, defining Wn(t) = µˆk0(βˆk, t) − µ0(t),
n1/2Wn(t) converges to a Gaussian distribution with mean zero. The variance-covariance
function between Wn(t) and Wn(s) is given by
φk(t, s)(β0) = E (νi(β0, t)νi(β0, s)) +
1−α
α E
(
ψIi (β0, t)ψ
I
i (β0, s)
)
+I(k = II)1−qq E
(
ψIIi (β0, t)ψ
II
i (β0, s)
)
,
where
νi(β0, t) =
[
r(t)′A−1
ˆ τ
0
(Zi(t)− e(t)) dMi(t) +
ˆ t
0
dMi(u)
E(Y1(u))
]
,
ψIi (β0, t) = (1−∆i)
[
r(t)′A−1
(
Ri(β0)−
ˆ τ
0
Yi(t)E((1−∆1)dRi(β0, t))
E((1−∆1)Yi(t))
)
+
ˆ t
0
1
E (Y1(u))
Yi(u)
[
β′0Zi(u)−
E ({1−∆1}Y1(u)β′0Z1(u))
E((1−∆1)Y1(u))
]
du
]
and
ψIIi (β0, t) = ∆i(1− ξi)r(t)′A(β0)−1
ˆ τ
0
dMZ˜,i(u)− Yi(u)E
[
dMZ˜,1(u) | ∆1 = 1, ξ1 = 0
]
E(Y1(u) | ∆1 = 1)

+ ∆i(1− ξi)
ˆ t
0
1
E (Y1(u))
{
dMi(u)− Yi(u)E [dM1(u) | ∆1 = 1, ξ1 = 0]
E(Y1(u) | ∆1 = 1)
}
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Each of these terms can be consistently estimated by their sample counterparts. φˆII(t, s)(β) =∑n
i=1
ξi
α˜ (νˆi(β, t)νˆi(β, s)) +
1−α˜−1
n
∑n
i=1
ξi
α˜
(
ψˆIi (β, t)ψˆ
I
i (β, s)
)
+1−q˜
−1
n
∑n
i=1
ηi
q˜
(
ψˆIIi (β, t)
×ψˆIIi (β, s)
)
, νˆi(β, t) = rˆ
I(β, t)′Aˆ−1MˆZ˜,i(β, t)+
´ t
0{Eˆ(Y1(u))}−1dMˆi(u), ψˆIi (β, t) =
[
rˆI(β, t)′Aˆ−1
(1−∆i) ×
{
RˆIIi (β, u)−
´ τ
0
Yi(u)Eˆ((1−∆i)Yi(u)Z˜i(u))dµˆ0I(u)
Eˆ((1−∆i)Yi(u)) −
´ τ
0
Yi(u)Eˆ((1−∆i)Yi(u)Z˜i(u))β′0Zi(u)du
Eˆ((1−∆i)Yi(u))
}
+(1−∆i)
´ t
0
(
β′Zi(u)− Eˆ((1−∆i)Yi(u)β
′Zi(u))
Eˆ((1−∆i)Yi(u))
)
× Yi(u)dµ0(u)
Eˆ(Yi(u))
]
, ψˆIIi (β, t) = ∆i(1−ξi)
[
rˆI(β, t)′Aˆ−1
´ τ
0
{
dMˆZ˜,i(u)− Yi(u)
Eˆ[dMZ˜,1(u)|∆1=1,ξ1=0]
Eˆ(Y1(u)|∆1=1)
}
+
´ t
0
1
Eˆ(Y1(u))
{
dMˆi(u)− Yi(u) Eˆ[dM1(u)|∆1=1,ξ1=0]Eˆ(Y1(u)|∆1=1)
}]
,
Eˆ((1−∆i)Yi(u)β′Zi(u)) = 1n
∑n
i=1(1−∆i) ξiα˜ Yi(t)β′Zi(t), Eˆ(Yi(u)) = 1n
∑n
i=1 Yi(u), rˆ
I(β, t) =
− ´ τ0 Z¯II(t)dt, Eˆ(∆i(1− ξi)Yi(u)β′Zi(u)) = 1n∑ni=1 ∆i(1− ξi)ηiq˜ Yi(t)β′Zi(t).
4.4 Simulation Studies
We conducted simulation studies to examine the finite sample properties of the proposed
estimators. For subject i, the (j + 1)-th event time is generated by
Ti,j+1 = Ti,j − log(1− Ui,j+1)
Qi +m0 + β0Zi
,
where m0 is the baseline rate, β0 is the unknown parameter, Ui,j+1 are independent Uni-
form(0,1) variates and Ti,0 = 0. The frailty variable, Qi, induces positive correlation among
the within-subject events. It follows a Gamma distribution with mean E(Qi) = 1 and vari-
ance σ2Q. We consider both discrete and continuous Z for the simulations. We considered
binary covariate generated from Bernoulli (0.5) and continuous covariate from Uniform (0,1).
We considered different cohort sizes: 1000, 2000 and 4000 and the number of simulation rep-
etition is 1000. We considered σ2 such that mean recurrence is 3 for those who had at least
one event. We considered β0 to be 0.5 or 0.
Table 4.1 summarizes simulation results for situations that the proportion of individuals
who experienced at least one event was low (5%, 10%, 20%). For the case-cohort sampling,
the sub-cohort sampling proportion was 25% and all cases were sampled. The simulation
results show that the coefficient estimates are approximately unbiased for all the situations
we considered. From Table 4.1, we note that the proposed estimated standard errors provide
good estimates of the true variability of βˆI in all the situations except for when both the full
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cohort and the event rate are very small. As the cohort size increases, the performance of the
estimated standard error improves. The variance of βˆI decreases as the cohort size and/or
the event proportion increases. The coverage rate of the nominal 95% confidence intervals
using the proposed method is in the 92 − 95% range in all the situations considered except
when both the event rate and the cohort size are small. As the cohort size or event rate
increases, the 95% confidence interval coverage rate improves. Specifically, when the event
rate is at 5%, the confidence interval coverage is around 80% when the cohort size is 1000
(case cohort size = 288). However, the performance improves as the cohort size or event rate
increases. Specifically, for continuous covariate, the confidence interval rate is close to the
nominal level when the cohort size is 6000, 4000 or 2000 for event rate of 5% (case cohort size
is 1725, 1300 or 800), 10% and 20% respectively. The corresponding required cohort size is
smaller for discrete covariate.
Table 4.1: Summary of Simulation Results of βˆI for Additive Model
Z β0 Cohort Event Bias Model Empirical Coverage
Size proportion Std. Error Std. Dev.
Bernoulli(0.5) 0 1000 0.05 0.008 0.712 0.729 0.822
0.10 0.018 0.555 0.556 0.905
0.20 -0.011 0.305 0.301 0.928
2000 0.05 0.020 0.499 0.508 0.872
0.10 -0.005 0.391 0.390 0.916
0.20 0.002 0.217 0.223 0.92
4000 0.05 0.0005 0.345 0.339 0.926
0.10 -0.005 0.274 0.273 0.951
0.20 -0.007 0.154 0.151 0.955
6000 0.05 0.005 0.280 0.269 0.952
0.10 -0.001 0.221 0.221 0.941
0.20 -0.004 0.124 0.124 0.94
0.5 1000 0.05 0.059 0.709 0.725 0.81
62
0.10 0.031 0.566 0.569 0.903
0.20 -0.005 0.319 0.315 0.935
2000 0.05 0.036 0.497 0.504 0.871
0.10 0.007 0.400 0.398 0.927
0.20 0.006 0.227 0.235 0.918
4000 0.05 0.006 0.344 0.336 0.92
0.10 -0.002 0.281 0.279 0.950
0.20 -0.006 0.161 0.162 0.949
6000 0.05 0.0057 0.279 0.269 0.946
0.10 0.002 0.227 0.227 0.935
0.20 -0.005 0.130 0.131 0.94
Unif(0,1) 0 1000 0.05 0.026 1.274 1.300 0.793
0.10 0.036 0.967 0.961 0.887
0.20 -0.004 0.530 0.513 0.938
2000 0.05 0.070 0.860 0.863 0.847
0.10 0.010 0.683 0.665 0.907
0.20 -0.001 0.375 0.384 0.922
4000 0.05 -0.002 0.598 0.595 0.893
0.10 -0.018 0.477 0.482 0.928
0.20 -0.013 0.267 0.263 0.944
6000 0.05 0.009 0.483 0.465 0.927
0.10 0.004 0.386 0.376 0.948
0.20 -0.006 0.217 0.213 0.952
0.5 1000 0.05 0.046 1.271 1.292 0.779
0.10 0.045 0.986 0.983 0.891
0.20 0.003 0.555 0.546 0.93
2000 0.05 0.084 0.857 0.860 0.847
0.10 0.024 0.697 0.674 0.919
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0.20 0.001 0.394 0.404 0.92
4000 0.05 0.005 0.596 0.595 0.888
0.10 -0.012 0.488 0.495 0.929
0.20 -0.009 0.280 0.278 0.944
6000 0.05 0.013 0.481 0.463 0.927
0.10 0.005 0.395 0.385 0.945
0.20 -0.006 0.227 0.223 0.955
Table 4.2 summarizes the simulation results for situations when the proportion of events
is not low (25%, 30% and 40%). We considered generalized case-cohort sampling. The
sub-cohort sampling proportion is 10% and sampling proportion for the cases outside the
sub-cohort is also 10%. The simulation results show that overall the coefficient estimates are
approximately unbiased, the proposed variance estimator is close to the empirical variance,
and the 95% confidence interval coverage is close to the nominal level for all the situations
considered, except for when both the cohort size (1000 and 2000) and the event rate (25%)
are both relatively low. As the cohort size or the event rate increases, the 95% confidence
interval coverage improves.
Table 4.2: Summary of Simulation Results of βˆII for Additive Model
Z β0 Cohort Event Bias Model Empirical Coverage
Size proportion Std. Error Std. Dev.
Bernoulli(0.5) 0 1000 0.25 0.028 1.199 1.257 0.969
0.30 0.037 1.249 1.310 0.965
0.40 0.062 1.129 1.181 0.949
2000 0.25 -0.031 0.850 0.897 0.963
0.30 -0.005 0.871 0.892 0.967
0.40 0.038 0.798 0.796 0.957
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4000 0.25 -0.006 0.612 0.635 0.954
0.30 -0.021 0.625 0.646 0.960
0.40 -0.015 0.557 0.586 0.946
6000 0.25 0.007 0.498 0.510 0.954
0.30 0.004 0.509 0.514 0.946
0.40 -0.014 0.456 0.453 0.958
8000 0.25 0.004 0.609 0.621 0.959
0.3 -0.0002 0.621 0.639 0.959
0.4 -0.004 0.564 0.591 0.942
0.5 1000 0.25 0.114 1.188 1.247 0.972
0.30 0.046 1.246 1.290 0.959
0.40 0.004 1.104 1.117 0.950
2000 0.25 -0.054 0.855 0.865 0.980
0.30 0.023 0.888 0.887 0.958
0.40 0.017 0.781 0.792 0.947
4000 0.25 0.016 0.613 0.611 0.965
0.30 0.009 0.621 0.635 0.958
0.40 -0.049 0.562 0.586 0.947
6000 0.25 0.018 0.500 0.515 0.939
0.30 -0.017 0.506 0.506 0.954
0.40 -0.007 0.454 0.453 0.959
8000 0.25 -0.007 0.613 0.617 0.965
0.3 0.007 0.624 0.626 0.960
0.4 -0.033 0.559 0.585 0.941
Unif(0, 1) 0 1000 0.25 0.069 2.093 2.183 0.971
0.30 0.069 2.171 2.258 0.959
0.40 0.118 1.94 2.098 0.954
2000 0.25 -0.029 1.480 1.553 0.971
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0.30 -0.013 1.506 1.536 0.972
0.40 0.041 1.356 1.364 0.957
4000 0.25 -0.013 1.059 1.089 0.974
0.30 -0.044 1.085 1.126 0.954
0.40 -0.013 0.963 1.018 0.946
6000 0.25 0.004 0.861 0.861 0.973
0.30 0.002 0.889 0.895 0.96
0.40 -0.014 0.784 0.777 0.967
8000 0.25 0.006 1.05 1.067 0.971
0.3 -0.001 1.067 1.095 0.960
0.4 0.014 0.979 1.023 0.946
0.5 1000 0.25 -0.035 2.070 2.263 0.960
0.30 0.007 2.129 2.255 0.969
0.40 -0.064 1.910 1.941 0.954
2000 0.25 0.031 1.498 1.480 0.972
0.30 0.060 1.520 1.559 0.967
0.40 0.044 1.387 1.393 0.957
4000 0.25 -0.043 1.042 1.050 0.97
0.30 -0.064 1.058 1.087 0.958
0.40 0.039 0.968 0.994 0.955
6000 0.25 -0.024 0.872 0.867 0.959
0.30 -0.013 0.877 0.883 0.960
0.40 -0.031 0.790 0.787 0.952
8000 0.25 -0.009 1.049 1.077 0.967
0.3 -0.003 1.066 1.086 0.963
0.4 0.017 0.972 0.997 0.954
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4.5 Real Data Application
In patients with cystic fibrosis, extracellular DNA (which are released by leukocytes)
accumulates in the lung. This leads to exacerbations of respiratory symptoms and progressive
deterioration of lung function. Lung disease has been considered as a leading cause of death
among cystic fibrosis patients, accounting for over 90% of eventual deaths. DNase I is a
human enzyme normally present in the mucus of human lungs that digests extracellular
DNA. Genentech Inc. cloned a highly purified recombinant DNase I (rhDNase) in an effort
to reduce the viscoelasticity of airway secretions and improving clearance (Therneau and
Hamilton 1997). The company conducted a randomized double-blind clinical trial in 1992
comparing rhDNase to placebo for pulmonary exacerbations. For the purpose of the analysis,
645 individuals were eligible who were randomly assigned rhDNase or placebo at the beginning
of the study. The primary end-point of the original study was the first pulmonary exacerbation
but data was collected on all exacerbation in the follow-up period. We have used information
on all the events for this analysis. The largest follow-up time was 170 days, with 37.52% of
the cohort experiencing at least one event. Among those individuals who had at least one
event, the average number of events is around 1.5. Further, for individuals who experienced
a pulmonary exacerbation, they were temporarily absent from the risk sets.
Since the event is not rare, we constructed a generalized case-cohort (GCC) sample based
on this cohort study to illustrate our proposed method. We consider the baseline forced
expiratory volume in 1 second (FEV1) as the expensive variable which is only available for the
GCC sample. We are interested in studying the effect of FEV1 on the recurrence of pulmonary
exacerbations. We considered the sub-cohort selection proportion to be 0.2. Fifteen percent
of all the individuals, who experienced at least one event but were not selected in the initial
sub-cohort, were selected in the second stage to form the generalized case cohort sample.
The total sample size of the GCC is 157 with 129 people in the sub-cohort. The following
covariates were considered in the analysis: treatment group (rhDNase vs placebo) and FEV1.
Table 4.3 summarizes the distribution of the baseline variables in the sub-cohort and the full
cohort.
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Figure 4.1: Plots of the cumulative rates function estimates vs time for the three variables
Table 4.3: Baseline Characteristics of the rhDNase study
Variables Full Cohort (n = 645) Subcohort (n˜ = 129)
Treatment (rhDNase vs. Placebo) 0.4977 0.4806
FEV1 57.6 (38.4, 83.2) 60.8 (41.6, 83.5)
Table 4.3 shows that the distribution of the variables in the subcohort are quite similar
to that in the full cohort. As an exploratory analysis, we have also looked at the cumulative
rates for the two variables considered. The cumulative rate function was calculated non-
parametrically for the different groups. It is defined as the ratio of the total number of events
at time t and the total number of individuals at risk at that time. To get an idea about the
cumulative rate function of FEV1, we have dichotomized it. Further, we have centered and
scaled FEV1 to reduce the variability in the variable.
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Table 4.4: Estimates and standard errors for the multiplicative rates model with data from
GCC sample from the rhDNase study
Effects Proposed method: GCC (α˜ = 0.2, q˜ =0.15)
Estimate SE
Treatment (Reference: Placebo) −0.00288 1.68× 10−3
FEV∗1 −0.00204 7.26× 10−4
Figure 4.1 shows that, as time (measured in days) increases, the differences in the cumu-
lative rates function estimates for two different levels of treatment as well as dichotomized
FEV1 increase approximately in a linear fashion. Therefore, it is reasonable to assume the
additive effect of both the variables on the rates functions for the recurrence of pulmonary
exacerbations. From the figure, one can visualize the effects to be different in the two groups.
We fit the multivariable additive rates model to the data to test whether the differences are
statistically significant. Table 4.4 provides results from the multivariable model. Adjusting
for the treatment, forced expiratory volume in 1 second, FEV1, is found to be statistically
significant predictor of the recurrence of pulmonary aggravation. Hence, for an 1 sd incre-
ment in FEV1, the risk of pulmonary exacerbations reduced by 0.2%. Further, the treatment
variable is also found to be not significant.
In the above analysis, we defined a case as an individual who has experienced at least one
event. One can use different definitions of a ‘case’ for recurrent events, based on the number
of events. It is of interest to examine the performance of the estimates based on the different
case definition for sampling. We conducted some simulations by sampling from the rhDNase
study. Sub-cohort proportion was selected as 20% and the number of simulations considered
is 1000. We have considered three definitions for ‘case’: subjects who experienced at least
one event, at least two events, or at least three events. Table 4.5 shows the results from the
simulations for the different case definitions. We note that the standard errors were quite
similar for each of the case definitions, all of which are very close to 0.
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Table 4.5: Estimates and standard errors for different definitions of ‘case’ for GCC sample
from the rhDNase study
Effects Case Definition
≥ One Event ≥ Two events ≥ Three events
Estimate SE Estimate SE Estimate SE
Treatment -0.00104 0.00543 -0.000980 0.00536 -0.00107 0.00544
FEV∗1 -0.00135 0.00012 -0.00135 0.00012 -0.00135 0.00012
4.6 Discussion
This article proposes methods of fitting marginal additive rates model for both the case-
cohort and the generalized case-cohort designs with time-varying weights. The proposed
estimators are natural generalizations of the full cohort estimators and possess intuitive inter-
pretation. The proposed estimators are consistent and asymptotically normally distributed.
They perform well in finite samples. We have applied the methods to the rhDNase data.
Throughout this article, we have assumed simple random sampling for both the sub-cohort
and when sampling from the individuals who experienced the event but were not selected in
the sub-cohort. Bernoulli sampling of the subcohort is another sampling scheme that can be
considered. In the proposed method, the indicator variables are correlated with each other
and the sub-cohort proportion is fixed, while in Bernoulli sampling scheme, the indicator
variables are independently distributed leading to the sub-cohort proportion being the target
value on the average. In our approach, we do not use all the covariate information that are
available for the entire cohort. There have been studies (Jiang and Zhou 2007) that have
examined the use of auxiliary covariates, available for all individuals, in the pseudo-score
equation for estimating the parameters in additive rates model. It can be of interest, for
future research, to extend the idea of using auxiliary variables to improve the efficiency of the
estimators in recurrent events data.
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CHAPTER 5: TWO-PHASE DESIGN SAMPLE SIZE AND POWER
CALCULATION FOR TESTING INTERACTION BETWEEN
TREATMENT AND EXPENSIVE BIOMARKER
5.1 Introduction
There is an increasing interest in discovering new biomarkers that can help predict the
best treatment for a patient in cancer trials. However, finding new biomarkers is often time-
consuming and costly, thus leading to the search for more efficient designs. In the new age
of cancer research, there are often large quantities of clinical data and specimen available for
further research after the randomized phase III trials are completed. Utilizing these already
collected clinical data as the first phase data and the available biospecimen in the second phase
of a two-phase design will shorten the discovery cycle. In the second phase, information from
the existing biospecimen, which can be expensive, can be collected. The sampling of the
second phase can utilize information that is already collected in the first phase, including the
patients’ disease status.
There have been extensive application of the two-phase design in epidemiologic cohort
studies. Applications in clinical trials have focused on the study of predictive biomarkers.
One of the most common schemes that is widely used is the case-cohort sampling design
(Prentice 1986). In this design, a simple random sample (sub-cohort) is selected from the
entire cohort along with all the subjects who experienced the event of interest (cases) during
the study period. The case-cohort design have been extensively studied in time to event
analysis (Prentice 1986, Lin and Ying 1993, Schouten et al. 1993, Barlow 1994, Liao et al.
1997, Barlow et al. 1999, Chen and Lo 1999, Savitz et al. 2000, Folsom et al. 2001, Chen 2001,
Kulich and Lin 2004, Kang and Cai 2009b). Prentice (1986) proposed a pseudo-likelihood
approach where the risk set at each failure consisted of only those subjects who were at risk
in the sub-cohort. Self and Prentice (1988) slightly modified the pseudo-likelihood approach
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where the risk set at each failure includes the cases outside the sub-cohort along with the
individuals in the sub-cohort. They also developed the asymptotic theory for the regression
parameters. Lin and Ying (1993), Borgan et al. (2000), Barlow (1994), among others proposed
different estimating equations and/or asymptotic variances for the parameters. There have
been some studies examining the sample size and power calculation in case-cohort studies.
Cai and Zeng (2004) provided an explicit procedure for calculating the sample size and power
of their proposed test when the event is rare and the main exposure effect is of interest. They
studied how much more power can be gained by using a case-cohort study instead of a simple
random sample. Hu et al. (2014) derived such results for the stratified case-cohort design.
They further studied the sample size and power for generalized case-cohort design (Cai and
Zeng 2007). The aforementioned sample size and power formula are designed for testing
main exposure effect. However, in studies of biomarker, the interaction between biomarker
and treatment are often of interest. For example, in the pooled analysis of LACE (Lung
Adjuvant Cisplatin Evaluation) and Cancer and Leukemia Group B (CALGB) 9633 databases
(Shepherd et al. 2013), one is interested in developing a two-phase design to study how the
effect of the KRAS-mutation on early stage resected non-small-cell lung cancer is different for
individuals on adjuvant chemotherapy and the individuals who are on observation.
In this article, we propose methods for computing sample size and power for case-cohort
studies when the event is rare and we are interested in assessing the interaction effect of an
expensive biomarker and the treatment. We propose the test and bounds in Section 5.2 and
investigate the finite sample properties by simulations in Section 5.3. In Section 5.4, we study
the cost efficiency of the case-cohort design and apply our method to design a two-phased
study based on information provided in LACE and CALGB 9633 databases. This example
is considered to elaborate how much power one can achieve in testing an interaction in a
case-cohort sampling scheme setting, for a particular sample size. Finally, in Section 5.5, we
conclude based on our findings.
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5.2 Methods
Assume that there are two biomarker groups (j = 0, 1) and two treatment groups (k = 0, 1)
with njk individuals in each group,
∑
j,k njk = n. Let T
∗
i,jk be the potential failure time which
can be censored by the potential censoring time, Ci,jk, for individual i in treatment k group
and biomarker j group. Tijk = min(T
∗
i,jk, Ci,jk) is the observed time to event for individual i,
(i = 1, . . . , n) in treatment k group and biomarker j group. Let ∆ijk = 1(T
∗
i,jk ≤ Ci,jk) denote
the failure indicator variable, Xi and Ai denote the biomarker and treatment covariates,
respectively, for individual i. Let λj0(t) (j = 0, 1) denote the hazard function for biomarker
group, j, in treatment group, 0. We assume that the hazard rate for treatment group 1
satisfies: λj1(t) = e
βjλj0(t), where βj is the unknown parameter for the effect of treatment
in the j-th biomarker group. We are interested in testing whether the treatment effects are
equal in the two biomarker groups, i.e., H0 : β1 = β0.
For the case-cohort design, we select a random sample of the full cohort, called the sub-
cohort, and all subjects who had the event. Let ξi,jk be the indicator that subject i of
treatment group k and biomarker group j is included in the sub-cohort. Define C˜ as the
set of sub-cohort data, nj and n˜j are the full cohort and sub-cohort sample sizes for the
biomarker group j, respectively. The at-risk process is defined as Yijk(t) = 1(Tijk ≥ t),
pijk(x) = P (Ci,jk ≥ x | Xi = j, Ai = k), Sj(x) = P (T ∗i,jk > x | Ai = 0, Xi = j) for all
i, r0 = 1 − r1 = P (Xi = 0), p0 = P (Ai = 1 | Xi = 0) and p1 = P (Ai = 1 | Xi = 1).
Let Y˜jk(t) =
∑n˜j
i=1 Yijk(t) denote the total number of subjects at risk in the sub-cohort for
biomarker j and treatment k and ψj as the sampling fraction for the subcohort of biomarker
group j. We have ψˆj =
n˜j
nj
, Y˜jk(t) = ψˆj Y¯jk(t) where Y¯jk(t) =
∑nj
i=1 Yijk(t) is the risk set at
time t for biomarker j and treatment k.
5.2.1 Proposed Tests
With the case-cohort design, the usual log-rank test statistic or the corresponding test
based on the parameter estimate cannot be calculated since we do not have enough covariate
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information on all the individuals at the event times. The score function is given by:
U˜j(βj) =
nj1∑
i=1
Y˜j0(Tij1)∆ij1
Y˜j0(Tij1) + eβj Y˜j1(Tij1)
−
nj0∑
i=1
eβj Y˜j1(Tij0)∆ij0
Y˜j0(Tij0) + eβj Y˜j1(Tij0)
∀j = 0, 1 (5.1)
Denote the solution to U˜j(βj) = 0 by βˆj . The score function is same as that of the pseudo-
partial likelihood function given by Self and Prentice (1988). Further, we have the asymptotic
variance of the score function given by σ2j+δj , where σ
2
j =
´ 1
0
(
s(2)(βj ,t)s
(0)(βj ,t)−s(1)(βj ,t)⊗2
[s(0)(βj ,t)]
)
λj(t)
×dt and δj =
´ 1
0
´ 1
0 G(βj , x, w)s
(0)(βj , x) s
(0)(βj , w)λj(x)λj(w)dxdw, q
(l)(βj , x, w) =
∑1
k=0 e
2kβj
×(1 − pj)1−kpkjpijk(x ∨ w)Sj(x ∨ w)e
kβj
kl ∀l = 0, 1 and 00 = 1, s(l)(βj , x) =
∑1
k=0 e
kβj (1 −
pj)
1−kpkjpijk(x) Sj(x)
ekβj kl ∀l = 0, 1, 2, and h(k+l)(βj , x, w) = q(k+l)(βj , x, w)− s(k)(βj , w)
s(l)(βj , x)
′ ∀l ≤ k = 0, 1. Since treatment is binary, q(1)(βj , x, w) = q(2)(βj , x, w) and
s(1)(βj , x) = s
(2)(βj , x). G(βj , x, w) =
1−ψj
ψj
[{
s(0)(βj , x)s
(0)(βj , w)
}−1
h(2)(βj , x, w)+{
s(0)(βj , x)s
(0)(βj , w)
}−2
s(1)(βj , x)s
(1)(βj , w) h
(0)(βj , x, w)− s(0)(βj , x)−1s(0)(βj , w)−2
s(1)(βj , w)h
(1)(βj , w, x)s
(0)(βj , w)
−1s(0)(βj , x)−2 −s(1)(βj , x)h(1)(βj , x, w)
]
. The first term of
the variance, σ2j , corresponds to the variability in the cohort whereas δj is the variability due
to sampling of the subcohort from the entire cohort. The asymptotic variance terms for each
j can be estimated by σˆ2j + δˆj , where σˆ
2
j can be approximated by
1
nj
nj0∑
i=1
e2βˆj Y˜j1(Tij0)
2∆ij0(
Y˜j0(Tij0) + eβˆj Y˜j1(Tij0)
)2 + nj1∑
i=1
Y˜j0(Tij1)
2∆ij1(
Y˜j0(Tij1) + eβˆj Y˜j1(Tij1)
)2

and
δˆj = 2
e2βˆj (1− ψˆj)
nj
1∑
k,k′=0
nk∑
i=1
nk′∑
i′=1
 ∆ijk∆i′jk′1(Tijk′ ≤ Tijk)Y˜j1(Tijk)Y˜j0(Tijk)(Y˜j0(Tijk) + eβˆj Y˜j1(Tijk))2(Y˜j0(Tijk′) + eβˆj Y˜j1(Tijk′))2
×
(
Y˜j1(Tijk′) + Y˜j0(Tijk′)
)}
− e
2βˆj (1− ψˆj)
nj
1∑
k=0
nk∑
i=1
 ∆ijkY˜j1(Tijk)Y˜j0(Tijk)(Y˜j0(Tijk) + eβˆj Y˜j1(Tijk))4
×
(
Y˜j1(Tijk) + Y˜j0(Tijk)
)}
.
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From Self and Prentice (1988), we have n1/2{βˆj − βj} converges to a Gaussian distribution
with mean 0 and variance r−1j
(
σ−2j + σ
−4
j δj
)
for j = 0, 1 independently. Based on this
asymptotic result, we propose the following test statistic:
TSn = n
1/2 {βˆ1 − βˆ0}√∑
j
n
nj
(
σˆ−2j + σˆ
−4
j δˆj
) , (5.2)
Assuming
nj
n → rj ∈ (0, 1) as n→∞, TSn
D−→ N(0, 1) under H0 : β1−β0 = 0. Hence, for level
of significance, α, the rejection region of the test will be given by TSn > Z1−α, where Z1−α
is the 100(1 − α)th percentile of a standard normal distribution for H1 : β1 > β0. One can
note that under the alternative hypothesis H1 : β1 − β0 ≷ 0 the distribution of the statistic,
n1/2{(βˆ1 − βˆ0)− (β1 − β0)} is N
(
0,
∑
j r
−1
j (σ
−2
j + σ
−4
j δj)
)
.
5.2.2 Power Calculation
We have the following assumptions for sample size/power calculation:
(a) The censoring distributions are the same in the two treatment groups within each
biomarker group.
(b) The proportion of failures are small in the full cohort.
(c) We assume the distribution of the underlying time to be continuous and hence, no ties
of failures are observed.
We can approximate the ratio of the risk sets with the corresponding ratio of the probability
of surviving at the end of the study. Under these assumptions and considering the alternative
hypothesis H1 : β1 − β0 = θ > 0, θ = O(n˜−1/2) (where n˜ =
∑
j n˜j and n˜j are of the same
order), the power of the test statistic TSn can be approximated by
Φ
√n (β1 − β0)

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
]
×
((
(1− pj)(1− pj0D ) + eβjpj(1− pj1D )
)2
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+[
e2βj (1− ψj)(1− pj1D )(1− pj0D )
] (
(1− pj)pj0D + pjpj1D
)2
ψj
(
e2βjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
)


−1/2
− Z1−α
 . (5.3)
where α is the level of significance, pj1D = P (T
∗
ij1 ≤ Cij1), pj0D = P (T ∗ij0 ≤ Cij0), j = 0, 1.
Define m∗j0 as the risk set for biomarker j and treatment 0 at the last event time. If we
assume that
pj1D
pj0D
≈ 1 and m∗j0nj ≈ (1 − pj)
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
, the power of the
test statistic can be written as
Φ
√n (β1 − β0)

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpjp
j0
D + (1− pj)pj1D
] × (((1− pj) + eβjpj)2
+
e2βj (1− ψj)
(
(1− pj)pj0D + pjpj1D
)2
ψj
(
e2βjpjp
j0
D + p
j1
D
)(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)


−1/2
− Z1−α
 . (5.4)
Assuming that the censoring variable is degenerate at τ with probability 1 − pC and the
approximation of the risk sets as
m∗j0
nj
≈ (1−pC)(1−pj)
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
and
m∗j1
nj
≈ (1− pC)pj
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
, the power of the test statistic is given by
Φ
√n (β1 − β0)

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpjp
j0
D + (1− pj)pj1D
] × (((1− pj) + eβjpj)2
+
e2βj (1− ψj)
(
(1− pj)pj0D + pjpj1D
)2
(1− pC)ψj
(
e2βjpjp
j0
D + p
j1
D
)(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)


−1/2
− Z1−α
 . (5.5)
5.2.3 Sample Size formula
Based on the approximated power formula in the previous section, for a given power ϑ,
significance level α, the entire cohort size n, and the denominator of any of the power formula
((5.3), (5.4) and (5.5)), denoted as σden, to detect the ratio of the hazard ratio, exp(β1−β0),
for the treatment effect between the two biomarker groups, the required total cohort size is
(Zϑ + Z1−α)2 σ2den
(β1 − β0)2 . (5.6)
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Specifically, based on power function, (5.3), the required sample size is
(Zϑ + Z1−α)2
(β1 − β0)2

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
] (((1− pj)
×(1− pj0D ) + eβjpj(1− pj1D )
)2
+
[
e2βj (1− ψj)(1− pj1D )(1− pj0D )
] (
(1− pj)pj0D + pjpj1D
)2
ψj
(
e2βjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
)


(5.7)
Similarly, based on formula (5.4)
(Zϑ + Z1−α)2
(β1 − β0)2

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpjp
j0
D + (1− pj)pj1D
] × (((1− pj) + eβjpj)2
+
e2βj (1− ψj)
(
(1− pj)pj0D + pjpj1D
)2
ψj
(
e2βjpjp
j0
D + p
j1
D
)(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)

 (5.8)
and based on (5.5) we have
(Zϑ + Z1−α)2
(β1 − β0)2

1∑
j=0
r−1j
1
pj(1− pj)
[
e2βjpjp
j0
D + (1− pj)pj1D
] × (((1− pj) + eβjpj)2
+
e2βj (1− ψj)
(
(1− pj)pj0D + pjpj1D
)2
(1− pC)ψj
(
e2βjpjp
j0
D + p
j1
D
)(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)

 (5.9)
For a particular proportion of biomarker rj and sub-cohort proportion ψj , the sample size
required for the sub-cohort is
n˜j = n× rj × ψj ∀j = 0, 1.
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5.2.4 Bounds for the power formula
We consider the bounds for the power function. This also serves as a check for whether
the power lies within the bounds. The bounds for power are defined as
Φ
 √n (β1 − β0)√∑1
j=0 r
−1
j
(
σ−2j + σ
−4
j δj,ub
) − Z1−α
 ≤ Power ≤ Φ
 √n (β1 − β0)√∑1
j=0 r
−1
j
(
σ−2j + σ
−4
j δj,lb
) − Z1−α
 ,
(5.10)
where σ2j ≈ (1− pj)pj e
2βj pj(1−pj1D )2pj0D+(1−pj)(1−pj0D )2pj1D(
(1−pj)(1−pj0D )+eβj pj(1−pj1D )
)2 ,
δˆj,ub ≈ 2 e
2βˆj (1−ψj)pj(1−pj)(1−pj1D )(1−pj0D )
njψj
(
(1−pj)(1−pj0D )+eβˆj pj(1−pj1D )
)3 (pj(1− pj1D ) + (1− pj)(1− pj0D ))
×∑ml=1∑1k=0 dlj−1/2(
{nj(1−pj)−lj,0+1}(1+eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)
)1−k 1(
{njpj−lj,1+1}(eβˆj+
(1−pj)(1−pj0D )
pj(1−pj1D )
)
)k ,
δˆj,lb ≈ 2 e
2βˆj (1−ψj)pj(1−pj)(1−pj1D )(1−pj0D )(pj(1−pj1D )+(1−pj)(1−pj0D ))
njψj
(
(1−pj)(1−pj0D )+eβˆj pj(1−pj1D )
)3
×∑ml=1∑1k=0 dlj−1/2(
{nj(1−pj)−nj0C−Dj0}(1+eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)
)1−k(
{njpj−nj1C−Dj1}(eβˆj+
(1−pj)(1−pj0D )
pj(1−pj1D )
)
)k ,
where dlj is the risk set in the biomarker group j at the l-th index of the ordered failure
time and m is the total number of failures, njkC and D
j
k are the total number of censored
individuals in [0, τ) and number of deaths for biomarker j and treatment group k respectively.
5.3 Simulation Results
We conducted simulations to examine the finite sample properties of the formulae. The
empirical results based on the test statistic from the full-cohort and sub-cohort are also
reported. It should be noted that full cohort design is not possible when one considers the
case-cohort sampling scheme as information is not collected on individuals who are not in
the case-cohort. We have reported the simulation results to provide an upper bound. We
examined different scenarios to ascertain the performance of the proposed formula. In all the
situations, we assumed that the treatment is randomly assigned with probability 0.5. Different
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biomarker proportions (0.3, 0.5) are considered. We generated the censoring time from a
mixture distribution, with probability pC from uniform distribution in [0, τ ] and probability
(1 − pC) being degenerate at τ . For the simulations, we considered pC = 0.3, 0.2, 0.1. The
bound for the censoring distribution, τ , is calculated such that the censoring proportion for
the (0, 0) group of the (Biomarker, Treatment) combination (denoted by 1−p00D ) is 95%, 90%
and 80%.
The effect of treatment is assumed to be multiplicative in all the cases. Table 5.1 show
that the Type I error of the test based on data from the Weibull distribution with hazard
given by λj1(t) = 2λjte
βj , t ∈ (0,∞), and λj0(t) = 2λjt, j = 0, 1 and pC = 0.2. Both the
biomarker proportions were considered for the simulations with λ0 = 1 and λ1 = 0.75, 1 and
1.25. The number of simulations was 20000. The Type I error is always very close to 0.05
(the nominal level) for each of the designs for all the situations considered which shows that
the proposed test is reliable.
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Table 5.1: Summary of Type I Error for Weibull (2) for β1 − β0 = 0.25 and 1− pC = 0.8)
Distribution Event prop. Biomarker prop. Full Cohort Case-Cohort Sub-cohort
(l0, l1) (p
00
D ) r0
(1, 0.75) (0.05) 0.3 0.0517 0.0518 0.0422
0.5 0.0484 0.0501 0.0468
(0.1) 0.3 0.0492 0.0460 0.0501
0.5 0.0521 0.0494 0.0504
(0.2) 0.3 0.0505 0.0513 0.0507
0.5 0.0508 0.0495 0.049
(1, 1) (0.05) 0.3 0.0502 0.0501 0.0419
0.5 0.0493 0.0487 0.0406
(0.1) 0.3 0.0498 0.0477 0.0485
0.5 0.0486 0.0505 0.0484
(0.2) 0.3 0.0482 0.0486 0.0494
0.5 0.0485 0.0509 0.0474
(1, 1.25) (0.05) 0.3 0.0489 0.0473 0.036
0.5 0.0479 0.0490 0.0231
(0.1) 0.3 0.0493 0.0512 0.0502
0.5 0.0509 0.0509 0.0503
(0.2) 0.3 0.0486 0.0499 0.0508
0.5 0.0492 0.0503 0.0493
After confirming the performance of the empirical Type I error, we compared the empirical
and theoretical powers under different situations. Tables 5.5 - 5.10 show data from Weibull
distribution with hazard, λj0(t) = lλjt
l−1, t ∈ (0,∞) for treatment group 0 and λj1(t) =
lλjt
l−1eβj , t ∈ (0,∞), j = 0, 1, l = 2, 3 for treatment group 1. The sample size considered
was 4000. Tables 5.2 - 5.4 & 5.11 - 5.13 summarized the power for data from an exponential
distribution with hazards in one biomarker group = 1 and considering 0.75, 1 or 1.25 for the
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other group. For the power calculation, we considered 5000 simulations with 10% sub-cohort
sampling proportion. We considered β0 = 0.5 and β1 = 1 for Tables 5.2 - 5.10 and β0 = 0.5
and β1 = 0.75 for Tables 5.11 - 5.13 and P (Treatment = 1 | X = j) = 0.5 for illustration
purposes. We summarized the theoretical formula for the power by the following and reported
in the tables.
When the event rate is low (≤ 0.05) and the percentage of individuals censored at the end
of the study is < 90%, the power formula (5.3) and (5.4) overestimates the attainable power
whereas (5.5) under-estimates the empirical power slightly whereas when the percentage of
individuals censored is ≥ 90%, (5.3) works quite well. For event rate ∈ (0.05, 0.1], then for the
situation with pC = 0.3, we have (5.5), for pC = 0.2, we have (5.3) and finally, for pC = 0.1,
(5.4) was found to be closest to the empirical power. When the event rate is ∈ (0.1, 0.2],
(5.4) works well for pC < 0.3 whereas for pC = 0.3, (5.3) best estimates the power. Based on
these performances of the different theoretical power formulae with the empirical formulae,
we summarized our recommendations below :
Eqn(5.4) if 1− pC ≥ 0.9, p00D ≥ 0.2 or if 0.8 ≤ 1− pC < 0.9, p00D ≥ 0.2,
Eqn(5.3) if 1− pC ≥ 0.9, p00D < 0.2 or if 0.8 ≤ 1− pC < 0.9, p00D ≥ 0.1 or if 1− pC < 0.8, p00D ≥ 0.2,
Eqn(5.5) if 0.8 ≤ 1− pC < 0.9, p00D < 0.1 or if 1− pC < 0.8, p00D < 0.2. (5.11)
The combined power formula (5.11) is more or less conservative for all the distributions
for all event rates. For Weibull distribution, when the hazard function is a cubic polynomial
and censoring degenerate probability (1 − pC) is 0.8, the formula slightly over-estimates the
empirical formula whereas for all the other scenarios, it is conservative. One can note that
there is a gain in using case-cohort design rather than only a sample of the subjects. For rare
event, the proposed formula works pretty well. Even though the event rate is quite low, we
have calculated the empirical bounds for the power function based on (5.10). The empirical
and theoretical powers for the case-cohort design almost always lie within the bounds.
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Table 5.2: Summary of Power Calculation for Exponential Distribution with β1 − β0 = 0.5 and 1− pC = 0.7
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.502 0.391 0.408/0.410/0.378 0.378 (0.367, 0.413) 0.129
0.5 0.571 0.45 0.453/0.456/0.420 0.420 (0.423, 0.474) 0.124
(0.1) 0.3 0.782 0.536 0.537/0.547/0.481 0.481 (0.467, 0.563) 0.211
0.5 0.848 0.599 0.593/0.607/0.537 0.537 (0.524, 0.612) 0.223
(0.2) 0.3 0.957 0.634 0.597/0.626/0.528 0.597 (0.492, 0.663) 0.324
0.5 0.980 0.683 0.656/0.693/0.590 0.656 (0.559, 0.716) 0.339
(1, 1) (0.05) 0.3 0.540 0.414 0.423/0.426/0.391 0.391 (0.38, 0.428) 0.142
0.5 0.612 0.490 0.480/0.485/0.444 0.444 (0.448, 0.499) 0.169
(0.1) 0.3 0.816 0.547 0.547/0.560/0.490 0.490 (0.465, 0.575) 0.29
0.5 0.885 0.617 0.618/0.630/0.553 0.553 (0.535, 0.638) 0.233
(0.2) 0.3 0.966 0.650 0.596/0.632/0.529 0.596 (0.483, 675) 0.348
0.5 0.989 0.707 0.652/0.702/0.591 0.652 (0.544, 0.724) 0.384
(1, 1.25) (0.05) 0.3 0.558 0.424 0.433/0.436/0.399 0.399 (0.391, 0.437) 0.152
0.5 0.649 0.49 0.499/0.505/0.460 0.460 (0.462, 0.517) 0.159
(0.1) 0.3 0.826 0.557 0.553/0.568/0.495 0.495 (0.472, 0.586) 0.228
0.5 0.905 0.619 0.620/0.644/0.561 0.561 (0.533, 0.662) 0.259
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(0.2) 0.3 0.972 0.639 0.590/0.633/0.527 0.590 (0.470, 0.679) 0.356
0.5 0.991 0.698 0.652/0.702/0.591 0.652 (0.521, 0.735) 0.392
Table 5.3: Summary of Power Calculation for Exponential Distribution with β1 − β0 = 0.5 and 1− pC = 0.8
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.519 0.404 0.418/0.421/0.400 0.400 (0.388, 0.419) 0.134
0.5 0.598 0.459 0.464/0.467/0.444 0.444 (0.446, 0.481) 0.131
(0.1) 0.3 0.798 0.551 0.545/0.555/0.512 0.545 (0.501, 0.572) 0.223
0.5 0.864 0.622 0.602/0.616/0.570 0.602 (0.565, 0.63) 0.242
(0.2) 0.3 0.958 0.633 0.597/0.626/0.561 0.626 (0.539, 0.674) 0.336
0.5 0.981 0.693 0.655/0.694/0.625 0.694 (0.604, 0.721) 0.353
(1, 1) (0.05) 0.3 0.569 0.436 0.433/0.437/0.413 0.413 (0.404, 0.439) 0.148
0.5 0.634 0.492 0.491/0.497/0.470 0.470 (0.472, 0.508) 0.169
(0.1) 0.3 0.836 0.57 0.554/0.568/0.522 0.554 (0.507, 0.585) 0.23
0.5 0.901 0.639 0.618/0.638/0.587 0.618 (0.571, 0.655) 0.239
(0.2) 0.3 0.967 0.643 0.594/0.631/0.563 0.631 (0.535, 0.679) 0.323
0.5 0.990 0.724 0.650/0.702/0.627 0.702 (0.593, 0.736) 0.371
(1, 1.25) (0.05) 0.3 0.564 0.435 0.443/0.447/0.422 0.422 (0.411, 0.451) 0.157
0.5 0.675 0.513 0.510/0.517/0.487 0.487 (0.488, 0.529) 0.180
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(0.1) 0.3 0.845 0.57 0.559/0.576/0.527 0.559 (0.509, 0.595) 0.243
0.5 0.915 0.650 0.625/0.651/0.596 0.625 (0.577, 0.67) 0.277
(0.2) 0.3 0.972 0.643 0.588/0.633/0.561 0.633 (0.526, 0.685) 0.343
0.5 0.992 0.721 0.640/0.705/0.624 0.705 (0.573, 0.748) 0.422
Table 5.4: Summary of Power Calculation for Exponential Distribution with β1 − β0 = 0.5 and 1− pC = 0.9
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.538 0.416 0.428/0.431/0.420 0.428 (0.412, 0.431) 0.145
0.5 0.613 0.483 0.475/0.479/0.467 0.475 (0.469, 0.489) 0.135
(0.1) 0.3 0.790 0.549 0.540/0.551/0.530 0.551 (0.518, 0.562) 0.217
0.5 0.858 0.619 0.597/0.611/0.588 0.611 (0.576, 0.622) 0.224
(0.2) 0.3 0.963 0.649 0.596/0.627/0.592 0.627 (0.579, 0.672) 0.327
0.5 0.980 0.706 0.654/0.694/0.656 0.694 (0.630, 0.726) 0.359
(1, 1) (0.05) 0.3 0.579 0.446 0.443/0.447/0.435 0.443 (0.429, 0.449) 0.148
0.5 0.653 0.514 0.502/0.508/0.494 0.502 (0.497, 0.518) 0.168
(0.1) 0.3 0.825 0.572 0.550/0.563/0.541 0.563 (0.527, 0.576) 0.231
0.5 0.893 0.630 0.611/0.633/0.607 0.633 (0.592, 0.636) 0.249
(0.2) 0.3 0.969 0.659 0.593/0.631/0.593 0.631 (0.577, 0.680) 0.348
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0.5 0.993 0.720 0.649/0.702/0.659 0.702 (0.623, 0.739) 0.386
(1, 1.25) (0.05) 0.3 0.589 0.449 0.453/0.457/0.445 0.453 (0.435, 0.456) 0.164
0.5 0.692 0.521 0.520/0.528/0.512 0.520 (0.509, 0.536) 0.173
(0.1) 0.3 0.841 0.572 0.555/0.571/0.547 0.571 (0.53, 0.585) 0.235
0.5 0.908 0.648 0.622/0.647/0.618 0.647 (0.598, 0.654) 0.259
(0.2) 0.3 0.974 0.656 0.587/0.633/0.592 0.633 (0.568, 0.686) 0.351
0.5 0.994 0.730 0.637/0.704/0.656 0.704 (0.614, 0.746) 0.413
Table 5.5: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.5 and 1− pC = 0.7
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.559 0.414 0.434/0.437/0.399 0.399 (0.388, 0.445) 0.149
0.5 0.621 0.469 0.481/0.485/0.445 0.445 (0.433, 0.488) 0.141
(0.1) 0.3 0.794 0.539 0.543/0.553/0.486 0.486 (0.475, 0.574) 0.221
0.5 0.852 0.601 0.599/0.613/0.541 0.541 (0.515, 0.616) 0.221
(0.2) 0.3 0.964 0.607 0.6/0.63/0.53 0.6 (0.477, 0.671) 0.329
0.5 0.983 0.681 0.658/0.698/0.593 0.658 (0.533, 0.710) 0.370
(1, 1) (0.05) 0.3 0.597 0.438 0.449/0.453/0.412 0.412 (0.405, 0.459) 0.159
0.5 0.672 0.497 0.508/0.514/0.467 0.467 (0.446, 0.510) 0.171
(0.1) 0.3 0.822 0.525 0.553/0.566/0.495 0.495 (0.479, 0.592) 0.227
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0.5 0.891 0.611 0.617/0.637/0.558 0.558 (0.533, 0.637) 0.251
(0.2) 0.3 0.969 0.619 0.598/0.635/0.531 0.598 (0.470, 0.677) 0.353
0.5 0.990 0.687 0.655/0.707/0.594 0.655 (0.520, 0.722) 0.392
(1, 1.25) (0.05) 0.3 0.623 0.450 0.458/0.463/0.419 0.419 (0.406, 0.466) 0.165
0.5 0.705 0.526 0.526/0.534/0.482 0.482 (0.456, 0.528) 0.183
(0.1) 0.3 0.826 0.547 0.557/0.499 0.499 (0.482, 0.595) 0.227
0.5 0.907 0.616 0.625/0.649/0.565 0.565 (0.530, 0.650) 0.270
(0.2) 0.3 0.978 0.621 0.592/0.637/0.529 0.592 (0.456, 0.682) 0.345
0.5 0.993 0.681 0.645/0.71/0.591 0.645 (0.496, 0.737) 0.409
Table 5.6: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.5 and 1− pC = 0.8
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.560 0.422 0.427/0.43/0.408 0.408 (0.406, 0.438) 0.151
0.5 0.608 0.47 0.474/0.478/0.453 0.453 (0.443, 0.475) 0.153
(0.1) 0.3 0.818 0.559 0.55/0.561/0.517 0.55 (0.506, 0.577) 0.225
0.5 0.865 0.625 0.606/0.622/0.574 0.606 (0.555, 0.630) 0.240
(0.2) 0.3 0.967 0.623 0.598/0.629/0.563 0.629 (0.531, 0.674) 0.328
0.5 0.984 0.691 0.656/0.697/0.627 0.697 (0.584, 0.719) 0.367
(1, 1) (0.05) 0.3 0.577 0.436 0.442/0.446/0.422 0.422 (0.412, 0.449) 0.154
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0.5 0.65 0.490 0.501/0.507/0.479 0.479 (0.467, 0.500) 0.17
(0.1) 0.3 0.830 0.553 0.559/0.573/0.526 0.559 (0.517, 0.589) 0.235
0.5 0.899 0.615 0.623/0.644/0.592 0.623 (0.564, 0.646) 0.251
(0.2) 0.3 0.975 0.647 0.596/0.634/0.565 0.634 (0.526, 0.679) 0.360
0.5 0.989 0.702 0.651/0.705/0.63 0.705 (0.575, 0.732) 0.396
(1, 1.25) (0.05) 0.3 0.605 0.454 0.452/0.456/0.43 0.43 (0.420, 0.454) 0.165
0.5 0.693 0.523 0.519/0.527/0.496 0.496 (0.475, 0.517) 0.183
(0.1) 0.3 0.849 0.557 0.562/0.58/0.531 0.562 (0.518, 0.597) 0.244
0.5 0.923 0.640 0.629/0.656/0.6 0.629 (0.571, 0.66) 0.277
(0.2) 0.3 0.979 0.634 0.589/0.635/0.563 0.635 (0.514, 0.687) 0.348
0.5 0.995 0.701 0.641/0.707/0.626 (0.553, 0.736) 0.420
Table 5.7: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.5 and 1− pC = 0.9
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.586 0.449 0.441/0.444/0.432 0.441 (0.434, 0.457) 0.160
0.5 0.640 0.490 0.489/0.493/0.48 0.489 (0.475, 0.497) 0.155
(0.1) 0.3 0.802 0.562 0.545/0.555/0.534 0.555 (0.525, 0.573) 0.216
0.5 0.862 0.626 0.601/0.615/0.592 0.615 (0.577, 0.623) 0.235
(0.2) 0.3 0.972 0.658 0.597/0.63/0.594 0.63 (0.565, 0.669) 0.336
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0.5 0.989 0.703 0.654/0.698/0.658 0.698 (0.631, 0.728) 0.377
(1, 1) (0.05) 0.3 0.600 0.457 0.456/0.46/0.447 0.456 (0.446, 0.467) 0.155
0.5 0.681 0.515 0.516/0.522/0.507 0.516 (0.501, 0.524) 0.171
(0.1) 0.3 0.828 0.564 0.554/0.568/0.545 0.568 (0.536, 0.586) 0.224
0.5 0.900 0.634 0.618/0.638/0.612 0.638 (0.592, 0.645) 0.259
(0.2) 0.3 0.982 0.656 0.593/0.634/0.595 0.634 (0.563, 0.674) 0.368
0.5 0.991 0.719 0.647/0.705/0.66 0.705 (0.616, 0.736) 0.408
(1, 1.25) (0.05) 0.3 0.635 0.476 0.465/0.47/0.456 0.465 (0.451, 0.478) 0.158
0.5 0.720 0.543 0.533/0.541/0.525 0.533 (0.51, 0.537) 0.186
(0.1) 0.3 0.836 0.568 0.558/0.575/0.55 0.575 (0.540, 0.595) 0.242
0.5 0.915 0.648 0.625/0.651/0.621 0.651 (0.601, 0.655) 0.270
(0.2) 0.3 0.983 0.662 0.585/0.634/0.59 0.634 (0.553, 0.676) 0.373
0.5 0.997 0.722 0.634/0.705/0.656 0.705 (0.605, 0.745) 0.427
Table 5.8: Summary of Power Calculation for Weibull(3) Distribution with β1 − β0 = 0.5 and 1− pC = 0.7
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.549 0.406 0.431/0.434/0.397 0.397 (0.391, 0.446) 0.145
0.5 0.620 0.465 0.479/0.483/0.442 0.442 (0.431, 0.485) 0.138
(0.1) 0.3 0.780 0.527 0.538/0.548/0.482 0.482 (0.472, 0.567) 0.217
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0.5 0.842 0.589 0.594/0.607/0.537 0.537 (0.513, 0.608) 0.215
(0.2) 0.3 0.964 0.589 0.6/0.63/0.531 0.6 (0.48, 0.665) 0.328
0.5 0.982 0.667 0.659/0.698/0.594 0.659 (0.536, 0.709) 0.364
(1, 1) (0.05) 0.3 0.587 0.434 0.45/0.454/0.413 0.413 (0.397, 0.456) 0.159
0.5 0.664 0.488 0.506/0.512/0.465 0.465 (0.447, 0.509) 0.173
(0.1) 0.3 0.808 0.516 0.552/0.566/0.494 0.494 (0.477, 0.582) 0.217
0.5 0.882 0.592 0.613/0.631/0.554 0.554 (0.528, 0.629) 0.249
(0.2) 0.3 0.97 0.603 0.599/0.505/0.532 0.599 (0.469, 0.676) 0.348
0.5 0.989 0.675 0.657/0.708/0.597 0.657 (0.516, 0.719) 0.391
(1, 1.25) (0.05) 0.3 0.612 0.444 0.456/0.46/0.418 0.418 (0.402, 0.464) 0.166
0.5 0.701 0.520 0.524/0.531/0.48 0.48 (0.455, 0.528) 0.186
(0.1) 0.3 0.813 0.532 0.553/0.568/0.496 0.496 (0.481, 0.589) 0.223
0.5 0.898 0.601 0.621/0.645/0.563 0.563 (0.522, 0.644) 0.259
(0.2) 0.3 0.977 0.605 0.594/0.638/0.531 0.594 (0.454, 0.680) 0.341
0.5 0.993 0.666 0.649/0.712/0.594 0.649 (0.491, 0.729) 0.405
Table 5.9: Summary of Power Calculation for Weibull(3) Distribution with β1 − β0 = 0.5 and 1− pC = 0.8
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.574 0.430 0.435/0.438/0.415 0.415 (0.406, 0.447) 0.157
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0.5 0.626 0.485 0.483/0.487/0.461 0.461 (0.453, 0.488) 0.152
(0.1) 0.3 0.801 0.54 0.543/0.553/0.511 0.543 (0.492, 0.564) 0.215
0.5 0.852 0.611 0.599/0.613/0.567 0.599 (0.546, 0.615) 0.232
(0.2) 0.3 0.959 0.613 0.598/0.627/0.563 0.627 (0.528, 0.667) 0.318
0.5 0.98 0.676 0.656/0.694/0.626 0.694 (0.584, 0.709) 0.347
(1, 1) (0.05) 0.3 0.596 0.441 0.45/0.454/0.429 0.429 (0.414, 0.457) 0.152
0.5 0.666 0.499 0.51/0.516/0.486 0.486 (0.47, 0.510) 0.172
(0.1) 0.3 0.819 0.539 0.552/0.566/0.52 0.552 (0.505, 0.577) 0.228
0.5 0.887 0.603 0.617/0.636/0.586 0.617 (0.559, 0.635) 0.245
(0.2) 0.3 0.969 0.634 0.597/0.632/0.565 0.632 (0.526, 0.677) 0.345
0.5 0.986 0.692 0.654/0.704/0.63 0.704 (0.577, 0.721) 0.378
(1, 1.25) (0.05) 0.3 0.626 0.462 0.459/0.464/0.437 0.437 (0.427, 0.466) 0.169
0.5 0.711 0.532 0.528/0.536/0.503 0.503 (0.481, 0.529) 0.192
(0.1) 0.3 0.831 0.550 0.557/0.573/0.525 0.557 (0.509, 0.580) 0.229
0.5 0.912 0.630 0.624/0.649/0.595 0.624 (0.564, 0.652) 0.270
(0.2) 0.3 0.972 0.622 0.591/0.634/0.564 0.634 (0.514, 0.679) 0.333
0.5 0.994 0.693 0.645/0.707/0.629 0.707 (0.559, 0.730) 0.408
Table 5.10: Summary of Power Calculation for Weibull(3) Distribution with β1 − β0 = 0.5 and 1− pC = 0.9
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
90
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.561 0.436 0.43/0.433/0.422 0.43 (0.424, 0.445) 0.157
0.5 0.622 0.478 0.477/0.481/0.469 0.477 (0.463, 0.482) 0.148
(0.1) 0.3 0.808 0.559 0.546/0.557/0.535 0.557 (0.525, 0.574) 0.219
0.5 0.862 0.624 0.602/0.617/0.593 0.582 (0.582, 0.627) 0.233
(0.2) 0.3 0.972 0.653 0.598/0.63/0.594 0.63 (0.563, 0.666) 0.333
0.5 0.988 0.698 0.655/0.697/0.658 0.697 (0.628, 0.730) 0.375
(1, 1) (0.05) 0.3 0.582 0.447 0.447/0.451/0.438 0.447 (0.437, 0.460) 0.145
0.5 0.657 0.502 0.504/0.51/0.496 0.504 (0.488, 0.509) 0.161
(0.1) 0.3 0.832 0.562 0.549/0.561/0.539 0.561 (0.535, 0.584) 0.224
0.5 0.899 0.631 0.619/0.64/0.597/0.613 0.64 (0.590, 0.646) 0.256
(0.2) 0.3 0.980 0.652 0.594/0.634/0.595 0.634 (0.559, 0.672) 0.366
0.5 0.991 0.715 0.648/0.705/0.661 0.705 (0.614, 0.737) 0.407
(1, 1.25) (0.05) 0.3 0.615 0.463 0.454/0.459/0.446 0.454 (0.447, 0.467) 0.156
0.5 0.698 0.535 0.522/0.53/0.514 0.522 (0.502, 0.530) 0.185
(0.1) 0.3 0.838 0.567 0.559/0.576/0.551 0.576 (0.538, 0.595) 0.241
0.5 0.916 0.646 0.626/0.652/0.622 0.652 (0.601, 0.658) 0.278
(0.2) 0.3 0.982 0.660 0.586/0.635/0.593 0.635 (0.550, 0.673) 0.371
0.5 0.996 0.717 0.636/0.706/0.657 0.706 (0.604, 0.745) 0.424
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Table 5.11: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.25 and 1− pC = 0.7
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.231 0.171 0.181/0.182/0.169 0.169 (0.166, 0.198) 0.086
0.5 0.251 0.188 0.196/0.197/0.184 0.184 (0.165, 0.200) 0.078
(0.1) 0.3 0.340 0.223 0.22/0.223/0.199 0.199 (0.181, 0.248) 0.111
0.5 0.388 0.246 0.242/0.245/0.219 0.219 (0.189, 0.257) 0.107
(0.2) 0.3 0.530 0.248 0.245/0.254/0.216 0.245 (0.168, 0.299) 0.149
0.5 0.592 0.278 0.271/0.283/0.239 0.271 (0.186, 0.319) 0.164
(1, 1) (0.05) 0.3 0.240 0.180 0.187/0.188/0.174 0.174 (0.168, 0.206) 0.091
0.5 0.270 0.199 0.207/0.208/0.192 0.192 (0.172, 0.215) 0.095
(0.1) 0.3 0.362 0.219 0.225/0.228/0.203 0.203 (0.179, 0.258) 0.12
0.5 0.402 0.243 0.251/0.255/0.225 0.225 (0.191, 0.267) 0.119
(0.2) 0.3 0.568 0.251 0.245/0.256/0.216 0.245 (0.164, 0.305) 0.154
0.5 0.618 0.279 0.272/0.287/0.24 0.272 (0.174, 0.324) 0.176
(1, 1.25) (0.05) 0.3 0.249 0.192 0.19/0.191/0.177 0.177 (0.171, 0.21) 0.093
0.5 0.290 0.222 0.214/0.215/0.198 0.198 (0.181, 0.222) 0.100
(0.1) 0.3 0.361 0.214 0.227/0.231/0.204 0.204 (0.181, 0.263) 0.111
0.5 0.441 0.257 0.255/0.261/0.228 0.228 (0.188, 0.284) 0.127
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(0.2) 0.3 0.572 0.262 0.244/0.256/0.215 0.244 (0.154, 0.308) 0.156
0.5 0.657 0.289 0.27/0.288/0.239 0.27 (0.166, 0.328) 0.175
Table 5.12: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.25 and 1− pC = 0.8
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.249 0.189 0.186/0.187/0.179 0.179 (0.181, 0.205) 0.095
0.5 0.261 0.195 0.202/0.203/0.194 0.194 (0.173, 0.198) 0.09
(0.1) 0.3 0.366 0.23 0.225/0.228/0.211 0.225 (0.197, 0.249) 0.113
0.5 0.410 0.255 0.247/0.251/0.232 0.247 (0.206, 0.256) 0.113
(0.2) 0.3 0.556 0.261 0.245/0.255/0.229 0.255 (0.185, 0.295) 0.153
0.5 0.615 0.284 0.272/0.284/0.254 0.284 (0.21, 0.321) 0.159
(1, 1) (0.05) 0.3 0.257 0.193 0.192/0.193/0.184 0.184 (0.185, 0.211) 0.095
0.5 0.284 0.207 0.212/0.214/0.203 0.203 (0.187, 0.216) 0.1
(0.1) 0.3 0.380 0.221 0.229/0.233/0.215 0.229 (0.2, 0.257) 0.126
0.5 0.423 0.244 0.255/0.26/0.239 0.255 (0.207, 0.271) 0.122
(0.2) 0.3 0.594 0.272 0.245/0.256/0.229 0.256 (0.182, 0.295) 0.165
0.5 0.644 0.292 0.271/0.287/0.255 0.287 (0.200, 0.331) 0.180
(1, 1.25) (0.05) 0.3 0.265 0.195 0.195/0.196/0.187 0.187 (0.185, 0.214) 0.1
0.5 0.302 0.227 0.219/0.221/0.209 0.209 (0.189, 0.222) 0.109
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(0.1) 0.3 0.388 0.230 0.231/0.235/0.217 0.231 (0.196, 0.260) 0.121
0.5 0.455 0.272 0.259/0.265/0.243 (0.213, 0.279) 0.132
(0.2) 0.3 0.597 0.269 0.243/0.256/0.228 0.256 (0.174, 0.300) 0.149
0.5 0.686 0.291 0.268/0.287/0.253 0.287 (0.187, 0.334) 0.182
Table 5.13: Summary of Power Calculation for Weibull(2) Distribution with β1 − β0 = 0.25 and 1− pC = 0.9
Distribution Event prop. Biom. prop. Full Cohort Case-Cohort Sub-cohort
(λ0, λ1) (p
00
D ) r0 Empirical Empirical Theoretical Final Bounds Empirical
(1, 0.75) (0.05) 0.3 0.258 0.202 0.191/0.192/0.187 0.191 (0.188, 0.202) 0.100
0.5 0.270 0.204 0.207/0.209/0.204 0.207 (0.191, 0.208) 0.093
(0.1) 0.3 0.378 0.231 0.228/0.232/0.223 0.232 (0.216, 0.255) 0.120
0.5 0.435 0.261 0.251/0.255/0.245 0.255 (0.225, 0.265) 0.116
(0.2) 0.3 0.574 0.269 0.245/0.255/0.241 0.255 (0.212, 0.305) 0.158
0.5 0.653 0.300 0.271/0.285/0.268 0.285 (0.234, 0.334) 0.171
(1, 1) (0.05) 0.3 0.268 0.200 0.196/0.197/0.193 0.196 (0.19, 0.207) 0.091
0.5 0.296 0.218 0.218/0.219/0.214 0.218 (0.201, 0.221) 0.094
(0.1) 0.3 0.411 0.228 0.232/0.236/0.227 0.236 (0.218, 0.262) 0.120
0.5 0.450 0.26 0.258/0.264/0.253 0.264 (0.236, 0.283) 0.123
(0.2) 0.3 0.622 0.279 0.244/0.256/0.241 0.256 (0.211, 0.309) 0.165
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0.5 0.668 0.302 0.269/0.287/0.268 0.287 (0.226, 0.338) 0.178
(1, 1.25) (0.05) 0.3 0.280 0.201 0.2/0.201/0.196 0.2 (0.195, 0.213) 0.096
0.5 0.311 0.236 0.224/0.227/0.22 0.224 (0.204, 0.228) 0.109
(0.1) 0.3 0.407 0.237 0.234/0.239/0.229 0.239 (0.223, 0.268) 0.130
0.5 0.480 0.278 0.261/0.269/0.257 0.269 (0.234, 0.293) 0.137
(0.2) 0.3 0.618 0.268 0.241/0.256/0.239 0.256 (0.204, 0.315) 0.167
0.5 0.712 0.310 0.265/0.286/0.266 0.286 (0.214, 0.346) 0.190
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In order to check how the formulae performs, we calculated the sample size formula based
on (5.6) for 80% power and pC = 0.15. We have considered β1 = 1 and β0 = 0.5 and P (A =
1 | X = j) = 0.5. Using the computed sample size, simulations were performed to get the
empirical powers. The number of simulations considered were 2500. Table (5.14) summarizes
the cohort size and empirical power that can be attained based on a theoretical power of
80% under various scenarios. We considered both exponential and Weibull(2) distributions
to illustrate which formula (5.3, 5.4 and 5.5) results in a smaller cohort size for different
sampling fractions without loss in power. It was found that for different scenarios, different
sample size performed well. When the event and biomarker proportions are really low (5%),
(5.5) is the only one that works well. When either one of the proportions improve, the other
formulas (5.3 and 5.4) start producing better results. If one wants to be conservative, (5.9)
is recommended.
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Table 5.14: Summary of Sample Size and Empirical Power for Theoretical Power = 80%
Event Biomarker Subcohort Exponential Weibull(2)
prop.(p00D ) prop. prop. n Empirical Power n Empirical Power
0.05 0.3 0.1 11940/11778/12617 0.7968/0.7828/0.8 11939/11776/12616 0.7932/0.7932/0.8192
0.2 9356/9284/9657 0.7888/0.7944/0.8088 9357/9284/9657 0.7908/0.7916/0.8048
0.4 0.1 10375/10207/10949 0.8108/0.7736/0.8244 10374/10205/10947 0.804/0.794/0.808
0.2 8101/8026/8356 0.798/0.8008/0.804 8102/8027/8356 0.8036/0.7876/0.808
0.5 0.1 9891/9704/10423 0.8016/0.7828/0.8224 9889/9702/10421 0.802/0.7908/0.816
0.2 7695/7612/7932 0.7956/0.7984/0.814 7696/7612/7932 0.8056/0.8008/0.7988
0.1 0.3 0.1 8797/8440/9385 0.818/0.8032/0.8344 8791/8435/9378 0.8032/0.7884/0.82
0.2 5951/5792/6212 0.816/0.8164/0.8292 5950/5791/6210 0.8064/0.8/0.8192
0.4 0.1 7703/7332/8175 0.8244/0.8032/0.8376 7696/7326/8167 0.8148/0.7816/0.832
0.2 5184/5019/5393 0.7916/0.8168/0.8188 5182/5017/5391 0.8016/0.784/0.8244
0.5 0.1 7399/6987/7812 0.814/0.806/0.8416 7392/6981/7803 0.8192/0.7964/0.8396
0.2 4953/4770/5137 0.8144/0.796/0.8168 4951/4768/5134 0.7976/0.8032/0.8268
0.2 0.3 0.1 8151/7290/8502 0.8504/0.8228/0.8708 8126/7272/8476 0.842/0.8144/0.8476
0.2 4660/4277/4816 0.8424/0.8236/0.8548 4650/4271/4806 0.8376/0.8252/0.8412
0.4 0.1 7236/6339/7438 0.8536/0.8156/0.8772 7209/6321/7412 0.8436/0.8108/0.852
0.2 4111/3713/4201 0.8456/0.8112/0.8412 4101/3706/4190 0.8436/0.808/0.838
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0.5 0.1 7046/6048/7140 0.8556/0.816/0.864 7016/6028/7110 0.864/0.79/0.8628
0.2 3979/3536/4021 0.8496/0.8004/0.8508 3967/3528/4009 0.8308/0.796/0.8444
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5.4 Practical Application
5.4.1 Cost Efficiency of Case-Cohort Design
In practice, one might be interested in the comparison of the cost efficiency of the test
based on the case-cohort sampling scheme and a random sample from the entire cohort,
assuming that the biomarker proportions (r0, r1), treatment proportion in each biomarker
group (p0, p1), the failure proportion in the four groups (p
j0
D , p
j1
D , j = 0, 1) and the log-hazard
of interest (abs{β1 − β0}) are constant. The cost efficiency is measured as the ratio of the
sample sizes required in the two sampling schemes to attain the same power ϑ. Note that from
(5.2), the corresponding test for a simple random sample design is ˜TSn =
√
n∗{βˆ1−βˆ0}√∑
j
1
rj
σˆj
where
σˆ2j =
1
n∗j
[∑n∗j0
i=1
e2βˆjW (Ti,j0)Y˜j1(Ti,j0)
2∆i,j0(
Y˜j0(Ti,j0)+e
βˆj Y˜j1(Ti,j0)
)2 +∑n∗j1i=1 W (Ti,j1)Y˜j0(Ti,j1)2∆i,j1(
Y˜j0(Ti,j1)+e
βˆj Y˜j1(Ti,j1)
)2
]
,
n∗j
n∗ → rj . Using
approximations similar to those for the case-cohort power calculation, the following is the
power function for simple random sample.
Φ
√n∗ (β1 − β0)

1∑
j=0
r−1j
pj(1− pj)
[
e2βjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
]
(
(1− pj)(1− pj0D ) + eβjpj(1− pj1D )
)2

1/2
− Z1−α
 .
(5.12)
Under the assumption that
pj1D
pj0D
≈ 1 and m∗j0nj ≈ (1− pj)
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
, the
power function for the simple random sample is
Φ
√n∗ (β1 − β0)

1∑
j=0
r−1j
pj(1− pj)
[
e2βjpjp
j0
D + (1− pj)pj1D
]
(
(1− pj) + eβjpj
)2

1/2
− Z1−α
 . (5.13)
Note that since (5.5) was based on an approximation of δˆj (see Appendix), it is not reflected
in the power formula based on only the sub-cohort. Denoting the denominator of ˜TSn for
SRS by σdenSRS , we have the SRS sample size as n
∗
SRS =
(Zϑ+Z1−α)2×σ2denSRS
(β1−β0)2 . The sample
size for the case-cohort design is n∗CC (5.6) Hence, the ratio of the two is given by R =
σ2
denSRS
ψσ2
den
∑1
j=0
[
rj
{
1+( 1−ψ
ψ
)(pjpj1D+(1−pj)pj0D )
}] for fixed total cohort size n and assuming that the
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Figure 5.1: The Cost-Efficiency Curve of the Case-Cohort Design
sub-cohort proportion , ψj is the same in the two biomarker groups. When R > 1, then
the case-cohort design is more cost-effective than the SRS. We used (5.9) for the sample size
required for the case-cohort design because it corresponds to the most conservative power
formula for the case-cohort design and the (5.13) for the simple random sample design which
is the most liberal formula for the simple random sample design. We plotted the corresponding
cost efficiency curve of the case-cohort design for different sub-cohort proportions and different
event proportions. We considered β0 = 0.5, β1 = 1, pj = rj = 0.5, p
00
D = p
10
D , p
11
D − p10D = 0.5
and p01D − p00D = 0.25. From figure 5.1, it can be noted that the cost efficiency of the case-
cohort study is always greater than the simple random sample design. For p00D = 0.05, the cost
efficiency curve reaches its maximum of 3.85 at around 10% sub-cohort proportion which is
higher than that achieved when p00D = 0.1 or 0.2. The cost efficiency curve increases, reaches a
maximum and then tapers down to 1 as the sub-cohort proportion reaches 1 for all the event
proportions considered.
5.4.2 Real Data Analysis
For illustration purposes, we used information from Lung Adjuvant Cisplatin Evaluation
(LACE) and Cancer and Leukemia Group B (CALGB) 9633 databases (Shepherd et al. 2013)
to design a two-stage study. The goal of the study is to examine whether the effect of
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adjuvant chemotherapy (ACT) with cisplatin/vinorelbine vs. Observation on early stage
resected non-small-cell lung cancer is different for those who have KRAS-wild-type and those
who have KRAS-mutated gene. There are 1543 individuals in the study, of which 780 are on
adjuvant chemotherapy (ACT) with cisplatin/vinorelbine and 763 are on observation (OBS)
alone. Data on the interaction effect of KRAS-mutation and treatment was available on
1422 patients as they had second primary cancer 1146 (80.6%) patients had KRAS-wild-type
biomarker whereas 276 (19.4%) patients had KRAS-mutated biomarker. In the KRAS-wild-
type biomarker group, 581 (50.7%) patient were in the ACT arm and 565 (49.3%) patients
were in the OBS arm. Similarly, 143 (51.8%) patients are in the ACT arm and 133 (48.2%)
are in the OBS arm. Further, the proportion of events (second primaries) in the KRAS-
wild-type biomarker group and OBS arm, p00D = 0.044, that in the KRAS-wild-type group
and ACT arm, p01D = 0.065, KRAS-mutated group and OBS arm, p
10
D = 0.098 and KRAS-
mutated group and ACT arm, p11D = 0.035. Based on the power formula (5.11) and the
corresponding sample size formula (5.6), with a significance level of 0.05 and power of 80%,
we were not able to calculate a subcohort sample size to detect a hazard ratio of 0.25, which
is based on the interaction term of KRAS and treatment variable in Shepherd et al. (2013).
We also considered exp(βˆ1) = 0.32 from the paper. For the above parameters, for power 60%,
70% and 75%, the subcohort sample sizes are 143, 347 and 837 respectively, using the most
conservative power formula (5.5). However, to attain 80% power for sub-cohort proportions
0.1 and 0.2, the required cohort sizes are 2441 and 1956 respectively.
5.5 Discussion
We have considered a log-rank type test statistic for testing the interaction between the
expensive biomarker and treatment for data from a two-stage study design. Explicit formulas
are obtained for the calculation of power and sample size and their performances are examined
for data from different distributions. When the incidence of disease is low, the simulation
studies show that the two-stage design produces fairly high power, compared to that based
on the full cohort. We have also demonstrated that the two-stage design is more cost efficient
than the simple random sampling scheme when the sub-cohort proportion is low and it tapers
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to being equal when the sub-cohort proportion tends to one. These formula can be used for
designing case-cohort studies as well.
The three power formulas that were derived based on different approximations of the power
formula are shown to work well for different situations. The sample size/power formula are
developed in the context of clinical trials but the methods can be adopted to any two-phase
study including case-cohort studies. In this paper, we have considered a binary biomarker
variable. A natural extension is to consider an expensive discrete biomarker covariate (number
of values > 2). Further development to extend to a continuous biomarker variable and to
stratified case-cohort design are worthwhile.
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CHAPTER 6: FUTURE RESEARCH
In this dissertation, we studied two perspectives of case-cohort study. Chapters 3 and
4 developed estimation procedures under the case-cohort design and the generalized case-
cohort design for recurrent events. Chapter 3 considered the marginal multiplicative rates
model whereas Chapter 4 investigated the marginal additive rates model. Both estimation
procedures can incorporate time-varying weights. They were shown to perform well in finite
samples through simulations. The proposed estimators are consistent and asymptotically
normally distributed.
We have assumed simple random sampling when selecting the sub-cohort and when sam-
pling from the individuals who experienced the event but were not selected in the sub-cohort.
Bernoulli sampling of the subcohort is another sampling scheme that can be considered. In
our approach, we do not use all the covariate information that is available for the entire
cohort. There have been studies (Jiang and Zhou 2007) that have examined the use of aux-
iliary covariates, available for all individuals, in the pseudo-score equation for estimating the
parameters in additive rates model. It can be of interest, for future research, to extend the
idea of using auxiliary variables to improve the efficiency of the estimators in recurrent events
data.
The marginal models considered in this dissertation do not explicitly model the intra-
subject correlation. When one is primarily interested in the effect of the risk factors on the
event times, rather than the correlation among the events for each subject, the marginal
model approach is the recommended method. However, in some situations, the interest
may lie in a more subject-level inference including the strength and nature of dependencies
within each individual’s recurrent event times. In such situations, the frailty models are
advocated. In our analyses, we modeled a single type of recurrent event. However, the
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data may comprise of different types of recurrent events. One such example is the time to
hospitalization. It can be further decomposed into hospitalizations due to different reasons.
Modeling the hospitalization times as originating from the same underlying process may not
depict the entire picture. In such cases, it is of interest to extend the approaches outlined in
Chapters 3 and 4 to incorporate multiple types of recurrent events. Kang and Cai (2009a) and
Kang et al. (2013) developed methods for single time-to-event data, which can be extended
to recurrent events. Further, the diagnostics under any of the two modeling approaches have
not been addressed. We have developed the two methodologies for recurrent events. Section
4.5 briefly discusses using exploratory methods to examine the use of additive rates model.
Nonetheless, rigorous tests of the error processes to study the fit of the data require further
consideration.
Chapter 5 considered the design aspect of the two-stage design for a single time to event
when the interest is in the interaction between two dichotomized variables. A log-rank type
test statistic was considered for testing the interaction between the expensive biomarker
and treatment for the analysis. Explicit formulas were developed for power and sample size
calculation and their performances are examined through simulation studies. Further, the
cost efficiency of the case-cohort design is shown as compared with a simple random sampling
scheme.
The formulae we developed considered dichotomized biomarker. A natural extension is
to consider an expensive discrete biomarker covariate (number of levels > 2). The test
statistics to examine whether the effects are equal in all of the groups need to be developed.
Furthermore, tests need to be developed for continuous biomarker variables. Even though it is
not common, interest may lie in testing the equality of multiple treatment effects in different
biomarker groups. In such a case, we will extend the proposed tests to incorporate multiple
treatment levels. Another extension is to develop tests for power/sample size calculation for
the interaction term of biomarker and treatment for stratified two-stage design. Hu et al.
(2014) studied the tests for only the treatment effect. Implementation of those tests to
interaction effect of treatment and expensive biomarker needs further study.
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APPENDIX A: TECHNICAL DETAILS FOR CHAPTER 3
Here is the Appendix containing the proofs of the theorems 1 and 2 in Chapter 3.
A.1 Regularity Conditions
(i) (T ∗i , Ci, Zi(t)) ∀i = 1, 2, . . . , n are independent and identically distributed.
(ii) P (Y (τ) > 0) > 0 and Ni(τ) (∀i = 1, 2, . . . , n) are bounded by a constant
(iii) | Zi(0) | +
´ τ
0 | dZi(u) |< Cz <∞ almost surely for some constant Cz
(iv) The matrix A(β0) =
´ τ
0 ϑ(β0, t)s
(0)(β0, t)dµ0(t) is positive definite.
(v) (Finite Interval)
´ τ
0 dµ0(t) <∞
(vi) (Asymptotic Stability) There exists a neighborhood B of β0 that satisfies the following:
(a) There exists functions s(0)(β, t), s(1)(β, t) and s(2)(β, t) defined on B × [0, τ ] such
that
sup
t∈[0,τ ],β∈B
‖S(d)(β, t)− s(d)(β, t)‖ P−→ 0
(b) There exists a matrix Q(β) such that
1
n
n∑
i=1
V ar(MZ˜,i(β0))
P−→ Q(β0)
(vii) (Asymptotic Regularity) For all β ∈ B, t ∈ [0, τ ], s(1)(β, t) = δδβ s(0)(β, t), s(2)(β, t) =
δ
δβ s
(1)(β, t) = δ
2
δβδβ′ s
(0)(β, t) where s(d)(β, t) are continuous functions of β ∈ B, uniformly
in t ∈ [0, τ ] and bounded on B×[0, τ ] and s(0)(β, t) is bounded away from zero on B×[0, τ ]
The following conditions are pertaining to the asymptotic convergences of case-cohort
sampling design.
(viii) (Non-trivial subcohort and cases) α˜ = n˜n
P−→ α ∈ (0, 1), q˜ → q, ncn
P−→ p ∈ (0, 1) as
n → ∞ where nc is the number of individuals in the cohort who experienced at least
one event.
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(ix) (Asymptotic Normality of subcohort averages at β0) For  > 0
sup
t
1
n
n∑
i=1
Yi(t){eβZi(t)}21(n−1/2Yi(t)eβZi(t) > ) P−→ 0
sup
t
1
n
n∑
i=1
Yi(t){|Zi(t)‖}2{eβZi(t)}21(n−1/2Yi(t)|Zi(t)‖eβZi(t) > ) P−→ 0
(x) (Asymptotic Normality of samples) As n→∞
1
n
sup
i,t∈[0,τ ]
exp
(
2β′Zi(t)
) P−→ 0, 1
n
sup
i,t∈[0,τ ]
‖Zi(t)‖2exp
(
2β′Zi(t)
) P−→ 0
(xi) (Asymptotic stability)As n→∞, we have the following
(a) There exists a positive definite matrix, V I(β0), such that
var
[
n−1/2
n∑
i=1
ˆ τ
0
(
Ri(β0, t)− Yi(t)E {1−∆i}Ri(β0, t)
E {(1−∆1)Y1(t)}
)
dµ0(t)
]
P−→ V I(β0),
where Ri(β0, t) = Yi(t)Z˜i(t)e
βZi(t).
(b) There is a positive definite matrix, V II(β0) such that
var
n−1/2 n∑
i=1
MZ˜,i(β0)− ˆ τ
0
Yi(t)E
{
dMZ˜,1(β0, t) | ∆1 = 1, ξ1 = 0
}
E {Y1(t) | ∆1 = 1}

| ∆i = 1, ξi = 0] P−→ V II(β0),
where MZ˜,i(β0) =
´ τ
0 Z˜i(t)dMi(t), dMZ˜,i(β0, t) = Z˜i(t)dMi(t) and Z˜i(t) = Zi(t) −
e(β0, t).
Lemma A1 :
Let ϕ = (ϕ1, ϕ2, . . . , ϕn) be a random vector containing n
∗ ones and n − n∗ zeroes, with
each permutation equally likely. Let Bi(t) be independent and identically distributed real-
valued processes on [0, τ ] with E(Bi(t)) = µB(t), var(Bi(0)) < ∞ and var(Bi(t)) < ∞. Let
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B(t) = (B1(t), B2(t), . . . , Bn(t)) and ϕ are independent and let us suppose that all paths of
Bi(t) have finite variation. Then n
−1/2∑n
i=1 ϕi [Bi(t)− µB(t)] converges weakly in l∞[0, τ ]
to a zero-mean Gaussian process and n−1
∑n
i=1 ϕi [Bi(t)− µB(t)] P−→ 0 uniformly in t. This
lemma was stated in (Kang and Cai 2009a).
Lemma A2 :
Let Wn(t) and Gn(t) be two sequences of bounded processes. For some constant, τ let us
assume that the following conditions hold.
(i) sup0≤t≤τ‖Wn(t)−W (t)‖ P−→ 0 for some bounded process, W (t),
(ii) Wn(t) is monotone on [0, τ ] and
(iii) Gn(t) converges to a zero-mean process with continuous sample paths. Then
sup
0≤s≤τ
‖
ˆ s
0
(Wn(t)−W (t))dGn(t)‖ P−→ 0, sup
0≤s≤τ
‖
ˆ s
0
(Gn(t)−G(t))dWn(t)‖ P−→ 0.
This was stated in Kang and Cai (2009b).
First we will look at the asymptotic properties of the time-varying sampling weights.
More specifically, αˆ(t) =
∑n
i=1(1−∆i)ξiYi(t)∑n
i=1(1−∆i)Yi(t) and qˆ(t) =
∑n
i=1 ∆i(1−ξi)ηiYi(t)∑n
i=1 ∆i(1−ξi)Yi(t) . Looking at the
Taylor series expansion of αˆ(t)−1 around α˜−1, we have
αˆ(t)−1 − α˜−1 = − 1
α∗(t)2
(αˆ(t)− α˜) = α˜
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
[
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
,
where α∗(t) is on the line between αˆ(t) and α˜. Now by the Glivenko-Cantelli theorem, one
can show that 1n
∑n
i=1(1−∆i)Yi(t) converges to E ((1−∆i)Yi(t)). (1−∆i)Yi(t) is bounded
and monotone functions of t. They are also independent of ξi. Hence, by Lemma A2,
n−1/2
∑n
i=1(1 − ξiα˜ ) [(1−∆i)Yi(t)] converges weakly to a zero-mean Gaussian process (Kang
and Cai 2009b). This implies that 1n
∑n
i=1(1− ξiα˜ ) [(1−∆i)Yi(t)]
P−→ 0 uniformly in t. Further,
αˆ(t), α∗(t) and α˜ converges to the same limit. Using Slutsky’s theorem, we have
n1/2(αˆ(t)−1 − α˜−1)
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= n1/2
α˜
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
[
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
=
1
α˜E((1−∆i)Yi(t))
[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
+ α˜
(
1
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
− 1
α˜2E((1−∆i)Yi(t))
)[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
=
1
α˜E((1−∆i)Yi(t))
[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
+ oP (1). (6.1)
Similarly,
qˆ(t)−1− q˜−1 = − 1
q∗(t)2
(qˆ(t)− q˜) = q˜
q∗(t)2
1∑n
i=1 ∆i(1− ξi)Yi(t)
[
n∑
i=1
∆i(1− ξi)(1− ηi
q˜
)Yi(t)
]
,
where q∗(t) is on the line between qˆ(t) and q˜. Proceeding as before, we can see that qˆ(t), q∗(t)
and q˜ converges to the same limit. Using Slutsky’s theorem, we have
n1/2(qˆ(t)−1 − q˜−1) = 1
q˜E(∆i(1− ξi)Yi(t))
[
n−1/2
n∑
i=1
∆i(1− ξi)(1− ηi
q˜
)Yi(t)
]
+ oP (1).
(6.2)
A.2 Proof of Theorem 1
Let us define Un(β) =
1
n Uˆ
II(β). Based on similar arguments, as in Foutz(1977), the
consistency of βˆII can be shown by proving the following :
 δδβ′Un(β) exists and is continuous in an open neighborhood of β0 in B
 δ
δβ′0
Un(β0) is negative definite w.p. → 1 as n→∞
 - δδβ′Un(β)
P−→ A(β0) uniformly for β in a neighborhood of β0
 Un(β)
P−→ 0
Taking derivative of the expression, we get
δ
δβ′
Un(β) = − 1
n
n∑
i=1
ˆ τ
0
wIIi (t)
Sˆ(2)(β, t)Sˆ(0)(β, t)− Sˆ(1)(β, t)⊗2
Sˆ(0)(β, t)2
dNi(t)
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= − 1
n
n∑
i=1
ˆ τ
0
wIIi (t)Vˆ (β, t)dNi(t) = −
ˆ τ
0
Vˆ (β, t)dN¯w(t), (6.3)
where dN¯w(t) =
1
n
∑n
i=1w
II
i (t)Ni(t). Define dM¯w(t) =
1
n
∑n
i=1w
II
i (t)Mi(t), dN¯(t) =
1
n
∑n
i=1
dNi(t), dM¯(t) =
1
n
∑n
i=1 dMi(t). Note that,
dMi(t) = dNi(t)−Yi(t)eβZi(t)dµ0(t)⇒
n∑
i=1
wIIi (t)dMi(t) =
n∑
i=1
wIIi (t)dNi(t)−nSˆ(0)(β, t)dµ0(t)
Now, we need to show that this goes to A(β) in probability. Using the above formula, we
have
‖− δ
δβ′
Un(β)−A(β)‖
= ‖
ˆ τ
0
Vˆ (β, t)dN¯w(t)−
ˆ τ
0
ϑ(β, t)s(0)(β, t)dµ0(t)‖
= ‖
ˆ τ
0
(
Vˆ (β, t)− ϑ(β, t)
)
dN¯w(t) +
ˆ τ
0
ϑ(β, t)dM¯w(t)
+
ˆ τ
0
ϑ(β, t)
{
Sˆ(0)(β, t)− s(0)(β, t)
}
dµ0(t)‖
≤ ‖
ˆ τ
0
(
Vˆ (β, t)− ϑ(β, t)
)
dN¯w(t)‖+ ‖
ˆ τ
0
ϑ(β, t)dM¯w(t)‖
+ ‖
ˆ τ
0
ϑ(β, t)
{
Sˆ(0)(β, t)− s(0)(β, t)
}
dµ0(t)‖
≤ ‖
ˆ τ
0
(
Vˆ (β, t)− ϑ(β, t)
)
dN¯(t)‖+ ‖ 1
n
n∑
i=1
ˆ τ
0
(
Vˆ (β, t)− ϑ(β, t)
)
(wIIi (t)− 1)dNi(t)‖
+ ‖
ˆ τ
0
ϑ(β, t)dM¯(t)‖+ 1
n
‖
n∑
i=1
ˆ τ
0
ϑ(β, t)(wIIi (t)− 1)dMi(t)‖
+ ‖
ˆ τ
0
ϑ(β, t)
{
Sˆ(0)(β, t)− s(0)(β, t)
}
dµ0(t)‖. (6.4)
We need to show that each of these terms converges to zero as n → ∞. The first term can
be rewritten as
‖
ˆ τ
0
(
Vˆ (β, t)− ϑ(β, t)
)
dN¯(t)‖
≤ ‖
ˆ τ
0
(
Sˆ(2)(β, t)
Sˆ(0)(β, t)
− s
(2)(β, t)
s(0)(β, t)
)
dN¯(t)‖+ ‖
ˆ τ
0
(
[
Sˆ(1)(β, t)
Sˆ(0)(β, t)
]⊗2 − [s
(1)(β, t)
s(0)(β, t)
]⊗2
)
dN¯(t)‖
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= ‖
ˆ τ
0
{(
Sˆ(2)(β, t)
Sˆ(0)(β, t)
− S
(2)(β, t)
S(0)(β, t)
)
+
(
S(2)(β, t)
S(0)(β, t)
− s
(2)(β, t)
s(0)(β, t)
)}
dN¯(t)‖
+ ‖
ˆ τ
0
{(
[
Sˆ(1)(β, t)
Sˆ(0)(β, t)
]⊗2 − [S
(1)(β, t)
S(0)(β, t)
]⊗2
)
+
(
[
S(1)(β, t)
S(0)(β, t)
]⊗2 − [s
(1)(β, t)
s(0)(β, t)
]⊗2
)}
dN¯(t)‖.
By the regularity condition (vi), we have noted the asymptotic properties of S(d)(β, t) uni-
formly in t,
sup
t∈[0,τ ],β∈B
‖S(d)(β, t)− s(d)(β, t)‖ P−→ 0.
In order to show that the first term of Equation (6.4) converges to 0 as n→∞, it is sufficient
to show that
sup
β∈B,t∈[0,τ ]
‖Sˆ(d)(β, t)− S(d)(β, t)‖ P−→ 0 for all d = 0, 1, 2.
We can write
Sˆ(d)(β, t)− S(d)(β, t) = 1
n
n∑
i=1
(1−∆i)ξi
αˆ(t)
Yi(t)Zi(t)
⊗deβZi(t) +
1
n
n∑
i=1
∆i(1− ξi)ηi
qˆ(t)
Yi(t)Zi(t)
⊗deβZi(t)
+
1
n
n∑
i=1
∆iξiYi(t)Zi(t)
⊗deβZi(t) − 1
n
n∑
i=1
Yi(t)Zi(t)
⊗deβZi(t)
=
1
n
n∑
i=1
(1−∆i)( ξi
αˆ(t)
− 1)Yi(t)Zi(t)⊗deβZi(t)
+
1
n
n∑
i=1
∆i(1− ξi)( ηi
qˆ(t)
− 1)Yi(t)Zi(t)⊗deβZi(t)
=
1
n
n∑
i=1
(1−∆i)(ξi
α˜
− 1)Yi(t)Zi(t)⊗deβZi(t)
+
1
n
n∑
i=1
(1−∆i)ξi( 1
αˆ(t)
− 1
α˜
)Yi(t)Zi(t)
⊗deβZi(t)
+
1
n
n∑
i=1
∆i(1− ξi)( ηi
q˜(t)
− 1)Yi(t)Zi(t)⊗deβZi(t)
+
1
n
n∑
i=1
∆i(1− ξi)ηi( 1
qˆ(t)
− 1
q˜
)Yi(t)Zi(t)
⊗deβZi(t).
Therefore,
∥∥∥Sˆ(d)(β, t)− S(d)(β, t)∥∥∥
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≤ 1
n
∥∥∥∥∥
n∑
i=1
(1−∆i)(ξi
α˜
− 1)Yi(t)Zi(t)⊗deβZi(t)
∥∥∥∥∥+ 1n | ( 1αˆ(t) − 1α˜) | ×∥∥∥∥∥
n∑
i=1
(1−∆i)ξiYi(t)Zi(t)⊗deβZi(t)
∥∥∥∥∥+ 1n
∥∥∥∥∥
n∑
i=1
∆i(1− ξi)( ηi
q˜(t)
− 1)Yi(t)Zi(t)⊗deβZi(t)
∥∥∥∥∥
+ | 1
qˆ(t)
− 1
q˜
| 1
n
∥∥∥∥∥
n∑
i=1
∆i(1− ξi)ηiYi(t)Zi(t)⊗deβZi(t)
∥∥∥∥∥
≤
∥∥∥∥∥ 1n
n∑
i=1
(1−∆i)(ξi
α˜
− 1)Zi(t)⊗dYi(t)eβZi(t)
∥∥∥∥∥
+
1
n
| ( 1
αˆ(t)
− 1
α˜
) |
n∑
i=1
(1−∆i)ξiYi(t)
∥∥∥Zi(t)⊗d∥∥∥ eβZi(t)
+
∥∥∥∥∥ 1n
n∑
i=1
∆i(1− ξi)(ηi
q˜
− 1)Zi(t)⊗dYi(t)eβZi(t)
∥∥∥∥∥
+
1
n
| ( 1
qˆ(t)
− 1
q˜
) |
n∑
i=1
∆i(1− ξi)ηiYi(t)
∥∥∥Zi(t)⊗d∥∥∥ eβZi(t). (6.5)
Note that (1−∆i)Yi(t)Zi(t)⊗deβZi(t) is bounded with total variation being finite in [0, τ ] by the
regularity condition (iii). Using Lemma A1 and the fact that E
(
(1−∆i)( ξiα˜ − 1)Yi(t)Zi(t)⊗d
×eβZi(t)) = 0, E (∆i(1− ξi)(ηiq˜ − 1)Yi(t)Zi(t)⊗deβZi(t)) = 0, we have the first term and third
terms of Equation (6.5) converge to zero in probability uniformly in t. For the second term, we
can note the asymptotic distribution of αˆ(t) proved earlier in equation (6.1) and the fact that
1
n
∑n
i=1(1−∆i)ξiYi(t)
∣∣Zi(t)⊗d∣∣ eβZi(t) converges to a finite quantity in probability uniformly
in t and β by Lemma A1. Similarly, based on equation (6.2) and Lemma A1, we have the
fourth term to converge to zero in probability uniformly in t and β. Combining these results,
Sˆ(d)(β, t) and S(d)(β, t) is shown to converge to the same limit. Therefore, we have
sup
t∈[0,τ ],β∈B
∥∥∥Vˆ (β, t)− ϑ(β, t)∥∥∥ P−→ 0 as n →∞
by using Slutsky’s theorem, the fact that supt∈[0,τ ],β∈B
∥∥∥Sˆ(d)(β, t)− s(d)(β, t)∥∥∥ P−→ 0 and since
s(0)(β, t) is bounded away from zero on B × [0, τ ] by condition (vii).
From the regularity condition (i), we can see that P (supi,t∈[0,τ ]Ni(t) < c) = 1 and so, it
can be easily seen that N¯(t) has bounded variation. Thus, the first term of (6.4) converges to
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zero in probability. Next, we look at n−1/2M¯(t), which is a sum of independent and identically
distributed zero-mean random variables, for fixed t. By CLT, one can show that n1/2M¯(t)
converges to a zero-mean Gaussian process , say WM (Lin et al. 2000). Further, Mi(t) can
be expressed as the difference of two monotone functions in t. As monotone functions have
pseudo-dimension 1 (Pollard 1990, Bilias et al. 1997, Lin et al. 2000), the processes {Mi(t) |
i = 1, 2, . . . , n} are manageable. From the functional Central Limit Theorem (Pollard 1990),
we can conclude that n−1/2M¯(t) is tight and converges weakly to WM (Van Der Vaart and
Wellner 1996). Furthermore, we can show that E(WM (t)−WM (s))4 ≤ K(µ0(t)−µ0(s))2 for
some constant K. Specifically, E(WM (t)−WM (s))4 = 3
(
E(WM (t)−WM (s))2
)2
since,WM (t)
is a zero-mean normal random variable, for fixed t. (E(WM (t) −WM (s))2 = E(WM (t))2 +
E(WM (s))2 − 2E(WM (t)WM (s)) which in turn can be written = E(WM (t))2 − E(WM (s))2
for s ≤ t. Next, note that E(WM (t))2 = E(Mi(t))2 = E(
´ t
0 Yi(u)exp{β′0Zi(u)}dµ0(u)) and so,
E(WM (t))2−E(WM (s))2 ≤
√
K(µ0(t)−µ0(s))⇒ E(WM (t)−WM (s))4 ≤ K(µ0(t)−µ0(s))2.
Then it follows from the Kolmogorov- Centsov Theorem (Karatzas and Shereve 1988) that
WM has continuous sample paths. Using Lemma A2, we get the third term of (6.4) converging
to 0 since ϑ(β, t) is a monotone function of t. We can conclude that the last term of (6.4)
converges to zero using the uniform convergence of Sˆ(d)(β, t) to s(d)(β, t). For the second term
of equation (6.4) we can write
1
n
n∑
i=1
(wIIi (t)− 1)dNi(t)
=
1
n
n∑
i=1
{
∆iξi +
(1−∆i)ξi
αˆ(t)
+
∆i(1− ξi)ηi
qˆ(t)
− 1
}
dNi(t)
=
1
n
n∑
i=1
(1−∆i)
{
ξi
αˆ(t)
− 1
}
dNi(t) +
1
n
n∑
i=1
∆i(1− ξi)
{
ηi
qˆ(t)
− 1
}
dNi(t)
=
1
n
n∑
i=1
(1−∆i)
{
ξi
α˜
− 1
}
dNi(t) +
1
n
n∑
i=1
(1−∆i)ξi
{
1
αˆ(t)
− 1
α˜
}
dNi(t)
+
1
n
n∑
i=1
∆i(1− ξi)
{
ηi
q˜
− 1
}
dNi(t) +
1
n
n∑
i=1
∆i(1− ξi)ηi
{
1
qˆ(t)
− 1
q˜
}
dNi(t)
=
1
n
n∑
i=1
(1−∆i)
{
ξi
α˜
− 1
}
dNi(t)
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+
1
n
n∑
i=1
(1−∆i)ξi
 1α˜E((1−∆1)Y1(t)
 1
n
n∑
j=1
(1−∆j)(1− ξj
α˜
)Yj(t)
 dNi(t)
+
1
n
n∑
i=1
∆i(1− ξi)
{
ηi
q˜
− 1
}
dNi(t)
+
1
n
n∑
i=1
∆i(1− ξi)ηi
 1q˜E(∆1(1− ξ1)Y1(t))
 1
n
∑
j
∆j(1− ξj)(1− ηj
q˜
)Yj(t)
 dNi(t) + oP (1)
=
1
n
n∑
i=1
(1−∆i)
{
ξi
α˜
− 1
}
dNi(t)
+
1
n
n∑
j=1
1
E((1−∆1)Y1(t)(1−∆j)(1−
ξj
α˜
)Yj(t)
[
1
n
n∑
i=1
(1−∆i)ξi
α˜
dNi(t)
]
+
1
n
n∑
i=1
∆i(1− ξi)
{
ηi
q˜
− 1
}
dNi(t)
+
1
n
n∑
j=1
1
E(∆1(1− ξ1)Y1(t))∆j(1− ξj)(1−
ηj
q˜
)Yj(t)
[
1
n
n∑
i=1
∆i(1− ξi)ηi
q˜
dNi(t)
]
+ oP (1)
(6.6)
Since, Ni(t) is bounded for all t, we have the first and third term of equation(6.6) to be also
bounded. 1n
∑n
i=1
ξi
α˜ [(1−∆i)dNi(t)− E((1−∆1)dN1(t))] and 1n
∑n
i=1
ηi
q˜ (1− ξi)
[∆idNi(t)− E(∆1dN1(t))] converges to zero in probability, uniformly in t respectively, by
Lemma A1. Using Lemma from Kulich and Lin (2004) we can note that E((1 − ∆i)(1 −
ξi
α˜ )dNi(t)) = E((1 − ∆i)(1 − ξiα˜ )dYi(t)) = E(∆i(1 − ξi)(1 − ηiq˜ )dNi(t)) = E(∆i(1 − ξi)(1 −
ηi
q˜ )dYi(t)) = 0. Hence, we have all the terms of (6.6) converging to zero in probability
uniformly in t. Hence, the second term of (6.4) converges to 0 in probability. Proceeding as
earlier, we can show that n−1/2
∑n
i=1
´ {wIIi (t)−1}dMi(t) converges to a zero-mean Guassian
process, since, E
(
(1−∆i)( ξiα˜ − 1)dMi(t)
)
= 0 and E
(
∆i(1− ξi)(ηiq˜ − 1)dMi(t)
)
= 0. This
implies that the fourth terms of (6.4) converges to zero in probability. Hence, we have
−δUn(β)
δβ′
P−→ A(β) as n →∞ uniformly in β ∈ B.
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Next, we want to look at n1/2Un(β).
n1/2Un(β) = n
−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
[
Zi(t)− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dNi(t)
= n−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
[
Zi(t)− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dNi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
[
Zi(t)− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
Yi(t)e
βZi(t)dµ0(t)
= n−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
{wIIi (t)− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
{wIIi (t)− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t). (6.7)
The first term converges to a zero-mean Gaussian process based on Lin et al. (2000) paper.
Further, we can replace it with n−1/2
∑n
i=1MZ˜,i(β) = n
−1/2∑n
i=1
´ τ
0 (Zi(t) − e(β, t))dMi(t)
which is asymptotically equivalent to it (since, Z˜i(t) = Zi(t) − e(β, t); e(β, t) = s
(1)(β,t)
s(0)(β,t)
).
One can note that for each t, n1/2M¯(t) is the sum of zero-mean i.i.d. random variables and
can be written as the difference of two monotone functions. Since, each of the functions
are bounded, n1/2M¯(t) is also a bounded process. Moreover, from example 2.11.16 of Van
Der Vaart and Wellner (1996) we have that n−1/2M¯(t) converges weakly to a zero-mean
Gaussian process, WM with E (WM (t)−WM (s))4 < C [µ0(t)− µ0(s)]2 for some positive
constant, C. By the Kolmogov-Centsov Theorem (Karatzas and Shereve 1988), WM (t) has
continuous sample paths. Also, from regularity condition (vi), we have that S(1)(β, t) and
S(0)(β, t) are of bounded variations and S(0)(β, t) is bounded away from zero such that S
(1)(β,t)
S(0)(β,t)
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also has bounded variation and can be written as the difference of two monotone functions,
specifically, S
(1)(β,t)
S(0)(β,t)
= G1(t)−G2(t) whereGi(t) are non-negative, monotone in t and bounded.
Similarly, we have Sˆ
(1)(β,t)
Sˆ(0)(β,t)
has bounded variation and is equal to H1(t)−H2(t) where Hi(t)
are non-negative, monotone in t and bounded. One can also note that since Sˆ
(1)(β,t)
Sˆ(0)(β,t)
converges
uniformly to s
(1)(β,t)
s(0)(β,t)
and regularity condition (vi) implies that Sˆ
(1)(β,t)
Sˆ(0)(β,t)
and S
(1)(β,t)
S(0)(β,t)
have the
same limit uniformly. Based on Lemma A2, we can rewrite the third quantity on the RHS of
(6.7) as
ˆ τ
0
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
n−1/2
n∑
i=1
dMi(t)
=
ˆ τ
0
[
S(1)(β, t)
S(0)(β, t
− s
(1)(β, t)
s(0)(β, t)
]
n−1/2
n∑
i=1
dMi(t)−
ˆ τ
0
[
Sˆ(1)(β, t)
Sˆ(0)(β, t
− s
(1)(β, t)
s(0)(β, t)
]
n−1/2
n∑
i=1
dMi(t)
P−→ 0.
Hence, the third term of equation (6.7) converges to zero in probability. Next, we look at the
fourth term of the equation.
n−1/2
n∑
i=1
ˆ τ
0
{wIIi (t)− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
{ξi∆i + (1−∆i) ξi
αˆ(t)
+ ∆i(1− ξi) ηi
qˆ(t)
− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){ ξi
αˆ(t)
− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ ηi
qˆ(t)
− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){ξi
α˜
− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
(1−∆i)ξi{ 1
αˆ(t)
− 1
α˜
}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ ηi
qˆ(t)
− 1}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi)ηi{ 1
qˆ(t)
− 1
q˜
}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t). (6.8)
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n−1/2
∑n
i=1(1 − ∆i)Mi(t) is the sum of independent and identically distributed zero-mean
random variables, for fixed t. Using Lemma A1 and noting that for finite samples, µB(t) =
1
n
∑n
i=1Bi(t), we have n
−1/2∑n
i=1(1 −∆i){ ξiα˜ − 1}Mi(t) converges to a zero-mean Gaussian
process. Using Kolmogorv-Centsov Theorem, we can show that the limiting process has
continuous sample paths. Further, we have by Slutsky’s theorem, S
(1)(β,t)
S(0)(β,t)
− Sˆ(1)(β,t)
Sˆ(0)(β,t)
P−→ 0,
uniformly in t. Hence, the first term of (6.8) converges to 0 in probability by using Lemma A2.
Similarly, the third term of (6.8) can be shown to converge to 0 in probability. Considering
the second term of the above equation, we have
n−1/2
n∑
i=1
ˆ τ
0
(1−∆i)ξi{ 1
αˆ(t)
− 1
α˜
}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i)ξi
∑
j
{
1
α˜E [(1−∆1)Y1(t)]
1
n
(1− ξj
α˜
)(1−∆j)Yj(t)
}
×
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t) + op(1)
= n−1/2
n∑
j=1
ˆ τ
0
1
E [(1−∆1)Y1(t)] (1−
ξj
α˜
)(1−∆j)Yj(t)
{
1
n
n∑
i=1
(1−∆i)ξi
α˜
dMi(t)
}
×
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
+ op(1)
From Lemma A1, we have 1n
∑n
i=1(1−∆i) ξiα˜ dMi(t) converges to zero in probability uniformly
in t and we have shown earlier that S(d)(β, t) and Sˆ(d)(β, t) have the same limit in probability
uniformly in t. S(0)(β, t) and Sˆ(0)(β, t) are bounded away from zero and hence, S
(1)(β,t)
S(0)(β,t
−
Sˆ(1)(β,t)
Sˆ(0)(β,t)
converges to zero in probability by the Slutsky’s theorem. Hence, the second term of
equation (6.8) converges to zero in probability. Similarly, we have the fourth term of (6.8) as
n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi)ηi{ 1
αˆ(t)
− 1
α˜
}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
dMi(t)
= n−1/2
n∑
j=1
ˆ τ
0
1
E [∆1(1− ξ1)Y1(t)] (1−
ηj
q˜
)∆j(1− ξj)Yj(t)
{
1
n
n∑
i=1
∆i(1− ξi)ηi
q˜
dMi(t)
}
[
S(1)(β, t)
S(0)(β, t
− Sˆ
(1)(β, t)
Sˆ(0)(β, t)
]
+ op(1)
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Proceeding in the same way, it can be easily shown that the fourth term of (6.8) converges
to 0 in probability, implying that the fourth term of equation (6.7) converges to zero. Next,
looking at the second term of the equation :
n−1/2
n∑
i=1
ˆ τ
0
{wIIi (t)− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
{ξi∆i + (1−∆i) ξi
αˆ(t)
+ ∆i(1− ξi) ηi
qˆ(t)
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){ ξi
αˆ(t)
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ ηi
qˆ(t)
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){ξi
α˜
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
(1−∆i)ξi{ 1
αˆ(t)
− 1
α˜
}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi)ηi{ 1
qˆ(t)
− 1
q˜
}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){1− ξi
α˜
}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
Yi(t)e
βZi(t)dµ0(t)
− n−1/2
n∑
i=1
ˆ τ
0
(1−∆i)ξi
∑
j
{
1
α˜E [(1−∆1)Y1(t)]
1
n
(1− ξj
α˜
)(1−∆j)Yj(t)
}[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
× Yi(t)eβZi(t)dµ0(t) + n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi)ηi
∑
j
{
1
q˜E [∆1(1− ξ1)Y1(t)]
1
n
(1− ηj
q˜
)∆j(1− ξj)Yj(t)
}
×
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t) + oP (1)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){1− ξi
α˜
} [Zi(t)− e(β, t)]Yi(t)eβZi(t)dµ0(t)
− n−1/2
n∑
j=1
ˆ τ
0
1
α˜E [(1−∆1)Y1(t)] (1−
ξj
α˜
)(1−∆j)Yj(t) 1
n
n∑
i=1
{
(1−∆i)ξi
α˜
[Zi(t)− e(β, t)]
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×Yi(t)eβZi(t)
}
dµ0(t) + n
−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1} [Zi(t)− e(β, t)] dMi(t)
+ n−1/2
n∑
j=1
ˆ τ
0
1
E [∆1(1− ξ1)Y1(t)] (1−
ηj
q˜
)∆j(1− ξj)Yj(t)
{
1
n
n∑
i=1
[
∆i(1− ξi)ηi
q˜
(Zi(t)
−e(β, t))] dMi(t)}+ oP (1). (6.9)
We get the last equality because Sˆ
(1)(β,t)
Sˆ(0)(β,t)
−e(β, t) P−→ 0 uniformly in t. Further, by Lemma A1,
1
n
∑n
i=1
{
(1−∆i) ξiα˜ [Zi(t)− e(β, t)]Yi(t)eβZi(t)
}
and 1n
∑n
i=1
[
∆i(1− ξi)ηiq˜ (Zi(t)− e(β, t))
]
×dMi(t) are asymptotically equivalent to E
{
(1−∆1) [Z1(t)− e(β, t)]Y1(t)eβ′Z1(t)
}
and
E [∆i(1− ξi) (Zi(t)− e(β, t)) dMi(t)], respectively. Therefore, the above can be simplified
into
n−1/2
n∑
i=1
ˆ τ
0
{wIIi (t)− 1}
[
Zi(t)− S
(1)(β, t)
S(0)(β, t)
]
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){1− ξi
α˜
}
[
(Zi(t)− e(β, t))Yi(t)eβZi(t)
−
Yi(t)E
[
(1−∆1) (Z1(t)− e(β, t))Y1(t)eβ′Z1(t)
]
E [(1−∆1)Y1(t)]
 dµ0(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1} [(Zi(t)− e(β, t)) dMi(t)−
Yi(t)E [(Z1(t)− e(β, t)) dM1(t) | ∆1 = 1, ξ1 = 0]
E [Y1(t) | ∆1 = 1]
]
+ oP (1)
= n−1/2
n∑
i=1
ˆ τ
0
(1−∆i){1− ξi
α˜
}
[
Ri(β, t)− Yi(t)E [(1−∆1)R1(β, t)]
E [(1−∆1)Y1(t)]
]
dµ0(t)
+ n−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}
dMZ˜,i(β, t)− Yi(t)E
[
dMZ˜,1(β, t) | ∆1 = 1, ξ1 = 0
]
E [Y1(t) | ∆1 = 1]

+ oP (1).
whereRi(β, t) = Yi(t)Z˜i(t)e
βZi(t) = Yi(t) (Zi(t)− e(β, t)) eβZi(t), MZ˜,i(β) =
´ τ
0 (Zi(t)− e(β, t))
×dMi(t) and dMZ˜,i(β, t) = (Zi(t)− e(β, t)) dMi(t). Therefore, we can state that n1/2Un(β)
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is asymptotically equivalent to
n−1/2
n∑
i=1
ˆ τ
0
dMZ˜,i(β) + n
−1/2
n∑
i=1
ˆ τ
0
{1− ξi
α˜
}(1−∆i)
(
Ri(β, t)− Yi(t)E [(1−∆i)Ri(β, t)]
E [(1−∆i)Yi(t)]
)
dµ0(t) + n
−1/2
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}
dMZ˜,i(β, t)− Yi(t)E
[
dMZ˜,1(β, t) | ∆1 = 1, ξ1 = 0
]
E [Y1(t) | ∆1 = 1]
 .
(6.10)
Under the regularity conditions, from Lin et al. (2000), the first term has covariance,
E(MZ˜,i(β0))
⊗2. The second and third terms can be shown to be asymptotically zero-mean
normal with covariance matrix, V I(β0) and V
II(β0) respectively based on Ha´jek’s (1960)
central limit theorem for finite population sampling. First we need to check the following
conditions in order to use Ha´jek’s Theorem.
(a) α˜ converges to α ∈ (0, 1).
(b) 1n
∣∣a′ (´ τ0 R∗i (β, t)dµ0(t)− 1n∑ni=1 ´ τ0 R∗i (β, t)dµ0(t))∣∣ converges to 0 in probability.
(c) 1n−1
∑n
i=1
(
a′
´ τ
0 R
∗
i (β, t)dµ0(t)− 1n
∑n
i=1 a
′ ´ τ
0 R
∗
i (β, t)dµ0(t)
)2
converges to some quan-
tity, σ2 > 0.
For this, let us take a = (a1, a2, . . . , ap)
′ be a p × 1 real-valued vector and let us define
R∗i (β, t) = Ri(β, t)− Yi(t)E[(1−∆i)Ri(β,t)]E[(1−∆i)Yi(t)] Then we have∣∣∣∣∣a′
(ˆ τ
0
R∗i (β, t)dµ0(t)−
1
n
n∑
i=1
ˆ τ
0
R∗i (β, t)dµ0(t)
)∣∣∣∣∣
≤
∣∣∣∣∣a′
(ˆ τ
0
Ri(β, t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
Ri(β, t)dµ0(t)
)∣∣∣∣∣
+
∣∣∣∣∣a′
(ˆ τ
0
e∗(β, t)Yi(t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
ˆ τ
0
e∗(β, t)Yi(t)dµ0(t)
)∣∣∣∣∣ . (6.11)
where e∗(β, t) = E[(1−∆i)Ri(β,t)]E[(1−∆i)Yi(t)] .
∣∣a′ (´ τ0 e∗(β, t)Yi(t)dµ0(t)− 1n∑ni=1 ´ τ0 ´ τ0 e∗(β, t)Yi(t)dµ0(t))∣∣ =∣∣a′ ´ τ0 e∗(β, t) (Yi(t)− Y¯ (t)) dµ0(t)∣∣, Y¯ (t) = ∑ni=1 Yi(t)n and −1 ≤ (Yi(t)− Y¯ (t)) ≤ 1. ⇒∣∣a′ ´ τ0 e∗(β, t) (Yi(t)− Y¯ (t)) dµ0(t)∣∣ ≤ ∣∣a′ ´ τ0 e∗(β, t)dµ0(t)∣∣. For the first term on the right
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hand side of (6.11),
∣∣∣∣∣a′
(ˆ τ
0
Ri(β, t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
Ri(β, t)dµ0(t)
)∣∣∣∣∣
=
∣∣∣∣∣
(
a′
ˆ τ
0
Z˜i(t)Yi(t)e
βZi(t)dµ0(t)
)
− 1
n
n∑
i=1
(
a′
ˆ τ
0
Z˜i(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣
≤
∣∣∣∣(a′ ˆ τ
0
Z˜i(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣+
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
Z˜i(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣
≤
∣∣∣∣(a′ ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣+ ∣∣∣∣(a′ ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣
+
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣+
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣ .
Next, we see that
max
i
(∣∣∣∣∣a′
(ˆ τ
0
R∗i (β, t)dµ0(t)−
1
n
n∑
i=1
ˆ τ
0
R∗i (β, t)dµ0(t)
)∣∣∣∣∣
)2
≤ max
i
(∣∣∣∣∣a′
(ˆ τ
0
Ri(β, t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
Ri(β, t)dµ0(t)
)∣∣∣∣∣
+
∣∣∣∣a′ ˆ τ
0
e∗(β, t)
(
Yi(t)− Y¯ (t)
)
dµ0(t)
∣∣∣∣)2
≤ max
i
(∣∣∣∣∣a′
(ˆ τ
0
Ri(β, t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
Ri(β, t)dµ0(t)
)∣∣∣∣∣
)2
+ 2 max
i
∣∣∣∣∣a′
(ˆ τ
0
Ri(β, t)dµ0(t)− 1
n
n∑
i=1
ˆ τ
0
Ri(β, t)dµ0(t)
)∣∣∣∣∣
∣∣∣∣a′ ˆ τ
0
e∗(β, t)
(
Yi(t)− Y¯ (t)
)
dµ0(t)
∣∣∣∣
+ max
i
(∣∣∣∣a′ ˆ τ
0
e∗(β, t)
(
Yi(t)− Y¯ (t)
)
dµ0(t)
∣∣∣∣)2 . (6.12)
The first term on the RHS of (6.12) can be rewritten as
max
i
(∣∣∣∣∣a′
(ˆ τ
0
R∗i (β, t)dµ0(t)−
1
n
n∑
i=1
ˆ τ
0
R∗i (β, t)dµ0(t)
)∣∣∣∣∣
)2
≤ max
i
(∣∣∣∣(a′ ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣+ ∣∣∣∣(a′ ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣
+
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣+
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣
)2
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≤
(
max
i
∣∣∣∣(a′ ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣+ maxi
∣∣∣∣(a′ ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣
+ max
i
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
Zi(t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣+ maxi
∣∣∣∣∣ 1n
n∑
i=1
(
a′
ˆ τ
0
e(β, t)Yi(t)e
βZi(t)dµ0(t)
)∣∣∣∣∣
)2
.
We can note that,
max
i
(∣∣∣∣ˆ τ
0
a′Zi(t)Yi(t)eβZi(t)dµ0(t)
∣∣∣∣) ≤ sup
i,t
(∣∣a′Zi(t)∣∣Yi(t)eβZi(t)µ0(t))
max
i
(∣∣∣∣ˆ τ
0
a′e(β, t)Yi(t)eβZi(t)dµ0(t)
∣∣∣∣) ≤ sup
i,t
(∣∣a′e(β, t)∣∣Yi(t)eβZi(t)µ0(t))
max
i
(∣∣∣∣∣ 1n
n∑
i=1
ˆ τ
0
a′Zi(t)Yi(t)eβZi(t)dµ0(t)
∣∣∣∣∣
)
≤ sup
i,t
(∣∣a′Zi(t)∣∣Yi(t)eβZi(t)µ0(t))
max
i
(∣∣∣∣∣ 1n
n∑
i=1
ˆ τ
0
a′e(β, t)Yi(t)eβZi(t)dµ0(t)
∣∣∣∣∣
)
≤ sup
i,t
(∣∣a′e(β, t)∣∣Yi(t)eβZi(t)µ0(t))
max
i
(∣∣∣∣a′ ˆ τ
0
e∗(β, t)
(
Yi(t)− Y¯ (t)
)
dµ0(t)
∣∣∣∣) ≤ sup
t
(|a′e∗(β, t)|µ0(t))
Note that, we can easily show that 1n supi,t
(|a′Zi(t)|Yi(t)eβZi(t)µ0(t)) P−→ 0 and 1n supi,t (|a′e(β, t)|
Yi(t)e
βZi(t)µ0(t)
) P−→ 0 as n→∞ as the functions are bounded from the regularity conditions,
and hence, we see that (b) holds. As for (c), note that, 1n
∑n
i=1
(
a′
´ τ
0 R
∗
i (β, t)dµ0(t)− 1n
∑n
i=1 a
′ ´ τ
0
R∗i (β, t)dµ0(t))
2 ≤ maxi
(
a′
´ τ
0 R
∗
i (β, t)dµ0(t)− 1n
∑n
i=1 a
′ ´ τ
0 R
∗
i (β, t)dµ0(t)
)2
which is bounded
and nn−1 → 1 as n → ∞. Hence, we have n−1/2
∑n
i=1
´ τ
0 a
′
(
{1− ξiα˜ }(1−∆i)R∗i (β, t)
)
dµ0(t)
converges to a normal distribution. Therefore, by Cramer- Wold device, we have n−1/2
∑n
i=1
´ τ
0(
{1− ξiα˜ }(1−∆i)R∗i (β, t)
)
dµ0(t) converges to a zero-mean Normal random variable with
variance,
1− α
α
V I(β) = E
(ˆ τ
0
(1−∆i)R∗i (β, t)dµ0(t)
)⊗2
= E
(ˆ τ
0
(1−∆i)
{
Ri(β, t)− Yi(t)E [(1−∆i)Ri(β, t)]
E [(1−∆i)Yi(t)]
}
dµ0(t)
)⊗2
.
Similarly, we can show that n−1/2
∑n
i=1{1− ηiq˜ }∆i(1− ξi)
´ τ
0
[
dMZ˜,i(β, t)− Yi(t)
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×E(dMZ˜,1(β,t)|∆1=1,ξ1=0)E(Y1(t)|∆1=1)
]
converges to a zero-mean Normal random variable with variance,
(1− α)1− q
q
P (∆1 = 1)V
II(β)
= var
ˆ τ
0
dMZ˜,i(β, t)− Yi(t)E
(
dMZ˜,1(β, t) | ∆1 = 1, ξ1 = 0
)
E (Y1(t) | ∆1 = 1)
 .
Next let us consider the covariance between n−1/2
∑n
i=1MZ˜,i(β, t) and n
−1/2∑n
i=1
´ τ
0 (1 −
ξi
α˜ )(1−∆i)R∗i (β, t)dµ0(t). Defining the marginal filtration as , Fi(t) = σ{Ni(t), Yi(t), Zi(t)}, t ∈
[0, τ ] for the i-th individual at time t, we have
cov(n−1/2
n∑
i=1
MZ˜,i(β, t), n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)
ˆ τ
0
R∗i (β, t)dµ0(t))
= E
(
n−1/2
n∑
i=1
MZ˜,i(β, t)n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)
ˆ τ
0
R∗i (β, t)dµ0(t)
)
= E
[
E
(
n−1/2
n∑
i=1
MZ˜,i(β, t)n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)
ˆ τ
0
R∗i (β, t)dµ0(t)
∣∣∣ F(τ))]
= E
[
n−1/2
n∑
i=1
MZ˜,i(β, t)n
−1/2
n∑
i=1
E
(
1− ξi
α˜
∣∣∣ F(τ)) (1−∆i) ˆ τ
0
R∗i (β, t)dµ0(t)
]
= 0.
Similarly, the covariance between n−1/2
∑n
i=1MZ˜,i(β, t) and n
−1/2∑n
i=1(
ηi
q˜ − 1)∆i(1− ξi)
M∗
Z˜,i
(β, t) where M∗
Z˜,i
(β, t) =
´ τ
0
[
dMZ˜,i(β, t)−
Yi(t)E(dMZ˜,1(β,t)|∆1=1,ξ1=0)
E(Y1(t)|∆1=1,ξ1=0)
]
is given by
cov
(
n−1/2
n∑
i=1
MZ˜,i(β, t), n
−1/2
n∑
i=1
(
ηi
q˜
− 1)∆i(1− ξi)M∗Z˜,i(β, t)
)
= E
(
n−1
n∑
i=1
MZ˜,i(β, t)
n∑
i=1
(
ηi
q˜
− 1)∆i(1− ξi)M∗Z˜,i(β, t)
)
= E
[
E
(
n−1
n∑
i=1
MZ˜,i(β, t)
n∑
i=1
(
ηi
q˜
− 1)∆i(1− ξi)M∗Z˜,i(β, t)
∣∣∣ F(τ))]
= E
[
n−1
n∑
i=1
MZ˜,i(β, t)
n∑
i=1
E
(
1− ξi)(1− ηi
q˜
)
∣∣∣ F(τ))∆iM∗Z˜,i(β, t)
]
= 0.
Finally, we can show that cov
(
n−1/2
∑n
i=1
´ τ
0 R
∗
i (β, t)dµ0(t), n
−1/2∑n
i=1(
ηi
q˜ − 1)∆i(1− ξi)
M∗
Z˜,i
(β, t)
)
= 0. Therefore, the variance of n1/2Un(β) is given by E(MZ˜,i(β))
⊗2 + 1−αα V
I(β)+
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(1 − α)1−qq P (∆1 = 1)V II(β). This implies that Un(β)
P−→ 0 as n → ∞. Further, we can use
Taylor Series expansion of n1/2Un(βˆ
II) around β0 to get
n1/2Un(βˆ
II) ≈ n1/2Un(β) + n1/2(βˆII − β0)′ δ
δβ
U IIn (β
∗)
where β∗ belongs to the line segment between β0 and βˆII . Hence, we can say that n1/2(βˆII −
β0) converges to a normal distribution with mean 0 and variance
A(β0)
−1
(
E(MZ˜,i(β))
⊗2 +
1− α
α
V I(β) + (1− α)1− q
q
P (∆1 = 1)V
II(β)
)
A(β0)
−1.
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A.3 Proof of Theorem 2
Next, we look at the distribution of the estimate of the rate function, µˆ0(βˆ
II , t).
n1/2{µˆ0(βˆII , t)− µ0(t)}
= n1/2{µˆ0(βˆII , t)−
ˆ t
0
∑n
i=1w
II
i (t)dNi(u)
nSˆ(0)(β0, u)
}+ n1/2{
ˆ t
0
∑n
i=1w
II
i (t)dNi(u)
nSˆ(0)(β0, u)
− µ0(t)}
= n1/2
ˆ t
0
{
1
nSˆ(0)(βˆII , u)
− 1
nSˆ(0)(β0, u)
}
n∑
i=1
wIIi (u)dMi(u) + n
1/2
ˆ t
0
{
1
Sˆ(0)(βˆII , u)
− 1
Sˆ(0)(β0, u)
}
Sˆ(0)(β0, u)dµ0(u) +
ˆ t
0
1
Sˆ(0)(β0, u)
{
n−1/2
n∑
i=1
wIIi (u)dMi(u)
}
= n1/2
ˆ t
0
{
1
nSˆ(0)(βˆII , u)
− 1
nSˆ(0)(β0, u)
}
n∑
i=1
dMi(u)
+ n1/2
ˆ t
0
{
1
nSˆ(0)(βˆII , u)
− 1
nSˆ(0)(β0, u)
}
n∑
i=1
(wIIi (u)− 1)dMi(u)
+ n1/2
ˆ t
0
{
1
Sˆ(0)(βˆII , u)
− 1
Sˆ(0)(β0, u)
}
Sˆ(0)(β0, u)dµ0(u) +
ˆ t
0
1
Sˆ(0)(β0, u)
{
n−1/2
n∑
i=1
dMi(u)
}
+
ˆ t
0
1
Sˆ(0)(β0, u)
{
n−1/2
n∑
i=1
(wIIi (u)− 1)dMi(u)
}
. (6.13)
By the Taylor series expansion of Sˆ(0)(βˆII , u)−1 around β0 we have,
Sˆ(0)(βˆII , u)−1 ≈ Sˆ(0)(β0, u)−1 − (βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
where β∗ belongs to the line segment β0 and βˆII . Therefore the first term of the equation
(6.13) can be written as
n1/2
ˆ t
0
{
1
nSˆ(0)(βˆII , u)
− 1
nSˆ(0)(β0, u)
}
n∑
i=1
dMi(u)
= n−1/2
ˆ t
0
{
−(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
dMi(u). (6.14)
Note that, Sˆ(1)(β∗, u) and Sˆ(0)(β∗, u) have bounded variations and Sˆ(0)(β∗, u) is bounded away
from zero; hence, Sˆ
(1)(β∗,u)
Sˆ(0)(β∗,u)
also has bounded variation and can be expressed as the difference
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of two monotone functions in t. Therefore, noting that βˆII
P−→ β0 and n−1/2
∑n
i=1 dMi(u)
converges to a zero-mean Gaussian process , having continuous sample paths, we can show
that converges to 0 as n →∞ by using Lemma A1 from Lin et al. (2000). Next, the second
term can be written as
n1/2
ˆ t
0
{
1
nSˆ(0)(βˆII , u)
− 1
nSˆ(0)(β0, u)
}
n∑
i=1
(wIIi (u)− 1)dMi(u)
= −n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
(
∆iξi +
(1−∆i)ξi
αˆ(u)
+
∆i(1− ξi)ηi
qˆ(u)
− 1
)
dMi(u)
+ oP (1)
= −n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
(
(1−∆i)( ξi
αˆ(u)
− 1) + ∆i(1− ξi)( ηi
qˆ(u)
− 1)
)
× dMi(u) + oP (1)
= −n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
(1−∆i)
(
ξi
α˜
− 1
)
dMi(u)
− n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
(1−∆i)ξi
 1
α˜E((1−∆1)Y1(t))
1
n
∑
j
(1−∆j)
(1− ξj
α˜
)Yj(t)
)
dMi(u)− n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
∆i(1− ξi)
(
ηi
q˜
− 1
)
dMi(u)
− n−1/2
ˆ t
0
{
(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
n∑
i=1
∆i(1− ξi)ηi
 1
q˜E(∆1(1− ξ1)Y1(t))
1
n
∑
j
∆j(1− ξj)
×(1− ηj
q˜
)Yj(t)
)
dMi(u) + oP (1) (6.15)
Note that βˆII − β0 P−→ 0 as n → ∞, Sˆ
(1)(β∗,t)
Sˆ(0)(β∗,t)
is bounded away from zero. Further, we
have already shown that n1/2(βˆII − β0)′ Sˆ
(1)(β∗,t)
Sˆ(0)(β∗,t)
converges to a zero-mean Gaussian process.
Similar, we have also shown that n−1/2
∑n
i=1(1−∆i){ ξiα˜ − 1}Mi(t) converges to a zero-mean
Gaussian process (Lin et al. (2000), Van Der Vaart and Wellner (1996)(example 2.11.16
pg 215)). Using Kolmogorv-Centsov Theorem, we can show that the limiting process has
continuous sample paths. Hence, the first term of (6.15) converges to 0 in probability by
using Lemma A2. Similarly, the third term of (6.15) can be shown to converge to 0 in
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probability. Considering the second term of the above equation, we have
n−1/2
n∑
i=1
ˆ t
0
(1−∆i)ξi
∑
j
{
1
α˜E [(1−∆1)Y1(u)]
1
n
(1− ξj
α˜
)(1−∆j)Yj(u)
}{
(βˆII − β0)′
× Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
dMi(t)
= (βˆII − β0)′n−1/2
n∑
j=1
ˆ t
0
1
E [(1−∆1)Y1(u)] (1−
ξj
α˜
)(1−∆j)Yj(u)
{
1
n
n∑
i=1
(1−∆i)ξi
α˜
dMi(u)
}
×
{
Sˆ(1)(β∗, u)
Sˆ(0)(β∗, u)
}
Note that n−1/2
∑n
j=1
´ t
0 (1−
ξj
α˜ )(1−∆j)Yj(u) is a bounded process. By Lemma A1, 1n
∑n
i=1(1−
∆i)
ξi
α˜ dMi(u) is asymptotically equivalent to E ((1−∆i)dMi(u)) in probability uniformly in
u and Sˆ
(1)(β∗,u)
Sˆ(0)(β∗,u)
P−→ e(β∗, u), uniformly in u. Hence, the above converges to zero in probability.
Similarly, we have the fourth term of (6.15) converging to zero in probability. Let us look at
the third term of (6.13).
n1/2
ˆ t
0
{
1
Sˆ(0)(βˆII , u)
− 1
Sˆ(0)(β0, u)
}
S(0)(β0, u)dµ0(u)
= n1/2
ˆ t
0
{
−(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
Sˆ(0)(β0, u)dµ0(u).
Proceeding as earlier, by the consistency of βˆII , uniform consistency of S(d)(β, t) and Sˆ(d)(β, t)
and the boundedness of µ0(t), we can further write
n1/2
ˆ t
0
{
−(βˆII − β0)′ Sˆ
(1)(β∗, u)
Sˆ(0)(β∗, u)
}
Sˆ(0)(β0, u)dµ0(u) = n
1/2(βˆII − β0)′r(β0, t) + oP (1),
where r(β, t) = − ´ t0 s(1)(β, u)dµ0(u). Now, for the fourth term of the equation (6.13), since
Sˆ(0)(β, t) converges to s(0)(β, t) uniformly in t and is bounded away from zero. n−1/2
∑n
i=1Mi(t)
converges to a zero-mean Gaussian process with continuous sample paths. Hence,
´ t
0
1
Sˆ(0)(β0,u)
{
n−1/2
∑n
i=1 dMi(u)
}
can be written as
´ t
0
1
s(0)(β0,u)
{
n−1/2
∑n
i=1 dMi(u)
}
. Now,
for the last term in (6.13), we can note similarly that S(0)(β, t) converges uniformly to s(0)(β, t)
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and is bounded away from zero. Hence, one can write the fifth term of (6.13) as
ˆ t
0
1
Sˆ(0)(β0, u)
{
n−1/2
n∑
i=1
(wIIi (u)− 1)dMi(u)
}
= n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
{
(1−∆i)( ξi
αˆ(t)
− 1)Yi(u)eβ′0Zi(u)dµ0(u)
}
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
{
∆i(1− ξi)( ηi
qˆ(t)
− 1)dMi(u)
}
= n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
{
(1−∆i)(ξi
α˜
− 1)Yi(u)eβ′0Zi(u)dµ0(u)
}
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
(1−∆i)ξi
{
1
αˆ(t)
− 1
α˜
}
Yi(u)e
β′0Zi(u)dµ0(u)
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
{
∆i(1− ξi)(ηi
q˜
− 1)dMi(u)
}
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
∆i(1− ξi)ηi
{
1
qˆ(t)
− 1
q˜
}
dMi(u). (6.16)
Using (6.1), (6.2) and Lemma A1, the second term of (6.16) = n−1/2
∑n
i=1
´ t
0
1
s(0)(β0,u)
(1 −
∆i)(1− ξiα˜ )
Yi(u)E
{
(1−∆i)Yi(u)eβ
′
0Zi(u)dµ0(u)
}
E[(1−∆i)Yi(t)] +oP (1) and the third term = n
−1/2∑n
i=1
´ t
0
1
s(0)(β0,u)
∆i(1−
ξi)(1− ηiq˜ )Yi(t)E{∆i(1−ξi)dMi(u)}E[∆i(1−ξi)Yi(t)] + oP (1). Therefore, the above equation can be rewritten as
ˆ t
0
1
Sˆ(0)(β0, u)
{
n−1/2
n∑
i=1
(wIIi (u)− 1)dMi(u)
}
= n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
(1−∆i)(ξi
α˜
− 1)
Yi(u)eβ′0Zi(u) − Yi(u)E
{
(1−∆1)Y1(u)eβ′0Z1(u)
}
E [(1−∆1)Y1(u)]

× dµ0(t) + n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
∆i(1− ξi)(ηi
q˜
− 1)
{
dMi(u)− Yi(u)E {∆1(1− ξ1)dM1(u)}
E [∆1(1− ξ1)Y1(u)]
}
+ oP (1). (6.17)
Combining all of the above, we have (6.13) as
n1/2{µˆ0(βˆII , t)− µ0(t)}
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≈ n1/2(βˆII − β0)′r(β0, t) +
ˆ t
0
1
s(0)(β0, u)
{
n−1/2
n∑
i=1
dMi(u)
}
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
(1−∆i)(1− ξi
α˜
)
Yi(u)eβ′0Zi(u) − Yi(u)E
{
(1−∆1)Y1(u)eβ′0Z1(u)
}
E [(1−∆1)Y1(u)]

× dµ0(t) + n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
∆i(1− ξi)(ηi
q˜
− 1)
{
dMi(u)− Yi(u)E {∆1(1− ξ1)dM1(u)}
E [∆1(1− ξ1)Y1(u)]
}
.
(6.18)
We know from the asymptotic expansion of n1/2(βˆII − β0) that
n1/2(βˆII − β0)
= A(β0)
−1n1/2Un(β0) + oP (1)
= A(β0)
−1
(
n−1/2
n∑
i=1
MZ˜,i(β0, t) + n
−1/2
n∑
i=1
ˆ τ
0
{1− ξi
α˜
}(1−∆i) (Ri(β0, t)− Yi(t)
×E [(1−∆i)Ri(β0, t)]
E [(1−∆i)Yi(t)]
)
dµ0(t)− n−1/2
n∑
i=1
ˆ τ
0
{1− ηi
q˜
}∆i(1− ξi)
(
dMZ˜,i(β0, t)− Yi(t)
E
[
dMZ˜,i(β0, t) | ∆i = 1, ξi = 0
]
E [Yi(t) | ∆i = 1, ξi = 0]
+ oP (1). (6.19)
Using equations (6.18) and (6.19), one can write
n1/2{µˆ0(βˆII , t)− µ0(t)}
= r(β0, t)
′A(β0)−1n1/2Un(β0) + n1/2(βˆII − β0)′r(β0, t) +
ˆ t
0
1
s(0)(β0, u)
{
n−1/2
n∑
i=1
dMi(u)
}
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
(1−∆i)(1− ξi
α˜
)
Yi(u)eβ′0Zi(u) − Yi(u)E
{
(1−∆1)Y1(u)eβ′0Z1(u)
}
E [(1−∆1)Y1(u)]
 dµ0(t)
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
∆i(1− ξi)(ηi
q˜
− 1)
{
dMi(u)− Yi(u)E {∆1(1− ξ1)dM1(u)}
E [∆1(1− ξ1)Y1(u)]
}
+ oP (1)
= r(β0, t)
′A(β0)−1
(
n−1/2
n∑
i=1
MZ˜,i(β0) + n
−1/2
n∑
i=1
ˆ τ
0
{1− ξi
α˜
}(1−∆i) (Ri(β0, t)−
Yi(t)E [(1−∆i)Ri(β, t)]
E [(1−∆i)Yi(t)]
)
dµ0(t)− n−1/2
n∑
i=1
ˆ τ
0
{1− ηi
q˜
}∆i(1− ξi)
(
dMZ˜,i(β0, t)−
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Yi(t)E
[
dMZ˜,i(β0, t) | ∆i = 1, ξi = 0
]
E [Yi(t) | ∆i = 1, ξi = 0]
+ ˆ t
0
n−1/2
∑n
i=1 dMi(u)
s(0)(β0, u)
+ n−1/2
n∑
i=1
ˆ t
0
{1− ξiα˜ }(1−∆i)Yi(u)
s(0)(β0, u)
(
eβ0Zi(u) − E
[
(1−∆i)Yi(u)eβ0Zi(u)
]
E [(1−∆i)Yi(u)]
)
dµ0(u)
+ n−1/2
n∑
i=1
ˆ t
0
1
s(0)(β0, u)
∆i(1− ξi)(ηi
q˜
− 1)
{
dMi(u)− Yi(u)E {∆1(1− ξ1)dM1(u)}
E [∆1(1− ξ1)Y1(u)]
}
+ oP (1)
= n−1/2
n∑
i=1
(
r(β0, t)
′A(β0)−1
(
MZ˜,i(β0)
)
+
ˆ t
0
dMi(u)
s(0)(β0, u)
)
+ n−1/2
n∑
i=1
{1− ξi
α˜
}(1−∆i)
[
r(β, t)′A(β)−1
ˆ τ
0
(
Ri(β0, t)− Yi(t)E [(1−∆i)Ri(β0, t)]
E [(1−∆i)Yi(t)]
)
dµ0(t)
+
ˆ t
0
Yi(u)
s(0)(β0, u)
(
eβ0Zi(u) − E
[
(1−∆i)Yi(u)eβ0Zi(u)
]
E [(1−∆i)Yi(u)]
)
dµ0(u)
]
+ n−1/2
n∑
i=1
{ηi
q˜
− 1}∆i(1− ξi)
[
r(β, t)′A(β)−1
ˆ τ
0
(
dMZ˜,i(β0, t)
−
Yi(t)E
[
dMZ˜,1(β0, t)(β0, t) | ∆1 = 1, ξ1 = 0
]
E [Y1(t) | ∆1 = 1, ξ1 = 0]

+
ˆ t
0
1
s(0)(β, u)
(
dMi(u)− Yi(t)E [dM1(u)(β0, t) | ∆1 = 1, ξ1 = 0]
E [Y1(t) | ∆1 = 1, ξ1 = 0]
)
dµ0(u)
]
+ oP (1)
= n−1/2
n∑
i=1
νi(β0, t) + n
−1/2
n∑
i=1
{1− ξi
α˜
}(1−∆i)ψi(β0, t)− n−1/2
n∑
i=1
{1− ηi
q˜
}∆i(1− ξi)ζi(β0, t)
+ op(1),
where νi(β0, t) =
(
r(β0, t)
′A(β0)−1
(
MZ˜,i(β0)
)
+
´ t
0
dMi(u)
s(0)(β0,u)
)
, ψi(β0, t) =
[
r(β, t)′A(β)−1
´ τ
0(
Ri(β, t)− Yi(t)E[(1−∆i)Ri(β,t)]E[(1−∆i)Yi(t)]
)
dµ0(t) +
´ t
0
Yi(u)
s(0)(β,u)
(
eβZi(u) − E[(1−∆i)Yi(u)e
βZi(u)]
E[(1−∆i)Yi(u)]
)
dµ0(u)
]
,
ζ(β0, t) = [r(β, t)
′A(β)−1
´ τ
0
(
dMZ˜,i(β0, t)−
Yi(t)E[dMZ˜,1(β0,t)(β0,t)|∆1=1,ξ1=0]
E[Y1(t)|∆1=1,ξ1=0]
)
+
´ t
0
1
s(0)(β,u)(
dMi(u)− Yi(t)E[dM1(u)(β0,t)|∆1=1,ξ1=0]E[Y1(t)|∆1=1,ξ1=0]
)
].
Note that, since r(β0, t), A(β0), E [(1−∆i)Ri(β, t)], E
[
(1−∆i)Yi(u)eβZi(u)
]
,
E
[
dMZ˜,i(β, t) | ∆i = 1, ξi = 0
]
and E [dMi(t) | ∆i = 1, ξi = 0] are bounded and s(0)(β0, u),
E [(1−∆i)Yi(u)] E [Yi(u) | ∆i = 1, ξi = 0] are bounded away from zero along with the asymp-
totic normality of the rest of the terms, we can say that νi(β0, t), ψi(β0, t) and ζi(β0, t) are
bounded processes. For any finite number of time-points, the joint distribution of n1/2Wn(t) =
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n1/2{µˆ0(βˆII , t)−µ0(t)} for various t would be asymptotically equivalent to a zero-mean Gaus-
sian process. Finally, let us look at the covariance between n−1/2
∑n
i=1 νi(β0, t), n
−1/2∑n
i=1{1−
ξi
α˜ }(1 −∆i)ψi(β0, t) and n−1/2
∑n
i=1{1 − ηiq˜ }∆i(1 − ξi)ζi(β0, t). The covariance between the
first two quantities is
cov(n−1/2
n∑
i=1
νi(β0, t), n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)ψi(β0, t))
= E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)ψi(β0, t)
)
= E
[
E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)ψi(β0, t)
∣∣∣ F(τ))]
= E
[
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
E
(
1− ξi
α˜
∣∣∣ F(τ)) (1−∆i)ψi(β0, t)] = 0
Similarly, the covariance between the first and third quantities is given by
cov(n−1/2
n∑
i=1
νi(β0, t), n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ζi(β0, t))
= E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ζi(β0, t)
)
= E
[
E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ζi(β0, t)
∣∣∣ F(τ))]
= E
[
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
E
(
(1− ξi)(1− ηi
q˜
)
∣∣∣ F(τ))∆iζi(β0, t)] = 0
Similarly the covariance between n−1/2
∑n
i=1(1 − ξiα˜ )(1 − ∆i)ψi(β0, t) and n−1/2
∑n
i=1(1 −
ηi
q˜ )∆i(1 − ξi)ζi(β0, t) = 0. Hence, the covariance of n1/2Wn(t) and n1/2Wn(s) is given by
E (νi(β0, t))νi(β0, s)) +
1−α
α E ((1−∆i)ψi(β0, t))ψi(β0, s))
+ (1− α)1−qq P (∆i = 1)E (ψi(β0, t))ψi(β0, s) | ∆i = 1, ξi = 0).
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APPENDIX B: TECHNICAL DETAILS FOR CHAPTER 4
Here is the Appendix containing the proofs of the theorems in Chapter 4.
B.1 Regularity Conditions
(i) (T ∗i , Ci, Zi(t)) ∀i = 1, 2, . . . , n are independent and identically distributed.
(ii) P (Y (τ) > 0) > 0 and Ni(τ) (∀i = 1, 2, . . . , n) are bounded by a constant.
(iii) | Zi(0) | +
´ τ
0 | dZi(u) |< Cz <∞ almost surely for some constant Cz.
(iv) The matrix A = E
[´ τ
0 Yi(t) {Zi(t)− e(t)}⊗2 dt
]
(where e(t) = E(Yi(t)Zi(t))E((Yi(t)) ) is positive
definite.
(v) (Finite Interval)
´ τ
0 dµ0(t) <∞.
(vi) As n→∞, n˜n = α˜→ α ∈ (0, 1), q˜ → q.
(vii) (Asymptotic stability)As n→∞, we have the following:
(a) There exists a positive definite matrix, V I(β0), such that
var
[
n−1/2
n∑
i=1
ˆ τ
0
(
dRi(β0, t)− Yi(t)E {1−∆1} dR1(β0, t)
E {(1−∆1)Y1(t)}
)]
P−→ V I(β0).
(b) There is a positive definite matrix, V II(β0) such that
var
 1√
n
n∑
i=1
MZ˜,i(β0)− ˆ τ
0
Yi(t)E
{
dMZ˜,1(β0, t) | ∆1 = 1, ξ1 = 0
}
E {Y1(t) | ∆1 = 1}

| ∆i = 1, ξi = 0] P−→ V II(β0).
(i) sup0≤t≤τ‖Wn(t)−W (t)‖ P−→ 0 for some bounded process, W (t),
(ii) Wn(t) is monotone on [0, τ ] and
(iii) Gn(t) converges to a zero-mean process with continuous sample paths. Then
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sup
0≤s≤τ
‖
ˆ s
0
(Wn(t)−W (t))dGn(t)‖ P−→ 0, sup
0≤s≤τ
‖
ˆ s
0
(Gn(t)−G(t))dWn(t)‖ P−→ 0.
This was stated in Kang and Cai (2009b).
Lemma A3 :
Let Bi(t), i = 1, 2, . . . , n be i.i.d. real-valued random processes on [0, τ ] with E(Bi(t)) =
µB(t), var(Bi(0)) < ∞, var(Bi(τ)) < ∞ and suppose that almost all paths of Bi(t) have
finite variation. Then, n−1/2
∑n
i=1 {Bi(t)− µB(t)} converges weakly to a zero-mean Gaussian
process in l∞[0, τ ] and therefore, n−1
∑n
i=1 {Bi(t)− µB(t)} converges in probability to zero,
uniformly in t. This lemma has been stated in Kulich and Lin (2004) as a proposition.
First we will look at the asymptotic properties of the time-varying sampling weights.
More specifically, αˆ(t) =
∑n
i=1(1−∆i)ξiYi(t)∑n
i=1(1−∆i)Yi(t) and qˆ(t) =
∑n
i=1 ∆i(1−ξi)ηiYi(t)∑n
i=1 ∆i(1−ξi)Yi(t) . Looking at the
Taylor series expansion of αˆ(t)−1 around α˜−1, we have
αˆ(t)−1 − α˜−1 = − 1
α∗(t)2
(αˆ(t)− α˜) = α˜
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
[
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
,
where α∗(t) is on the line between αˆ(t) and α˜. Now by the Glivenko-Cantelli theorem, one can
show that 1n
∑n
i=1(1−∆i)Yi(t) converges to E ((1−∆i)Yi(t)). (1−∆i)Yi(t) is bounded and
monotone functions of t. They are also independent of ξi. Hence, by Lemma A1 and noting
that when sampling from a finite population µB(t) =
∑n
i=1Bi(t) where Bi(t) = (1−∆i)Yi(t),
n−1/2
∑n
i=1(1 − ξiα˜ ) [(1−∆i)Yi(t)] converges weakly to a zero-mean Gaussian process(Kang
and Cai 2009b). This implies that 1n
∑n
i=1(1− ξiα˜ ) [(1−∆i)Yi(t)]
P−→ 0 uniformly in t. Further,
αˆ(t), α∗(t) and α˜ converges to the same limit. Using Slutsky’s theorem, we have
n1/2(αˆ(t)−1 − α˜−1)
= n1/2
α˜
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
[
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
=
1
α˜E((1−∆i)Yi(t))
[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
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+ α˜
(
1
α∗(t)2
1∑n
i=1(1−∆i)Yi(t)
− 1
α˜2E((1−∆i)Yi(t))
)[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
=
1
α˜E((1−∆i)Yi(t))
[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(t)
]
+ oP (1). (6.20)
Similarly, qˆ(t)−1−q˜−1 = − 1
q∗(t)2 (qˆ(t)−q˜) = q˜q∗(t)2 1∑ni=1 ∆i(1−ξi)Yi(t)
[∑n
i=1 ∆i(1− ξi)(1− ηiq˜ )Yi(t)
]
,
where q∗(t) is on the line between qˆ(t) and q˜. Proceeding as before, we can see that qˆ(t), q∗(t)
and q˜ converges to the same limit. Using Slutsky’s theorem, we have
n1/2(qˆ(t)−1 − q˜−1) = 1
q˜E(∆i(1− ξi)Yi(t))
[
n−1/2
n∑
i=1
∆i(1− ξi)(1− ηi
q˜
)Yi(t)
]
+ oP (1).
(6.21)
B.2 Proof of Theorem 3
: Let us define Un(β) =
1
nU
II(β). Based on similar arguments, as in Foutz(1977), the
consistency of βˆII can be shown by proving the following : (a) δδβ′Un(β) exists and is con-
tinuous in an open neighborhood of β0 in B, (b) δδβ′0Un(β0) is negative definite w.p. → 1 as
n→∞, (c) - δδβ′Un(β)
P−→ A(β0) uniformly for β in a neighborhood of β0 and (d) Un(β) P−→ 0.
Taking derivative of the expression, we get
δ
δβ′
Un(β) = − 1
n
n∑
i=1
ˆ τ
0
wIIi (t)
{
Zi(t)− Z¯II(t)
}
Yi(t)Zi(t)
′dt (6.22)
We need to show that this goes to A in probability. Using the above formula, one can rewrite
− δ
δβ′
Un(β) =
1
n
n∑
i=1
ˆ τ
0
wIIi (t){Zi(t)⊗2 − Z¯II(t)⊗2}Yi(t)dt. (6.23)
Hence, condition (a) of the consistency of βˆII is satisfied. To prove the other conditions, we
will first start with proving
sup
t∈[0,τ ]
‖Z¯II(t)− e(t)‖ P−→ 0 as n →∞.
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It suffices to show that
sup
t∈[0,τ ]
‖ 1
n
n∑
i=1
wIIi (t)Yi(t)Zi(t)
⊗d − 1
n
n∑
i=1
Yi(t)Zi(t)
⊗d‖ P−→ 0 as n →∞ for d = 0, 1.
Let us start with n−1/2
∑n
i=1w
II
i (t)Yi(t)Zi(t)
⊗d− n−1/2∑ni=1 Yi(t)Zi(t)⊗d. We can note that
n−1/2
n∑
i=1
wIIi (t)Yi(t)Zi(t)
⊗d − n−1/2
n∑
i=1
Yi(t)Zi(t)
⊗d
= n−1/2
n∑
i=1
{∆iξi + (1−∆i)ξi
αˆ(t)
+
∆i(1− ξi)ηi
qˆ(t)
}Yi(t)Zi(t)⊗d − n−1/2
n∑
i=1
Yi(t)Zi(t)
⊗d
= n−1/2
n∑
i=1
(1−∆i){ξi
α˜
− 1}Yi(t)Zi(t)⊗d + n−1/2
n∑
i=1
∆i(1− ξi){ηi
q˜
− 1}Yi(t)Zi(t)⊗d
− n−1/2
n∑
i=1
Yi(t)
E [(1−∆1)Y1(t)] (1−∆i)
(
ξi
α˜
− 1
) 1n
n∑
j=1
(1−∆j)ξj
α˜
Yj(t)Zj(t)
⊗d

− n−1/2
n∑
i=1
Yi(t)
E [∆1(1− ξ1)Y1(t)]∆i(1− ξi)
(
ηi
q˜
− 1
) 1n
n∑
j=1
∆j(1− ξj)ηj
q˜
Yj(t)Zj(t)
⊗d
+ oP (1).
(6.24)
For each j, from (iii) of the regularity conditions, one can note that the total variation of
∆i(1 − ξi)Yi(t)Zi(t)⊗2 and (1 − ∆i)Yi(t)Zi(t)⊗2 are finite for t ∈ [0, τ ]. From Lemma A1,
1
n
∑n
i=1 ∆i(1− ξi)ηiq˜ Yi(t)Zi(t)⊗d converges to some finite quantity E
(
∆i(1− ξi)Yi(t)Zi(t)⊗d
)
,
in probability uniformly in t. Similarly, we know that 1n
∑n
i=1(1 − ∆i) ξiα˜ Yi(t)Zi(t)⊗d
P−→
E
(
(1−∆i)Yi(t)Zi(t)⊗d
)
. Therefore,
n−1/2
n∑
i=1
wIIi (t)Yi(t)Zi(t)
⊗d − n−1/2
n∑
i=1
Yi(t)Zi(t)
⊗d
= n−1/2
n∑
i=1
(1−∆i){ξi
α˜
− 1}Yi(t)
{
Zi(t)
⊗d − E
(
(1−∆i)Yi(t)Zi(t)⊗d
)
E [(1−∆1)Y1(t)]
}
+ n−1/2
n∑
i=1
∆i(1− ξi){ηi
q˜
− 1}Yi(t)
{
Zi(t)
⊗d − E
(
∆i(1− ξi)Yi(t)Zi(t)⊗d
)
E [∆1(1− ξ1)Y1(t)]
}
+ oP (1).
(6.25)
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Now, note that, E
[
(1−∆i)Yi(t)
{
Zi(t)
⊗d − E((1−∆i)Yi(t)Zi(t)
⊗d)
E[(1−∆1)Y1(t)]
}]
= 0 and E [∆i(1− ξi)Yi(t)
×
{
Zi(t)
⊗d − E(∆i(1−ξi)Yi(t)Zi(t)
⊗d)
E[∆1(1−ξ1)Y1(t)]
}]
= 0. Hence, by Lemma A1, the terms on the RHS of
(6.25): n−1/2
∑n
i=1(1−∆i){ ξiα˜−1}Yi(t)
{
Zi(t)
⊗d − E((1−∆i)Yi(t)Zi(t)
⊗d)
E[(1−∆1)Y1(t)]
}
and n−1/2
∑n
i=1 ∆i(1−
ξi){ηiq˜ − 1}Yi(t) ×
{
Zi(t)
⊗d − E(∆i(1−ξi)Yi(t)Zi(t)
⊗d)
E[∆1(1−ξ1)Y1(t)]
}
converge weakly to zero-mean Gaus-
sian processes. Hence, 1n
∑n
i=1(1 − ∆i){ ξiα˜ − 1}Yi(t)
{
Zi(t)
⊗d − E((1−∆i)Yi(t)Zi(t)
⊗d)
E[(1−∆1)Y1(t)]
}
and
1
n
∑n
i=1 ∆i(1− ξi){ηiq˜ − 1}Yi(t)×
{
Zi(t)
⊗d − E(∆i(1−ξi)Yi(t)Zi(t)
⊗d)
E[∆1(1−ξ1)Y1(t)]
}
converge to zero in prob-
ability uniformly in t. Therefore, by Slutsky’s theorem, we have
∥∥∥∥∥ 1n
n∑
i=1
wIIi (t)Yi(t)Zi(t)
⊗d − 1
n
n∑
i=1
Yi(t)Zi(t)
⊗d
∥∥∥∥∥ P−→ 0 n →∞ for d = 0, 1. (6.26)
Therefore, 1n
∑n
i=1w
II
i (t)Yi(t)Zi(t)
⊗d and 1n
∑n
i=1 Yi(t)Zi(t)
⊗d converges to the same limit
uniformly. Also, since E(Yi(t)) is bounded away from zero by regularity condition (ii), we
have from the above convergence results,
sup
t∈[0,τ ]
‖Z¯II(t)− e(t)‖ P−→ 0 as n →∞
Now, one can rewrite − δ
δβ′0
Un(β) as the following :
1
n
n∑
i=1
ˆ τ
0
wIIi (t){Zi(t)⊗2 − Z¯II(t)⊗2}Yi(t)dt
=
1
n
n∑
i=1
ˆ τ
0
(1−∆i){ξi
α˜
− 1}Yi(t){Zi(t)⊗2 − Z¯II(t)⊗2}dt
+
1
n
n∑
i=1
ˆ τ
0
(1−∆i)ξi{αˆ(t)−1 − α˜−1}Yi(t){Zi(t)⊗2 − Z¯II(t)⊗2}dt
+
1
n
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}Yi(t){Zi(t)⊗2 − Z¯II(t)⊗2}dt
+
1
n
n∑
i=1
ˆ τ
0
∆i(1− ξi)ηi{qˆ(t)−1 − q˜−1}Yi(t){Zi(t)⊗2 − Z¯II(t)⊗2}dt
+
1
n
n∑
i=1
ˆ τ
0
{Zi(t)⊗2 − Z¯II(t)⊗2}Yi(t)dt.
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By the fact that Z¯II(t) converges uniformly in t to e(t), the first term of the right hand side
quantity is asymptotically equivalent to 1n
∑n
i=1
´ τ
0 (1−∆i){ ξiα˜ − 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt
and the third term converges to 1n
∑n
i=1
´ τ
0 ∆i(1− ξi){ηiq˜ − 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt. Fur-
ther, αˆ(t)−1 − α˜−1 P−→ 0 and qˆ(t)−1 − q˜−1 P−→ 0. Both (1 − ∆i)ξiYi(t)Zi(t)⊗2 and ∆i(1 −
ξi)ηiYi(t)Zi(t)
⊗2 have bounded variation and are monotone functions in t. Hence, 1n
∑n
i=1(1−
∆i)ξiYi(t)Zi(t)
⊗2 P−→ 0 and 1n
∑n
i=1 ∆i(1 − ξi)ηiYi(t)Zi(t)⊗2 P−→ 0 ∀t. Therefore, we have the
second term and fourth terms converging to zero in probability. In other words,
1
n
n∑
i=1
ˆ τ
0
wIIi (t){Zi(t)⊗2 − Z¯II(t)⊗2}Yi(t)dt
=
1
n
n∑
i=1
ˆ τ
0
(1−∆i){ξi
α˜
− 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt
+
1
n
n∑
i=1
ˆ τ
0
∆i(1− ξi){ηi
q˜
− 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt+ 1
n
n∑
i=1
ˆ τ
0
{Zi(t)⊗2 − e(t)⊗2}Yi(t)dt
+ oP (1).
Since, (1 − ∆i)Yi(t)
[
Zi(t)
⊗2 − e(t)⊗2] and ∆iYi(t) [Zi(t)⊗2 − e(t)⊗2] have bounded varia-
tion and each of these terms are independent and identically distributed. Further, note
that 1n
∑n
i=1 ∆iYi(t)
[
Zi(t)
⊗2 − e(t)⊗2] = 1n(1−α˜) ∑ni=1(1 − ξi)∆iYi(t) [Zi(t)⊗2 − e(t)⊗2] since
ξi’s are simple random sample from the finite population. It follows from Lemma A1,
1
n
∑n
i=1
´ τ
0 (1 − ∆i){ ξiα˜ − 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt
P−→ E
[´ τ
0 (1−∆i){ ξiα˜ − 1}Yi(t){Zi(t)⊗2
−e(t)⊗2}] dt and 1n∑ni=1 ´ τ0 ∆i(1− ξi){ηiq˜ − 1}Yi(t){Zi(t)⊗2 − e(t)⊗2}dt P−→ E [´ τ0 ∆i(1− ξi)
{ηiq˜ − 1}Yi(t) ×{Zi(t)⊗2 − e(t)⊗2}
]
dt, which are equal to zero. Hence,
− δ
δβ′0
Un(β)
P−→ A as n →∞. (6.27)
Thus, conditions (b) and (c) of the consistency of βˆII are satisfied. For condition (d), we
start by looking at n1/2Un(β). Note that n
1/2Un(β) can be decomposed into
n−1/2
n∑
i=1
ˆ τ
0
wIIi (t)
{
Zi(t)− Z¯II(t)
}
(dMi(t) + Yi(t)dµ0(t))
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= n−1/2
n∑
i=1
ˆ τ
0
{
Zi(t)− Z¯II(t)
}
dMi(t) + n
−1/2
n∑
i=1
ˆ τ
0
(
wIIi (t)− 1
) {
Zi(t)− Z¯II(t)
}
dMi(t).
(6.28)
The first part of the above equation can be further decomposed into
n−1/2
n∑
i=1
ˆ τ
0
{
Zi(t)− Z¯II(t)
}
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
{
Zi(t)− Z¯(t)
}
dMi(t) + n
−1/2
n∑
i=1
ˆ τ
0
{
Z¯(t)− Z¯II(t)} dMi(t). (6.29)
The first quantity on the right hand side is the pseudo partial likelihood score function for
the entire cohort data. Note that for fixed t, n−1/2
∑n
i=1Mi(t) is the sum of zero-mean in-
dependent and identically distributed random variables. From the regularity conditions (iii)
and (v) and by CLT, Mi(t) has bounded variation and hence, from Lemma A3, we have that
n−1/2
∑n
i=1Mi(t) converges weakly to a zero-mean Gaussian process, say WM (t) (Schaubel
et al. 2006). From the functional Central Limit Theorem (Pollard, 1990 page 53) we can con-
clude that n−1/2
∑n
i=1Mi(t) is tight and converges weakly to WM (t). It can be shown that
E {WM (t)−WM (s)}4 = 3
(
E {WM (t)−WM (s)}2
)2
by properties of a Gaussian distribu-
tion. Further, E {WM (t)−WM (s)}2 = E {WM (t)}2 +E {WM (s)}2−2E {WM (t)WM (s)}2 =
E {WM (t)}2−E {WM (s)}2 for s ≤ t, since E {WM (t)}2 = E {Mi(t)}2 = E
(´ t
0 Yi(u) {dµ0(u)
+β′0Zi(u)du}) and E {WM (t)−WM (s)}2 = E
(´ t
s Yi(u) {dµ0(u) + β′0Zi(u)du}
)
. Note that
the conditions (iii) and (v) ensure boundedness of µ0(t) and β
′
0Zi(t) in [0, τ ]. Thus, by the
Mean Value theorem, there is a constant such that, E {WM (t)−WM (s)}2 = E
(´ t
s Yi(u)
{dµ0(u) + β′0Zi(u)du}) ≤ K(t − s) for s ≤ t and E {WM (t)−WM (s)}4 ≤ 3 (E {WM (t)−
WM (s)}2
)2 ≤ K∗(t − s)2. Then, by the Kolmogorov-Centsov Theorem (Karatzas and
Shereve 1988),WM (t) has continuous sample paths. We can also note that, 1n
∑n
i=1 Yi(t)Zi(t)
and 1n
∑n
i=1 Yi(t) have bounded variations and
1
n
∑n
i=1 Yi(t) is bounded away from zero from
the regularity conditions. By Lin et al. (2000), Z¯(t) is of bounded variation and can be
written as the difference of two monotone functions in t. Hence, one can write Z¯(t) =
Z∗1 (t) − Z∗2 (t) where each of the functions are non-negative, monotone in t and bounded.
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Since, Z¯II(t) is also of bounded variation by the same arguments and equation (6.26), one
can express that as the difference of two monotone bounded functions in t. We can rewrite
n−1/2
∑n
i=1
´ τ
0
{
Z¯(t)− Z¯II(t)} dMi(t) = n1/2 ´ τ0 {Z¯(t)− e(t)} dM¯(t)−n1/2 ´ τ0 {Z¯II(t)− e(t)} dM¯(t),
where M¯(t) = 1n
∑n
i=1Mi(t). Noting that n
1/2M¯(t) is bounded and the uniform convergence
of Z¯(t) and Z¯II(t) to e(t), both the terms on the RHS of (6.29) converges to zero in probability
by Lemma A2 as n → ∞. Therefore, n−1/2∑ni=1 ´ τ0 {Zi(t)− Z¯II(t)} ×dMi(t) is asymptot-
ically equivalent to n−1/2
∑n
i=1
´ τ
0 {Zi(t)− e(t)} dMi(t). The second term of (6.28) can be
rewritten as
n−1/2
n∑
i=1
ˆ τ
0
(
wIIi (t)− 1
) {
Zi(t)− Z¯II(t)
}
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(
ξi
α˜
− 1
)
(1−∆i)
{
Zi(t)− Z¯II(t)
}
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
(
ηi
q˜
− 1
)
∆i(1− ξi)
{
Zi(t)− Z¯II(t)
}
dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
(
αˆ(t)−1 − α˜−1) ξi(1−∆i){Zi(t)− Z¯II(t)} dMi(t)
+ n−1/2
n∑
i=1
ˆ τ
0
(
qˆ(t)−1 − q˜−1) ηi∆i(1− ξi){Zi(t)− Z¯II(t)} dMi(t). (6.30)
From the uniform convergence of Z¯II(t) to e(t), the first term on the right hand side of 6.30
can be written as
n−1/2
n∑
i=1
ˆ τ
0
(
ξi
α˜
− 1
)
(1−∆i)
{
Zi(t)− Z¯II(t)
}
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(
ξi
α˜
− 1
)
(1−∆i) {Zi(t)− e(t)} dMi(t) + oP (1)
= n−1/2
n∑
i=1
ˆ τ
0
(
1− ξi
α˜
)
(1−∆i) {Zi(t)− e(t)}Yi(t)
[
dµ0(t) + β
′
0Zi(t)dt
]
+ oP (1).
The last equality holds because only those individuals with ∆i = 0 contribute to the summa-
tion, i.e., only individuals who did not experience a single event. By (6.20), (6.21), and the
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fact that Z¯II(t) converges uniformly to e(t) in probability, we have the third term of (6.30):
n−1/2
n∑
i=1
ˆ τ
0
(
αˆ(t)−1 − α˜−1) ξi(1−∆i){Zi(t)− Z¯II(t)} dMi(t)
= n−1/2
n∑
j=1
ˆ τ
0
(1−∆j)(ξj
α˜
− 1)
(
Yj(t)
E((1−∆1)Y1(t))
)
×
{
1
n
n∑
i=1
ξi
α˜
(1−∆i) {Zi(t)− e(t)}Yi(t)
[
dµ0(t) + β
′
0Zi(t)dt
]}
+ oP (1).
Similarly, we can show that
n−1/2
n∑
i=1
ˆ τ
0
(
qˆ(t)−1 − q˜−1) ηi∆i(1− ξi){Zi(t)− Z¯II(t)} dMi(t)
= n−1/2
n∑
j=1
ˆ τ
0
∆j(1− ξj)(ηj
q˜
− 1)
(
Yj(t)
(1− α˜)E(∆1Y1(t))
)
×
{
1
n
n∑
i=1
ηi
q˜
∆i(1− ξi) {Zi(t)− e(t)} dMi(t)
}
+ oP (1).
From Lemma A1, we have 1n
∑n
i=1
ηi
q˜ ∆i(1− ξi) {Zi(t)− e(t)} dMi(t) converges to
E [{Zi(t)− e(t)} dMi(t) | ∆i = 1, ξi = 0]P (∆i = 1, ξi = 0) in probability uniformly in t.
Thus,
n−1/2
n∑
j=1
ˆ τ
0
∆j(1− ξj)(ηj
q˜
− 1)
(
Yj(t)
(1− α˜)E(∆1Y1(t))
)
×
{
1
n
n∑
i=1
ηi
q˜
∆i(1− ξi) {Zi(t)− e(t)}
×dMi(t)}
= n−1/2
n∑
j=1
ˆ τ
0
∆j(1− ξj)(ηj
q˜
− 1)
(
Yj(t)
E(∆1Y1(t))
)
E [{Zi(t)− e(t)} dMi(t) | ∆i = 1, ξi = 0]
× P (∆i = 1) + oP (1)
= n−1/2
n∑
j=1
ˆ τ
0
∆j(1− ξj)(ηj
q˜
− 1)
(
Yj(t)
E(Yi(t) | ∆i = 1)
)
E [{Zi(t)− e(t)} dMi(t) | ∆i = 1,
ξi = 0] + oP (1).
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Rewrite dMZ˜,i(t) = (Zi(t)− e(t))dMi(t), the left hand side of (6.30) is asymptotically equiv-
alent to
n−1/2
n∑
i=1
ˆ τ
0
(wIIi (t)− 1)
{
Zi(t)− Z¯II(t)
}
dMi(t)
= n−1/2
n∑
i=1
ˆ τ
0
(
1− ξi
α˜
)
(1−∆i) {Zi(t)− e(t)}Yi(t)
[
dµ0(t) + β
′
0Zi(t)dt
]
+ n−1/2
n∑
j=1
ˆ τ
0
(1−∆j)(ξj
α˜
− 1)
(
Yj(t)
E((1−∆1)Y1(t))
)
{E [(1−∆i) {Zi(t)− e(t)}Yi(t)] dµ0(t)
+E
[
1−∆i) {Zi(t)− e(t)}Yi(t)β′0Zi(t)dt
]}
+ n−1/2
n∑
i=1
ˆ τ
0
(
1− ηi
q˜
)
∆i(1− ξi) {Zi(t)− e(t)}
× dMi(t) + n−1/2
n∑
j=1
ˆ τ
0
∆j(1− ξj)(ηj
q˜
− 1)
(
Yj(t)
E(Yi(t) | ∆i = 1)
)
× E [{Zi(t)− e(t)} dMi(t) | ∆i = 1, ξi = 0] + oP (1)
= n−1/2
n∑
i=1
(
1− ξi
α˜
)
(1−∆i)
ˆ τ
0
{{Zi(t)− e(t)} [Yi(t)dµ0(t) + Yi(t)β′0Zi(t)dt]
−Yi(t)E [(1−∆i) {Zi(t)− e(t)} (Yi(t)dµ0(t) + Yi(t)β
′
0Zi(t)dt)]
E((1−∆i)Yi(t))
}
+ n−1/2
n∑
i=1
(
1− ηi
q˜
)
∆i(1− ξi)
MZ˜,i(τ)−
ˆ τ
0
Yi(t)
E
[
dMZ˜,i(t) | ∆i = 1, ξi = 0
]
E(Yi(t) | ∆i = 1)
+ oP (1).
Now, defining dRi(β, t) = Yi(t) {Zi(t)− e(t)} {dµ0(t) + β′Zi(t)dt}, we have the above
expression as
n−1/2
n∑
i=1
(
1− ξi
α˜
)
(1−∆i)
ˆ τ
0
{
dRi(β0, t)− Yi(t)E ((1−∆i)dRi(β, t))
E ((1−∆i)Yi(t))
}
+n−1/2
n∑
i=1
(
1− ηi
q˜
)
∆i(1− ξi)
MZ˜,i(τ)−
ˆ τ
0
Yi(t)
E
[
dMZ˜,i(t) | ∆i = 1, ξi = 0
]
E(Yi(t) | ∆i = 1)
 .
Further, denote dRi(β0, t)−Yi(t)E((1−∆i)dRi(β0,t))E((1−∆i)Yi(t)) by dR∗i (β, t) and dMZ˜,i(t)−Yi(t)
E[dMZ˜,i(t)|∆i=1,ξi=0]
E(Yi(t)|∆i=1)
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as dR∗∗i (t), R
∗
i (β) =
´ τ
0 dR
∗
i (β, t) and R
∗∗
i (τ) =
´ τ
0 dR
∗∗
i (t). Hence, n
−1/2U II(β0) is asymp-
totically equivalent to
n−1/2
n∑
i=1
MZ˜,i(β0)+n
−1/2
n∑
i=1
(
1− ξi
α˜
)
(1−∆i)R∗i (β0)++n−1/2
n∑
i=1
(
1− ηi
q˜
)
∆i(1−ξi)R∗∗i (τ).
(6.31)
The first term of the (6.31) is asymptotically normally distributed with mean zero and vari-
ance, Q(β) = E
(
MZ˜,1(β)
)⊗2
by Schaubel et al. (2006). To study the variance terms of the
second and third terms of the (6.31), we use Ha´jek’s (1960) central limit theorem for finite
population sampling. Using (6.11) and (6.12), we can show that the following conditions for
the Ha´jek’s Theorem are satisfied.
(a) α˜ converges to α ∈ (0, 1).
(b) 1n
∣∣a′ (´ τ0 dR∗i (β, t)− 1n∑ni=1 ´ τ0 dR∗i (β, t))∣∣ and 1n ∣∣a′ (´ τ0 dR∗∗i (t)− 1n∑ni=1 ´ τ0 dR∗∗i (t))∣∣
converges to 0 in probability.
(c) 1n−1
∑n
i=1
(
a′
´ τ
0 dR
∗
i (β, t)− 1n
∑n
i=1 a
′ ´ τ
0 dR
∗
i (β, t)
)2
and 1n−1
∑n
i=1
(
a′
´ τ
0 dR
∗∗
i (t)dµ0(t)
− 1n
∑n
i=1 a
′ ´ τ
0 dR
∗∗
i (t)
)2
converges to some quantity, σ∗2 > 0 and σ∗∗2 > 0 respectively.
Hence, based on Ha´jek’s Theorem for finite population sampling, the second term of (6.31) can
be shown to be asymptotically normally distributed with mean zero and covariance 1−αα V
I(β)
where
V I(β) = var
(
(1−∆i)
ˆ τ
0
{
dRi(β, t)− Yi(t)E ((1−∆i)dRi(β, t))
E ((1−∆i)Yi(t))
})
.
Further, based on the regularity condition and Cramer- Wold device, we have n−1/2
∑n
i=1(
{1− ηiq˜ }∆i(1− ξi)R∗∗i (τ)
)
converges to a zero-mean Normal random variable with variance
1−q
q (1− α)P (∆1 = 1)V II(β), where
V II(β) = var
MZ˜,i(τ)− ˆ τ
0
Yi(t)
E
[
dMZ˜,i(t) | ∆i = 1, ξi = 0
]
E(Yi(t) | ∆i = 1)
 .
Next let us consider the covariance between n−1/2
∑n
i=1MZ˜,i(β), n
−1/2∑n
i=1(1 − ξiα˜ )(1 −
∆i)R
∗
i (β) and n
−1/2∑n
i=1(1−ηiq˜ )∆i(1−ξi)R∗∗i (τ). We have already proved that cov(n−1/2
∑n
i=1
141
MZ˜,i(β), n
−1/2∑n
i=1(1− ξiα˜ )(1−∆i)R∗i (τ)) = 0 in Chapter 3. Defining the marginal filtration
as Fi(t) = σ{Ni(t), Yi(t), Zi(t)} for the i-th individual at time t, we have
cov(n−1/2
n∑
i=1
MZ˜,i(β), n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ))
= E
(
n−1/2
n∑
i=1
MZ˜,i(β)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ)
)
= E
[
E
(
n−1/2
n∑
i=1
MZ˜,i(β)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ)
∣∣∣ F(τ))]
= E
[
n−1/2
n∑
i=1
MZ˜,i(β)n
−1/2
n∑
i=1
E
(
(1− ηi
q˜
)(1− ξi)∆i
∣∣∣ F(τ))R∗∗i (τ)
]
= E
[
n−1/2
n∑
i=1
MZ˜,i(β)n
−1/2
n∑
i=1
(
P (ηi = 0, ξi = 0,∆i = 1
∣∣∣ F(τ))+
q˜ − 1
q˜
P (ηi = 1, ξi = 0,∆i = 1
∣∣∣ F(τ)))R∗∗i (τ)]
= 0.
The last step is a direct consequence of the fact that (P (ηi = 0, ξi = 0,∆i = 1
∣∣∣ F(τ)) =
P (ηi = 0
∣∣∣ ξi = 0,∆i = 1,F(τ))P (ξi = 0,∆i = 1 ∣∣∣ F(τ)) = 1− q˜ = 1− P (ηi = 1 ∣∣∣ ξi = 0,∆i =
1,F(τ))P (ξi = 0,∆i = 1
∣∣∣ F(τ)). Looking at the covariance between n−1/2∑ni=1(1− ξiα˜ )(1−
∆i)R
∗
i (β) and n
−1/2∑n
i=1(1− ηiq˜ )∆i(1− ξi)R∗∗i (τ), we have
cov(n−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)R∗i (β), n−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ))
= E
(
n−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)R∗i (β)n−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ)
)
= E
[
E
(
n−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)R∗i (β)n−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ)
∣∣∣ F(τ))]
= E
[
1
n
n∑
i=1
(1−∆i)R∗i (β)E
(
(1− ηi
q˜
)(1− ξi
α˜
)(1− ξi)
∣∣∣ F(τ))∆iR∗∗i (τ)
]
+
∑
i 6=j
E
[
1
n
(1−∆i)R∗i (β)E
(
(1− ηj
q˜
)(1− ξi
α˜
)(1− ξj)
∣∣∣ F(τ))∆jR∗∗j (τ)]
Now, the first term is zero as ∆i(1−∆i) = 0∀i and the second term E
(
(1− ηjq˜ )(1− ξiα˜ )(1− ξj)
∣∣∣
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F(τ)) = E
(
(1− ηjq˜ )(1− ξj)
∣∣∣ Fj(τ))E ((1− ξiα˜ ) ∣∣∣ Fi(τ)) as the i-th and j-th subjects are
independent and we can easily show that this term equals 0. Therefore, the variance of
n1/2Un(β) is given by E(MZ˜,i(β))
⊗2 + 1−αα V
I(β) + (1−α)1−qq P (∆1 = 1)V II(β). This implies
that Un(β)
P−→ 0 as n → ∞. Further, we can use Taylor Series expansion of n1/2Un(βˆII)
around β0 to get
n1/2Un(βˆ
II) ≈ n1/2Un(β) + n1/2(βˆII − β0)′ δ
δβ
Un(β
∗),
where β∗ belongs to the line segment joining β0 and βˆII . Hence, we can say that n1/2(βˆII−β0)
converges to a normal distribution with mean 0 and variance
A−1
(
E(MZ˜,i(β))
⊗2 +
1− α
α
V I(β) + (1− α)1− q
q
P (∆1 = 1)V
II(β)
)
A−1.
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B.3 Proof of Theorem 4
: We can decompose µˆII0 (β, t) in the following way:
n1/2{µˆII0 (βˆII , t)− µ0(t)}
= n1/2{µˆII0 (βˆII , t)− µˆII0 (β0, t) + µˆII0 (β0, t)− µ0(t)}
= n1/2

ˆ t
0
∑n
i=1w
II
i (u)
[
dNi(u)− Yi(u)Zi(u)′βˆIIdu
]
∑n
i=1w
II
i (u)Yi(u)
−
ˆ t
0
∑n
i=1w
II
i (u) [dNi(u)− Yi(u)β′0Zi(u)du]∑n
i=1w
II
i (u)Yi(u)
+
ˆ t
0
∑n
i=1w
II
i (u) [dNi(u)− Yi(u)β′0Zi(u)du]∑n
i=1w
II
i (u)Yi(u)
−
ˆ t
0
∑n
i=1w
II
i (u)Yi(u)dµ0(u)∑n
i=1w
II
i (u)Yi(u)
}
= n1/2

ˆ t
0
∑n
i=1w
II
i (u)
[
β0 − βˆII
]′
Yi(u)Zi(u)du∑n
i=1w
II
i (u)Yi(u)
+ n1/2
{ˆ t
0
∑n
i=1w
II
i (u)dMi(u)∑n
i=1w
II
i (u)Yi(u)
}
= n1/2
ˆ t
0
∑n
i=1w
II
i (u)
[
β0 − βˆII
]′
Yi(u)Zi(u)du∑n
i=1w
II
i (u)Yi(u)
+ n1/2
ˆ t
0
∑n
i=1 dMi(u)∑n
i=1w
II
i (u)Yi(u)
+ n1/2
ˆ t
0
∑n
i=1{wIIi (u)− 1}dMi(u)∑n
i=1w
II
i (u)Yi(u)
. (6.32)
By the uniform convergence of Z¯II to e(t), the first term on the right hand side of (6.32) is
asymptotically equivalent to n1/2r(t)′{βˆII−β0} where r(t) = −
´ t
0 e(u)du. (
1
n
∑n
i=1w
II
i (t)Yi(t))
−1
can be written as the sum of two monotone functions in t and converges uniformly to
E(Yi(t))
−1 where E(Yi(t)) is bounded away from zero (Lin et al. 2000). n−1/2
∑n
i=1Mi(t)
converges to a zero-mean Gaussian process with continuous sample paths. Hence, by Lemma
A2, n1/2
´ t
0
∑n
i=1 dMi(u)∑n
i=1 w
II
i (u)Yi(u)
=
´ t
0
n−1/2
∑n
i=1 dMi(u)
E(Yi(u))
+ oP (1). The last term of (6.32) is
n1/2
ˆ t
0
∑n
i=1{wIIi (u)− 1}dMi(u)∑n
i=1w
II
i (u)Yi(u)
= n1/2
ˆ t
0
∑n
i=1{∆iξi + ξi(1−∆i)αˆ(t) + ∆i(1−ξi)ηiqˆ(t) − 1}dMi(u)∑n
i=1w
II
i (u)Yi(u)
= n1/2
ˆ t
0
∑n
i=1
(
ξi
α˜ − 1
)
(1−∆i)dMi(u)∑n
i=1w
II
i (u)Yi(u)
+ n1/2
ˆ t
0
∑n
i=1
(
ηi
q˜ − 1
)
∆i(1− ξi)dMi(u)∑n
i=1w
II
i (u)Yi(u)
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+ n1/2
ˆ t
0
∑n
i=1
(
αˆ(u)−1 − α˜−1) ξi(1−∆i)dMi(u)∑n
i=1w
II
i (u)Yi(u)
+ n1/2
ˆ t
0
∑n
i=1
(
qˆ(u)−1 − q˜−1) ηi∆i(1− ξi)dMi(u)∑n
i=1w
II
i (u)Yi(u)
= n−1/2
ˆ t
0
∑n
i=1
(
1− ξiα˜
)
(1−∆i)Yi(u) [dµ0(u) + β′0Zi(u)du]
E(Y1(u))
+ n−1/2
ˆ t
0
∑n
i=1
(
ηi
q˜ − 1
)
∆i(1− ξi)dMi(u)
E(Y1(u))
− n−1/2
ˆ t
0
∑n
i=1
(
αˆ(u)−1 − α˜−1) ξi(1−∆i)Yi(u) [dµ0(u) + β′0Zi(u)du]
E(Y1(u))
+ n−1/2
ˆ t
0
∑n
i=1
(
qˆ(u)−1 − q˜−1) ηi∆i(1− ξi)dMi(u)
E(Y1(u))
+ oP (1) (6.33)
Using (6.20) and Lemma A1, we have the third term of (6.33) as:
ˆ t
0
1
E(Y1(u))
n1/2
(
1
αˆ(u)
− 1
α˜
)
× n−1
n∑
i=1
(1−∆i)ξiYi(u)
[
dµ0 + β
′
0Zi(u)du
]
=
ˆ t
0
1
E(Y1(u))
1
E(1−∆1)Y1(u))
[
n−1/2
n∑
i=1
(1−∆i)(1− ξi
α˜
)Yi(u)
]
× n−1
n∑
i=1
(1−∆i)ξiYi(u)
[
dµ0(u) + β
′
0Zi(u)du
]
= n−1/2
n∑
i=1
ˆ t
0
1
E(Y1(u))
(1−∆i)(1− ξi
α˜
)Yi(u)
E [Y1(u)(1−∆1)(dµ0(u) + β′0Z1(u)du)]
E((1−∆1)Y1(u)) + oP (1).
(6.34)
Using (6.21) and Lemma A1, we have the fourth term of (6.33) as:
ˆ t
0
1
E(Y1(u))
n1/2
(
1
qˆ(u)
− 1
q˜
)
× n−1
n∑
i=1
∆i{1− ξi}ηidMi(u)
=
ˆ t
0
1
E(Y1(u))
1
E(∆1(1− ξ1))Y1(u))
[
n−1/2
n∑
i=1
∆i(1− ξi)(1− ηi
q˜
)Yi(u)
]
n−1
n∑
i=1
∆i{1− ξi}
× ηidMi(u)
= n−1/2
n∑
i=1
ˆ t
0
1
E(Y1(u))
∆i(1− ξi)(1− ηi
q˜
)Yi(u)
E [dM1(u) |∆1 = 1, ξ1 = 0]
E(Y1(u) |∆1 = 1, ξ1 = 0) + oP (1).
(6.35)
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Therefore,
n1/2
ˆ t
0
∑n
i=1{wIIi (u)− 1}dMi(u)∑n
i=1w
II
i (u)Yi(u)
= n−1/2
n∑
i=1
(
1− ξi
α˜
)
(1−∆i)
ˆ t
0
Yi(u)
E(Y1(u))
×
{
β′0Zi(u)du−
E [(1−∆1)Y1(u)β′0Z1(u)du]
E((1−∆1)Y1(u))
}
+ n−1/2
n∑
i=1
(
1− ηi
q˜
)
∆i(1− ξi)
ˆ τ
0
1
E(Y1(u))
×
{
dMi(u)− Yi(u)E [dM1(u) | ∆1 = 1, ξ1 = 0]
E(Y1(u) | ∆1 = 1)
}
+ oP (1). (6.36)
Hence, using (6.36), (6.32) can be written as
n1/2{µˆII0 (βˆII , t)− µ0(t)}
= n1/2r(t)′
{
βˆII − β0
}
+ n−1/2
{ˆ t
0
∑n
i=1 dMi(u)
E(Y1(u))
}
+ n−1/2
n∑
i=1
(
1− ξi
α˜
)
(1−∆i)
ˆ t
0
Yi(u)
E(Y1(u))
×
{
β′0Zi(u)du−
E [(1−∆1)Y1(u)β′0Z1(u)du]
E((1−∆1)Y1(u))
}
+ n−1/2
n∑
i=1
(
1− ηi
q˜
)
∆i(1− ξi)
ˆ τ
0
1
E(Y1(u))
×
{
dMi(u)− Yi(u)E [dM1(u) | ∆1 = 1, ξ1 = 0]
E(Y1(u) | ∆1 = 1)
}
+ oP (1). (6.37)
By Taylor Series expansion of Un(βˆ
II) around β0, we have
n1/2{βˆII − β0} = A−1 × n−1/2{Un(β0)}+ oP (1)
= A−1
[
n−1/2
n∑
i=1
MZ˜,i(β0) + n
−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)R∗i (β0)
+n−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)R∗∗i (τ)
]
+ op(1).
Plugging the above in (6.37), we have
n1/2{µˆII0 (βˆII , t)− µ0(t)}
= n−1/2
n∑
i=1
[
r(t)′A−1MZ˜,i(β0) +
ˆ t
0
dMi(u)
E(Y1(u))
]
+ n−1/2
n∑
i=1
(1− ξi
α˜
)(1−∆i)
(
r(t)′A−1R∗i (β0)
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+ˆ t
0
1
E (Y1(u))
Yi(u) ×
[
β′0Zi(u)−
E ({1−∆1}Y1(u)β′0Z1(u))
E((1−∆1)Y1(u))
]
du
)
+ n−1/2
n∑
i=1
(1− ηi
q˜
)∆i
(1− ξi)
(
r(t)′A−1R∗∗i (τ) +
ˆ t
0
1
E (Y1(u))
{
dMi(u)− Yi(u)E [dM1(u) | ∆1 = 1, ξ1 = 0]
E(Y1(u) | ∆1 = 1)
})
+ oP (1)
= n−1/2
n∑
i=1
νi(β0, t) + n
−1/2
n∑
i=1
(1− ξi
α˜
)ψI(β0, t) + n
−1/2
n∑
i=1
(1− ηi
q˜
)ψII(β0, t) + oP (1).
(6.38)
νi(β0, t) = r(t)
′A−1MZ˜,i(β0) +
ˆ t
0
dMi(u)
E(Y1(u))
= r(t)′A−1
ˆ τ
0
(Zi(t)− e(t)) dMi(t) +
ˆ t
0
dMi(u)
E(Y1(u))
.
ψIi (β0, t)
= (1−∆i)
[
r(t)′A−1R∗i (β0) +
ˆ t
0
1
E (Y1(u))
Yi(u)
[
β′0Zi(u)−
E ({1−∆1}Y1(u)β′0Z1(u))
E((1−∆1)Y1(u))
]
du
]
= (1−∆i)
[
r(t)′A−1
(ˆ τ
0
dRi(β0, t)−
ˆ τ
0
Yi(t)E((1−∆1)dRi(β0, t))
E((1−∆1)Yi(t))
)
+
ˆ t
0
1
E (Y1(u))
Yi(u)
[
β′0Zi(u)−
E ({1−∆1}Y1(u)β′0Z1(u))
E((1−∆1)Y1(u))
]
du
]
and
ψIIi (β0, t) = ∆i(1− ξi)r(t)′A(β0)−1
ˆ τ
0
dMZ˜,i(u)− Yi(u)E
[
dMZ˜,1(u) | ∆1 = 1, ξ1 = 0
]
E(Y1(u) | ∆1 = 1)

+ ∆i(1− ξi)
ˆ t
0
1
E (Y1(u))
{
dMi(u)− Yi(u)E [dM1(u) | ∆1 = 1, ξ1 = 0]
E(Y1(u) | ∆1 = 1)
}
LetW1(t) = n
−1/2∑n
i=1 νi(β0, t), W2(t) = n
−1/2∑n
i=1(1− ξiα˜ )ψI(β0, t) andW3(t) = n−1/2
∑n
i=1
(1− ηiq˜ )ψII(β0, t). Since, r(t), E ({1−∆1}Y1(u)β′0Z1(u)), E
[
dMZ˜,1(u) | ∆1 = 1, ξ1 = 0
]
and
E [dM1(u) | ∆1 = 1, ξ1 = 0] are of bounded variations, E(Y1(t)) is bounded away from zero
and A is positive definite, along with the asymptotic normality of the rest of the terms, we can
say that νi(β0, t), ψ
I
i (β0, t) and ψ
II
i (β0, t) are bounded processes. Hence, by multivariate CLT,
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W1(t), W2(t) and W3(t) would converge to a zero-mean Guassian processes, which has contin-
uous sample paths under the Euclidean distance(Lin et al. 2000). The covariance function for
the three Gaussian processes are given by E
(
νIIi (β0, t)ν
II
i (β0, s)
)
+ 1−αα E
(
ψIi (β0, t)ψ
I
i (β0, s)
)
1−q
q E
(
∆i(1− ξi)ψIIi (β0, t)ψIIi (β0, s)
)
. One can note that, Wn(t) = W1(t) + W2(t) + W3(t)
converges to a zero-mean Gaussian process, W(t) with continuous sample paths, as it is the
sum of independent and identically distributed zero-mean terms for fixed t(Lin et al. 2000).
The covariance between W1(t) and W3(t) = 0 since
cov(n−1/2
n∑
i=1
νi(β0, t), n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ψIIi (β0, t))
= E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ψIIi (β0, t)
)
= E
[
E
(
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
(1− ηi
q˜
)∆i(1− ξi)ψIIi (β0, t)
∣∣∣ F(τ))]
= E
[
n−1/2
n∑
i=1
νi(β0, t)n
−1/2
n∑
i=1
E
(
1− ηi
q˜
(1− ξi)
∣∣∣ F(τ))∆iψIIi (β0, t)
]
= 0.
Similarly, the covariance between W1(t) and W2(t) and W2(t) and W3(t) are equal to zero ∀t.
Hence, Wn(t) converges weakly to a zero-mean Gaussian process with the covariance function
betweenW(t) andW(s) is given by E (νi(β0, t)νi(β0, s)) + 1−αα E
(
(1−∆i)ψIi (β0, t))ψIi (β0, s)
)
+ 1−qq E
(
∆i(1− ξi)ψIIi (β0, t))ψIIi (β0, s)
)
.
148
APPENDIX C: TECHNICAL DETAILS FOR CHAPTER 5
Here is the Appendix containing the simplification of the power formula in Chapter 5.
C.1 Asymptotic Distribution of Test Statistic
Self and Prentice (1988) proposed a score function whose asymptotic distribution is given
by
n
−1/2
j U˜j(β
0
j ) −→
D
N(0, σ2j (β
0
j ) + δj(β
0
j )) ∀j = 0, 1
By Taylor series expansion, n1/2
(
βˆj − βj
)
−→
D
N(0, r−1j
(
σ−2j (βj)+σ
−4
j (βj)δj(βj)
)
), j = 0, 1
and βˆj are independent. Hence, we have under H0 : β0 = β1, the asymptotic distribution of
n1/2
(
βˆ1 − βˆ0
)
follows:
n1/2
(
βˆ1 − βˆ0
)
−→
D
N
0, 1∑
j=0
r−1j
(
σ−2j (βj) + σ
−4
j (βj)δj(βj)
)
C.2 Consistent Estimator Of The Variance Components
To obtain consistent estimators of different variance components, note that
∑nj
i=1 Yijk(x)
n˜j
−→
P
(1− pj)1−kpkjpijk(x)Sj(x)e
kβj ∀j, k = 0, 1
˜
Q(l)j(βj , x, w) =
1
n˜j
∑
i∈C˜j
Yi(x ∨ w)Z lie2Ziβj , ∀l = 0, 1, j = 0, 1
S(l)(βj , x) =
1
n˜j
∑
i∈C˜j
Yi(x)Z
l
ie
Ziβj , ∀l = 0, 1, j = 0, 1
n˜j
nj
→ ψj , ˜Q(l)j(βj , x, w) P−→ q(l)(βj , x, w), S(l)(βj , x) P−→ s(l)(βj , x) ∀l = 0, 1, j = 0, 1
149
Note that the sub-cohort averages converges to the full cohort averages as n → ∞. Hence,
the variance terms can be written as
σ2j =
ˆ 1
0
(
s(2)(βj , t)
s(0)(βj , t)
− (s
(1)(βj , t)
s(0)(βj , t)
)⊗2
)
s(0)(βj , t)λj(t)dt
=
ˆ 1
0
(
s(2)(βj , t)s
(0)(βj , t)− s(1)(βj , t)⊗2
[s(0)(βj , t)]
)
λj(t)dt
and δj =
ˆ 1
0
ˆ 1
0
G(βj , x, w)s
(0)(βj , x)s
(0)(βj , w)λj(x)λj(w)dxdw,
Since,
h(k+l)(βj , x, w) = q
(k+l)(βj , x, w)− s(k)(βj , w)s(l)(βj , x)′ ∀l ≤ k = 0, 1
we can rewrite G(βj , x, w) as
G(βj , x, w) =
1− ψj
ψj
{s(0)(βj , x)s(0)(βj , w)}−2
[(
q(2)(βj , x, w)− s(1)(βj , x)s(1)(βj , w)
)
×s(0)(βj , x)s(0)(βj , w) +
(
q(0)(βj , x, w)− s(0)(βj , x)s(0)(βj , w)
)
s(1)(βj , x)s
(1)(βj , w)
−s(0)(βj , x)s(1)(βj , w)
(
q(1)(βj , x, w)− s(0)(βj , w)s(1)(βj , x)
)
− s(0)(βj , w)s(1)(βj , x)
×
(
q(1)(βj , x, w)− s(0)(βj , x)s(1)(βj , w)
)]
=
1− ψj
ψj
{s(0)(βj , x)s(0)(βj , w)}−2
[
q(2)(βj , x, w)s
(0)(βj , x)s
(0)(βj , w) + q
(0)(βj , x, w)
s(1)(βj , x)s
(1)(βj , w)−
(
s(0)(βj , x)s
(1)(βj , w) + s
(0)(βj , w)s
(1)(βj , x)
)
q(1)(βj , x, w)
]
Hence, G(βj , x, w) can be further simplified as
G(βj , x, w)
=
1− ψj
ψj
{s(0)(βj , x)s(0)(βj , w)}−2
[
q(1)(βj , x, w)
(
s(0)(βj , x)s
(0)(βj , w)− s(0)(βj , x)s(1)(βj , w)
−s(0)(βj , w)s(1)(βj , x)
)
+ q(0)(βj , x, w)s
(1)(βj , x)s
(1)(βj , w)
]
Now, for the variance term of the statistic, we examined each of the variances of the score
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functions separately. G(βj , x, w) can be simplified as
ψj
1− ψjG(βj , x, w)
= {s(0)(βj , x)s(0)(βj , w)}−2
[
q(1)(βj , x, w)(1− pj)2pij0(x)pij0(w)Sj(x)Sj(w)
+ (1− pj)pij0(x ∨ w)Sj(x ∨ w)s(1)(βj , x)s(1)(βj , w)
]
= {s(0)(βj , x)s(0)(βj , w)}−2
[
e2βjpjpij1(x ∨ w)Sj(x ∨ w)e
βj × (1− pj)2pij0(x)pij0(w)Sj(x)Sj(w)
+ (1− pj)pij0(x ∨ w)Sj(x ∨ w)× e2βjp2jpij1(x)pij1(w) (Sj(x)Sj(w))e
βj
]
=
e2βj (1− pj)pj
∑1
k=0(1− pj)1−kpkjpij,(1−k)(x ∨ w)pij,k(x)pij,k(w)Sj(x ∨ w)e
(1−k)βj(∑1
k=0 e
kβj (1− pj)1−kpkjpijk(x)Sj(x)e
kβj
)2 (∑1
k=0 e
kβj (1− pj)1−kpkjpijk(w)Sj(w)e
kβj
)2
× Sj(x)e
kβj
Sj(w)
ekβj
Therefore,
δj =
1− ψj
ψj
ˆ 1
0
ˆ 1
0
∑1
k=0(1− pj)1−kpkjpij,(1−k)(x ∨ w)pij,k(x)pij,k(w)Sj(x ∨ w)e
(1−k)βj(∑1
k=0 e
kβj (1− pj)1−kpkjpijk(x)Sj(x)e
kβj
)
× Sj(x)e
kβj
Sj(w)
ekβj e
2βj (1− pj)pjdΛj(x)dΛj(w)(∑1
k=0 e
kβj (1− pj)1−kpkjpijk(w)Sj(w)e
kβj
)
and
σ2j =
ˆ 1
0
(
s(1)(βj , t)
(
s(0)(βj , t)− s(1)(βj , t)
)
[s(0)(βj , t)]
)
λj(t)dt
=
ˆ 1
0
(
s(1)(βj , t) ((1− pj)pij0(t)Sj(t))
[s(0)(βj , t)]
)
λj(t)dt
=
ˆ 1
0
eβj (1− pj)pjpij0(t)pij1(t)Sj(t)e
βj∑1
k=0 e
kβj (1− pj)1−kpkjpijk(t)Sj(t)e
kβj
Sj(t)dΛj(t)
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Under H0 : β0 = β1, and Λ˜j(t) =
´ t
0
dN¯j0(u)+N¯j1(u)
Y˜j0(u)+e
βj Y˜j1(u)
≈ Λj(t)/ψj , the consistent estimates of
the variance components, δj and σ
2
j for X = j are :
δˆj =
ψˆj(1− ψˆj)
n˜j
ˆ 1
0
ˆ 1
0
e2βˆj
(∑1
k=0 Y˜j,1−k(x ∨ w)Y˜jk(x)Y˜jk(w)
)
dΛ˜j(x)dΛ˜j(w)
(
∑1
k=0 e
kβˆj Y˜j,k(x))(
∑
k e
kβˆj Y˜jk(w))
.
and dΛ˜j(x) =
∑
k dN¯jk(x)∑
k e
kβˆj Y˜jk(x)
imply
δˆj =
ψˆj(1− ψˆj)
n˜j
ˆ 1
0
ˆ 1
0
e2βˆj
(∑1
k=0 Y˜j,1−k(x ∨ w)Y˜jk(x)Y˜jk(w)
)(∑1
k=0 dN¯jk(x)
)
(
∑1
k=0 e
kβˆj Y˜jk(x))2(
∑1
k=0 e
kβˆj Y˜jk(w))2
×
(
1∑
k=0
dN¯jk(w)
)
Also, we have the estimate of σ2j as
σˆ2j =
ψj
n˜j
ˆ 1
0
eβˆj Y˜j0(x)Y˜j1(x)
(∑
k dN¯jk(x)
)(∑1
k=0 e
kβˆj Y˜j,k(x)
)2
≈ 1
nj
ˆ 1
0
Y˜j0(x)
2dN¯j1(x) + e
2βˆj Y˜j1(x)
2dN¯j0(x)(∑1
k=0 e
kβˆj Y˜jk(x)
)2 (6.39)
C.3 Power/Sample Size for Rare Event
Assume that the distribution of the censoring distribution Ci does not depend on Zi and
Xi, we have
pijk(x) = pij(x) ∀j, k = 0, 1
and all the results hold as earlier.
We can rewrite δˆj as
δˆj =
ψˆj(1− ψˆj)
n˜j
1∑
k,k′=0
nk∑
i=1
nk′∑
i′=1
[ e2βˆj∆ijk∆i′jk′(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)2(
Y˜j0(Tijk′) + eβˆj Y˜j1(Tijk′)
)2
×
(
Y˜j0(Tijk)Y˜j0(Tijk′)Y˜j1(Tijk ∨ Tijk′) + Y˜j1(Tijk)Y˜j1(Tijk′)Y˜j0(Tijk ∨ Tijk′)
)]
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= 2
e2βˆj ψˆj(1− ψˆj)
n˜j
1∑
k,k′=0
nk∑
i=1
nk′∑
i′=1
 ∆ijk∆i′jk′1(Tijk′ ≤ Tijk)Y˜j1(Tijk)Y˜j0(Tijk)(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)2(
Y˜j0(Tijk′) + eβˆj Y˜j1(Tijk′)
)2
×
(
Y˜j1(Tijk′) + Y˜j0(Tijk′)
)]
− e
2βˆj ψˆj(1− ψˆj)
n˜j
1∑
k=0
nk∑
i=1
∆ijkY˜j1(Tijk)Y˜j0(Tijk)(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)4
×
(
Y˜j1(Tijk) + Y˜j0(Tijk)
)
= 2
e2βˆj (1− ψˆj)
nj
1∑
k,k′=0
∑
i,∆ijk=1
∑
i,∆i′jk′=1
1(Tijk′ ≤ Tijk)Y˜j1(Tijk)Y˜j0(Tijk)(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)2
×
(
Y˜j1(Tijk′) + Y˜j0(Tijk′)
)
(
Y˜j0(Tijk′) + eβˆj Y˜j1(Tijk′)
)2
− e2βˆj (1− ψˆj)
nj
1∑
k=0
∑
i,∆ijk=1
Y˜j1(Tijk)Y˜j0(Tijk)(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)4
×
(
Y˜j1(Tijk) + Y˜j0(Tijk)
)
(6.40)
In order to derive the formula which can be used in the design stage of the study, we
need to simplify (6.40) so that it only involves quantities that can be assumed in the design.
We order the failure times from smallest to largest for each of the two treatment groups for
biomarker j in the full cohort and the corresponding risk sets are m1jk,m2jk, . . . , j, k = 1, 2.
The size of the risk set in the sub-cohort is about q times that of the full cohort. In the
case of rare events, Yijk(Tijk) = Yijk(τ) ∀i, j, k, τ = last observed time. In other words,
mljk = m∗jk ∀l, m∗jk is the number of individuals at risk at the last observed failure time
and
mlj0
mlj1
≈ (1−pj)(1−p
j0
D )
pj(1−pj1D )
∀j = 0, 1, dlj is the number of failure times ≥ l-th failure time; Djk
is the number of failure for the k-th treatment in the j-th biomarker group. Hence, δˆj can be
rewritten as
δˆj ≈ 2e
2βˆj (1− ψj)
nj
∑
l
ψ2jmlj0mlj1
ψ2j
(
mlj0 + eβˆjmlj1
)2 ∑
l′≤l
ψj
(
ml′,j,0 +ml′,j,1
)
ψ2j
(
ml′,j,0 + eβˆjml′,j,1
)2
− e
2βˆj (1− ψj)
nj
∑
l
ψ2jmlj0mlj1 (mlj0 +mlj1)ψj
ψ4j
(
mlj0 + eβˆjmlj1
)4
= 2
e2βˆj (1− ψj)
njψj
∑
l
1(
1 + eβˆj
mlj1
mlj0
)(
eβˆj +
mlj0
mlj1
)∑
l′≤l
(
1 +
ml′,j,1
ml′,j,0
)
(
1 + eβˆj
ml′,j,1
ml′,j,0
)(
ml′,j,0 + eβˆjml′,j,1
)
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− e
2βˆj (1− ψj)
ψjnj
∑
l
(
1 +
mlj1
mlj0
)
(
1 + eβˆj
mlj1
mlj0
)2(
eβˆj +
mlj0
mlj1
)(
mlj0 + eβˆjmlj1
)
≈ 2e
2βˆj (1− ψj)
njψj
∑
l
1(
1 + eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)(
eβˆj +
(1−pj)(1−pj0D )
pj(1−pj1D )
)
×
∑
l′≤l
(
1 +
pj(1−pj1D )
(1−pj)(1−pj0D )
)
(
1 + eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
) 1(
ml′,j,0 + eβˆjml′,j,1
) − e2βˆj (1− ψj)
ψjnj
∑
l
(
1 +
pj(1−pj1D )
(1−pj)(1−pj0D )
)
(
1 + eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)2
× 1(
eβˆj +
(1−pj)(1−pj0D )
pj(1−pj1D )
)(
mlj0 + eβˆjmlj1
)
= 2
e2βˆj (1− ψj)
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
njψj(1− pj)(1− pj0D )
(
1 + eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)2(
eβˆj +
(1−pj)(1−pj0D )
pj(1−pj1D )
)∑
l
djl − 1/2(
mlj0 + eβˆjmlj1
)
= 2
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
njψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
×
∑
l
dlj − 1/2(
mlj0 + eβˆjmlj1
)
≈
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
njψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
(
Dj0 +D
j
1
)2(
m∗j0 + eβˆjm∗j1
)
(6.41)
Further,
m∗j1
nj
≈ pj(1− pj1D ) and m∗j0nj ≈ (1− pj)(1− p
j0
D ) and therefore, δˆj is given by
δˆj ≈
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
njψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
(
Dj0 +D
j
1
)2(
m∗j0 + eβˆjm∗j1
)
≈
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
ψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
×
(
(1− pj)pj0D + pjpj1D
)2(
m∗j0
nj
+ eβˆj
m∗j1
nj
)
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≈
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
ψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)4
×
(
(1− pj)pj0D + pjpj1D
)2
. (6.42)
Similarly, σˆ2j can be written as
σˆ2j =
1
nj
∑
k
nk∑
i=1
Y˜j0(Tijk)
2∆ij1 + e
2βˆj Y˜j1(Tijk)
2∆ij0(
Y˜j0(Tijk) + eβˆj Y˜j1(Tijk)
)2
=
1
nj
n0∑
i=1
e2βˆj Y˜j1(Tij0)
2∆ij0(
Y˜j0(Tij0) + eβˆj Y˜j1(Tij0)
)2 + 1nj
n1∑
i=1
Y˜j0(Tij1)
2∆ij1(
Y˜j0(Tij1) + eβˆj Y˜j1(Tij1)
)2
≈ 1
nj
∑
l
e2βˆjψ2jm
2
lj1I(l ∈ L0j ) + ψ2jm2lj0I(l ∈ L1j )
ψ2j
(
mlj0 + eβˆjmlj1
)2
=
1
nj
∑
l
e2βˆj (
mlj1
mlj0
)2I(l ∈ L0j ) + I(l ∈ L1j )(
1 + eβˆj
mlj1
mlj0
)2
≈ 1
nj
e2βˆj (
pj(1−pj1D )
(1−pj)(1−pj0D )
)2Dj0 +D
j
1(
1 + eβˆj
pj(1−pj1D )
(1−pj)(1−pj0D )
)2 = 1nj e
2βˆj (pj(1− pj1D ))2Dj0 + ((1− pj)(1− pj0D ))2Dj1(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)2
where Lkj , k = 0,1 is the index set of individuals experiencing an event who are in treatment
group k and biomarker group j. Therefore, approximatingDjk by njp
k
j (1−pj)1−k(pj1D )k(pj0D )1−k,
k = 0, 1, we have
σˆ2j ≈ pj(1− pj)
e2βˆjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)2 . (6.43)
Based on the approximations, the asymptotic variance of n
1/2
j (βˆj − βj) is given by
varj ≈ r−1j

pj(1− pj)e2βˆjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)2

−1
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+pj(1− pj)e2βˆjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)2

−2
×
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
(1− pj)(1− pj0D ) + pj(1− pj1D )
)
ψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)4
×
(
(1− pj)pj0D + pjpj1D
)2)
= r−1j
1
pj(1− pj)
[
e2βˆjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
]
×
((1− pj)(1− pj0D ) + eβˆjpj(1− pj1D ))2 +
[
e2βˆj (1− ψj)(1− pj1D )(1− pj0D )
]
ψj
(
e2βˆjpj(1− pj1D )2pj0D + (1− pj)(1− pj0D )2pj1D
)
×
{
(1− pj)(1− pj0D ) + pj(1− pj1D )
}(
(1− pj)pj0D + pjpj1D
)2]
(6.44)
Approximating
1−pj1D
1−pj0D
≈ 1 and m∗j0nj ≈ (1−pj)
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
and
m∗j1
nj
≈
pj
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
, (6.40) can be written as
δˆj ≈
e2βˆj (1− ψj)pj(1− pj)
(
(1− pj)pj0D + pjpj1D
)2
ψj
(
(1− pj) + eβˆjpj)
)4 (
pj(1− pj1D ) + (1− pj)(1− pj0D )
) (6.45)
and (6.39) is
σˆ2j ≈ pj(1− pj)
e2βˆjpjp
j0
D + (1− pj)pj1D(
(1− pj) + eβˆjpj
)2 . (6.46)
Noting that the censoring distribution is a mixture distribution with probability 1−pC being
degenerate at τ and the event proportion being low, we can approximate
m∗j0
nj
by (1−pC)(1−
pj)
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
and
m∗j1
nj
by (1− pC)pj
[
pj(1− pj1D ) + (1− pj)(1− pj0D )
]
,
which relates to the proportion of people remaining at the risk set at the end of the study.
Therefore,
δˆj ≈
e2βˆj (1− ψj)pj(1− pj)
(
(1− pj)pj0D + pjpj1D
)2
ψj
(
(1− pj) + eβˆjpj)
)4
(1− pC)
(
pj(1− pj1D ) + (1− pj)(1− pj0D )
) (6.47)
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and σˆ2j ≈ pj(1− pj)
e2βˆjpjp
j0
D + (1− pj)pj1D(
(1− pj) + eβˆjpj
)2 . (6.48)
C.4 Bounds of Power/Sample Size under Non-Rare Event Assumption
We propose the following lower bound and upper bound for the power calculation. Let
us denote the risk set for the treatment group biomarker group j, at the lj1-th time-point
of the index set, by mlj1 and that for the control group in biomarker group j, at the lj0-th
time-point of the index set, by mlj0. Based on Cai and Zeng (2007), we have the following
bound for treatment group :
njpj − nj1C −Dj1 ≤ mlj1 ≤ njpj − lj1 + 1, j = 0, 1,
and for control group, it is
nj(1− pj)− nj0C −Dj0 ≤ mlj0 ≤ nj(1− pj)− lj0 + 1, j = 0, 1.
where nj1C and nj0C are the total number of dropouts in the treated group and non-treated
group in biomarker group j respectively, in [0, τ). If all individuals experience the event at
the beginning of the study, then the risk set is the lower bound. Similarly, if at all the event
times there is only one event, we have the upper bound of the risk sets. Using the above
conditions, we define δj,ub and δj,lb as the upper and lower bounds of δˆj respectively.
δˆj,ub ≈ 2
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)
njψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
×
m∑
l=1
1∑
k=0
dlj − 1/2(
{nj(1− pj)− lj0 + 1}(1 + eβˆj pj(1−p
j1
D )
(1−pj)(1−pj0D )
)
)1−k
× 1(
{njpj − lj1 + 1}(eβˆj + (1−pj)(1−p
j0
D )
pj(1−pj1D )
)
)k
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and δˆj,lb ≈ 2
e2βˆj (1− ψj)pj(1− pj)(1− pj1D )(1− pj0D )
(
pj(1− pj1D ) + (1− pj)(1− pj0D )
)
njψj
(
(1− pj)(1− pj0D ) + eβˆjpj(1− pj1D )
)3
×
m∑
l=1
1∑
k=0
dlj − 1/2(
{nj(1− pj)− nj0C −Dj0}(1 + eβˆj pj(1−p
j1
D )
(1−pj)(1−pj0D )
)
)1−k
× 1(
{njpj − nj1C −Dj1}(eβˆj + (1−pj)(1−p
j0
D )
pj(1−pj1D )
)
)k ,
Using this, one can get the bounds for power as
Φ
 √n (β1 − β0)√∑1
j=0 r
−1
j
(
σ−2j + σ
−4
j δj,ub
) − Z1−α
 ≤ Power ≤ Φ
 √n (β1 − β0)√∑1
j=0 r
−1
j
(
σ−2j + σ
−4
j δj,lb
) − Z1−α
 ,
where σ2j ≈ (1− pj)pj e
2βj pj(1−pj1D )2pj0D+(1−pj)(1−pj0D )2pj1D(
(1−pj)(1−pj0D )+eβj pj(1−pj1D )
)2 .
158
REFERENCES
Aalen, O. O. (1980). A model for nonparametric regression analysis of counting processes.
Lecture notes in statistics 2, 25.
Albert, P. S. (1991). A two-state markov mixture model for a time series of epileptic seizure
counts. Biometrics 47, 1371–1381.
Amorim, L. D. and Cai, J. (2015). Modelling recurrent events : a tutorial for analysis in
epidemiology. International Journal of Epidemiology pages 324–333.
Andersen, P. K. and Gill, R. D. (1982). Cox’s regression model for counting processes: a large
sample study. The Annals of Statistics 10, 1110–1120.
Barlow, W. E. (1994). Robust variance estimation for the case-cohort design. Biometrics 50,
1064–1072.
Barlow, W. E., Ichikawa, L., Rosner, D., and Izumi, S. (1999). Analysis of case-cohort designs.
Journal of Clinical Epidemiology 52, 1165–1172.
Barreto, M. L., Farenzena, G. G., Fiaccone, R. L., Santos, L. M. P., Assis, A. M. O., Araujo,
M. P. N., and Santos, P. A. B. (1994). Effect of vitamin a supplementation on diarrhoea and
acute lower-respiratory-tract infections in young children in brazil. Lancet 344, 228–231.
Bilias, Y., Gu, M., and Ying, Z. (1997). Towards a general asymptotic theory for cox model
with staggered entry. The Annals of Statistics 25, 662–682.
Borgan, O., Goldstein, L., and Langholz, B. (1995). Methods for the analysis of sampled
cohort data in the cox proportional hazards model. The Annals of Statistics 23, 1749–
1778.
Borgan, O., Langholz, B., Samuelson, S., Goldstein, L., and Pogoda, J. (2000). Exposure
stratified case-cohort designs. Lifetime Data Analysis 6, 39–58.
Breslow, N. E. and Wellner, J. A. (2006). Weighted likelihood for semiparametric models and
two-phase stratified samples, with application to cox regression. Scandinavian Journal of
Statistics 34, 86–102.
Cai, J. and Schaubel, D. E. (2004). Marginal means/rates models for multiple type recurrent
event data. Lifetime Data Analysis 10, 121–138.
Cai, J. and Zeng, D. (2004). Sample size/power calculation for case-cohort studies. Biometrics
60, 1015–1024.
Cai, J. and Zeng, D. (2007). Power calculation for case-cohort studies with non-rare events.
Biometrics 63, 1288–1295.
Cao, Y. and Yu, J. (2017). Optimal generalized case-cohort sampling design under the additive
hazard model. Communications in Statistics - Theory and Methods 46, 4484–4493.
Chang, S.-H. and Wang, M.-C. (1999). Conditional regression analysis for recurrence time
data. Journal of the American Statistical Association 94, 1221–1230.
159
Chen, F. and Chen, K. (2014). Case-cohort analysis of clusters of recurrent events. Lifetime
Data Analysis 20, 1 – 15.
Chen, K. (2001). Generalized case-cohort sampling. Journal of Royal Statistical Society Series
B 63, 791–809.
Chen, K. and Lo, S.-H. (1999). Case-cohort and case-control analysis with cox’s model.
Biometrika 86, 755–764.
Cole, E. H., Cattran, D. C., Farewell, V. T., Aprile, M., Bear, R. A., Pei, Y. P., Fenton, S. S.,
Tober, J. A. L., and Cardella, C. J. (1994). A comparison of rabbit antithymocyte serum
and okt3 as prophylaxis against renal allograft rejection. Transplantation 57, 60–67.
Cook, R. J., Lawless, J. F., Lakhal-Chaieb, L., and Lee, K.-A. (2009). Robust estimation of
mean functions and treatment effects for recurrent events under event-dependent censor-
ing and termination: Application to skeletal complications in cancer metastatic to bone.
Journal of the American Statistical Association 104, 60–75.
Cook, R. J., Lawless, J. F., and Nadeau, C. (1996). Robust tests for treatment comparisons
based on recurrent event responses. Biometrics 52, 557–571.
Cox, D. R. (1972). Regression models and life-tables (with discussion). Journal of the Royal
Statistical Society, Series B 34, 187–220.
Cox, D. R. (1975). Partial likelihood. Biometrika 62, 269–276.
Cui, J., Forbesa, A., Kirby, A., Marschner, I., Simes, J., Weste, M., and Tonkina, A. (2008).
Parametric conditional frailty models for recurrent cardiovascular events in the lipid study.
Clinical Trials 5, 565–574.
Dong, C.-L., Zhou, J., and Sun, L.-Q. (2014). A class of weighted estimators for additive
hazards model in case-cohort studies. Acta Mathematicae Applicatae Sinica, English Series
30, 1153–1168.
Folsom, A., Aleksic, N., Park, E., Salomaa, V., Juneja, H., and Wu, K. K. (2001). Prospective
study of fibrinolytic factors and incident coronary heart disease : The atherosclerosis risk in
communities (aric) study. Arteriosclerosis, Thrombosis, and Vascular Biology 21, 611–617.
Gail, M. H., Santner, T. J., and Brown, C. C. (1980). An analysis of comparative carcino-
genesis experiments based on multiple times to tumor. Biometrics 36, 255–266.
He, S., Wang, F., and Sun, L. (2013). A semiparametric additive rates model for clustered
recurrent event data. Acta Mathematicae Applicatae Sinica, English Series 29, 53–62.
Hu, W., Cai, J., and Zeng, D. (2014). Sample size/power calculation for stratified case-cohort
design. Statisics in Medicine 33, 3973–3985.
Huang, Y. and Chen, Y. Q. (2003). Marginal regression of gaps between recurrent events.
Lifetime Data Analysis 9, 293–303.
Huffer, F. W. and McKeague, I. W. (1991). Weighted least squares estimation for aalen’s
additive risk model. Journal of the American Statistical Association 86, 114–129.
160
Jahn-Eimermacher, A., Ingel, K., Ozga, A.-K., Preussler, S., and Binder, H. (2015). Simulat-
ing recurrent event data with hazard functions defined on a total time scale. BMC Medical
Research Methodology 15, 16–24.
Jiang, J. and Zhou, H. (2007). Additive hazard regression with auxiliary covariates.
Biometrika 94, 359–369.
Kalbfleisch, J. D. and Lawless, J. F. (1988). Likelihood analysis of multi-state models for
disease incidence and mortality. Statisics in Medicine 7, 149–160.
Kalbfleisch, J. D. and Prentice, R. L. (2002). The Statistical Analysis of Failure Time Data,
2nd Ed. John Wiley, New York.
Kang, S. and Cai, J. (2009a). Marginal hazards model for case-cohort studies with multiple
disease outcomes. Biometrika 96, 887–901.
Kang, S. and Cai, J. (2009b). Marginal hazards regression for retrospective studies within
cohort with possibly correlated failure time data. Biometrics 65, 405–414.
Kang, S., Cai, J., and Chambless, L. (2013). Marginal additive hazards model for case-
cohort studies with multiple disease outcomes: an application to the atherosclerosis risk in
communities (aric) study. Biostatistics 14, 28–41.
Karatzas, I. and Shereve, S. E. (1988). Brownian Motion and Stochastic Calculus. Springer
New York.
Kim, S., Cai, J., and Couper, D. (2016). Improving the efficiency of estimation in the additive
hazards model for stratified casecohort design with multiple diseases. Statistics in Medicine
35, 282–293.
Klien, J. (1992). Semiparametric estimation of the random effects using the cox model based
on the em algorithnm. Biometrics 48, 795–806.
Kulich, M. and Lin, D. (2000). Additive hazards regression for case-cohort studies. Biometrika
87, 73–87.
Kulich, M. and Lin, D. (2004). Improving the efficiency of relative-risk estimation in case-
cohort studies. Journal of the American Statistical Association 99, 832–844.
Langholz, B. and Thomas, D. C. (1990). Nested case-control and case-cohort methods of
sampling from a cohort : A critical comparison. American Journal of Epidemiology 131,
169–176.
Lawless, J. F. (1995). The analysis of recurrent events for multiple subjects. Journal of the
Royal Statistical Society. Series C (Applied Statistics) 44, 487–498.
Lawless, J. F. and Nadeau, C. (1995). Some simple robust methods for the analysis of
recurrent events. Technometrics 37, 158–168.
Li, Q. H. and Lagakos, S. W. (1997). Use of the wei-lin-weissfeld method for the analysis of
a recurring and a terminating event. Statisics in Medicine 16, 925–940.
161
Liang, K.-Y. and Zeger, S. L. (1986). Longitudinal data analysis using generalized linear
models. Biometrika 73, 13–22.
Liao, D., Cai, J., Rosamond, W. D., Barnes, R. W., Hutchinson, R. G., Whrtsel, E. A.,
Rautaharju, P., and Heiss, G. (1997). Cardiac autonomic function and incident coronary
heart disease: A population-based case-cohort study. American Journal of Epidemiology
145, 696–706.
Lin, D. and Ying, Z. (1994). Semiparametric analysis of the additive risk model. Biometrika
81, 61–71.
Lin, D. Y., Oakes, D., and Ying, Z. (1998). Additive hazards regression with current status
data. Biometrika 85, 289–298.
Lin, D. Y., Sun, W., and Ying, Z. (1999). Nonparametric estimation of the gap time distri-
butions for serial events with censored data. Biometrika 86, 59–70.
Lin, D. Y., Wei, L. J., Yang, I., and Ying, Z. (2000). Semiparametric regression for the mean
and rate functions of the recurrent events. Journal of the Royal Statistical Society (Series
B) 62, 711–730.
Lin, D. Y. and Ying, Z. (1993). Cox regression with incomplete covariate measurements.
Journal of the American Statistical Association 88, 1341–1349.
Liu, Y., Sun, L., and Zhou, Y. (2013). Additive transformation models for recurrent events.
Communications in Statistics - Theory and Methods 42, 4043–4055.
Liu, Y., Wu, Y., Cai, J., and Zhou, H. (2010). Additiv-multiplicative rates model for recurrent
events. Lifetime Data Analysis 16, 353–373.
Lu, S.-E. and Shih, J. H. (2006). Case-cohort designs and analysis for clustered failure time
data. Biometrics 62, 1138–1148.
Lu, W. and Tsiatis, A. (2006). Semiparametric transformation models for the case-cohort
study. Biometrika 93, 207–214.
Ma, S. (2007). Additive risk model with case-cohort sampled current status data. Statistical
Papers 48, 595–608.
Martinussen, T. and Scheike, T. H. (2002). Efficient estimation in additive hazards regression
with current status data. Biometrika 89, 649–658.
Nan, B. (2004). Efficient estimation of case-cohort studies. The Canadian Journal of Statistics
32, 403–419.
Nelson, W. (1988). Graphical analysis of system repair data. Journal of Quality Technology
20, 24–35.
Pepe, M. S. and Cai, J. (1993). Some graphical displays and marginal regression analyses for
recurrent failure times and time dependent covariates. Journal of the American Statistical
Association 88, 811–820.
162
Pollard, D. (1990). Empirical Processes: Theory and Applications. Institute of Mathematical
Statistics.
Prentice, R. L. (1986). A case-cohort design for epidemiologic cohort studies and disease
prevention trials. Biometrika 73, 1–11.
Prentice, R. L., Williams, B. J., and Peterson, A. V. (1981). On the regression analysis of
multivariate failure time data. Biometrika 68, 373–379.
Savitz, D. A., Cai, J., Wijngaarden, E. V., Loomis, D., Mihlan, G., Dufort, V., Kleckner,
R. C., Nylander-French, L., Kromhout, H., and Zhou, H. (2000). Case-cohort analysis
of brain cancer and leukemia in electric utility workers using a rened magnetic field job-
exposure matrix. American Journal of Industrial Medicine 38, 417–425.
Schaubel, D. E. and Cai, J. (2004). Regression methods for gap time hazard functions of
sequentially ordered multivariate failure time data. Biometrika 91, 291–303.
Schaubel, D. E. and Cai, J. (2005). Semiparametric methods for clustered recurrent event
data. Lifetime Data Analysis 11, 405–425.
Schaubel, D. E., Zeng, D., and Cai, J. (2006). A semiparametric additive rates model for
recurrent event data. Lifetime Data Analysis 12, 389–406.
Schouten, E. G., Dekker, J. M., Kok, F. J., Cessie, S. L., Van Houwelingen, H. C., Pool, J.,
and Vanderbroucke, J. P. (1993). Risk ratio and rate ratio estimation in case-cohort designs
: Hypertension and cardiovascular mortality. Statistics in Medicine 12, 1733–1745.
Self, S. G. and Prentice, R. L. (1988). Asymptotic distribution theory and efficiency results
for case-cohort studies. The Annals of Statistics 16, 64–81.
Shepherd, F. A., Domerg, C., Hainaut, P., Jo¨nne, P. A., Pignon, J.-P., Graziano, S., Douillard,
J.-Y., Brambilla, E., Chevalier, T. L., Seymour, L., Bourredjem, A., Teuff, G. L., Pirker,
R., Filipits, M., Rosell, r., Kratzke, R., Bandarchi, B., Ma, X., Capelletti, M., Soria, J.-C.,
and Tsao, M.-S. (2013). Pooled analysis of the prognostic and predictive effects of kras
mutation status and kras mutation subtype in early-stage resected nonsmall-cell lung cancer
in four trials of adjuvant chemotherapy. Journal of Clinical Oncology 31, 2173–2181.
Spiekerman, C. F. and Lin, D. Y. (1999). Marginal regression models for multivariate failure
time data. Journal of the American Statistical Association 93, 1164–1175.
Sun, J., Sun, L., and Flournoy, N. (2004). Additive hazards model for competing risks analysis
of the case-cohort design. Communications in Statistics - Theory and Methods 33, 351–366.
Sun, L., Park, D.-H., and Sun, J. (2006). The additive hazards model for recurrent gap times.
Statistica Sinica 16, 919–932.
Therneau, T. M. and Grambsch, P. M. (2001). Modeling Survival Data. Springer New York.
Therneau, T. M. and Hamilton, S. A. (1997). rhdnase as an example of recurrent event
analysis. Statistics in Medicine 16, 2029–2047.
163
Van Der Vaart, A. W. and Wellner, J. A. (1996). Weak Convergence and Empirical Processes.
Springer New York.
Wacholder, S. (1991). Practical considerations in choosing between the case-cohort and nested
case-control designs. Epidemiology 2, 155–158.
Wacholder, S., Gail, M. H., Pee, D., and Brookmeyer, R. (1989). Alternative variance and
efficiency calculations for the case-cohort design. Biometrika 76, 117–123.
Wei, L. J., Lin, D. Y., and Weissfeld, L. (1989). Regression analysis of multivariate incomplete
failure time data by modeling marginal distributions. Journal of the American Statistical
Association 84, 1065–1073.
Yin, G. and Cai, J. (2004). Additive hazards model with multivariate failure time data.
Biometrika 91, 801–818.
Yu, J. C., Shi, Y. Y., Yang, Q. L., and Liu, Y. Y. (2014). Additive hazards regression under
generalized case-cohort sampling. Acta Mathematica Sinica, English Series 30, 251–260.
Zeng, D. and Cai, J. (2010). A semiparametric additive rate model for recurrent events with
an informative terminal event. Biometrika 97, 699–712.
Zeng, D., Lin, D. Y., Avery, C. L., North, K. E., and Bray, M. S. (2006). Efficient semi-
parametric estimation of haplotype-disease associations in case-cohort and nested case-
control studies. Biostatistics 7, 486–502.
Zhang, H., Schaubel, D., and Kalbeisch, J. D. (2011). Proportional hazards regression for the
analysis of clustered survival data from case-cohort studies. Biometrics 67, 18–28.
164
